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PART 1
Voorwoord

9Voorwoord
Mijn proefschrift getiteld ‘Bladder urothelium involvement in afferent signaling 
and barrier function’ omvat een groot deel van het wetenschappelijk werk dat 
ik sinds 2008 heb verricht aan de afdeling Urologie van het Radboud UMC. Het 
onderzoek met een biomedisch karakter gaat over de rol van het blaasslijmvlies. 
Enerzijds bij de regulering van de zenuwsignalen die de vullingstoestand van de 
blaas weergeven en anderzijds de bescherming van de blaaswand tegen agressieve 
moleculen en pathogenen uit de urine. Deze beide functies zijn essentieel voor 
het normaal functioneren van de lage urinewegen. Een verstoring hierin, zoals bij 
ziekten als Overactieve blaas syndroom (OAB) of het blaaspijn syndroom (BPS), 
lijdt vaak tot klachten zoals verhoogde en frequente aandrang om te plassen, 
urine incontinentie en pijn in de blaasregio. 
Mijn onderzoek heeft zich toegespitst op een rekreceptor in het blaasslijmvlies, 
genaamd transient receptor potential vanilliod 4 (TRPV4). We hebben onderzocht 
of dit ion kanaal betrokken is bij de regulatie van het meten van de hoeveelheid 
vulling in de blaas. Daarnaast heb ik de functies onderzocht van een groep 
moleculen, genaamd glycosaminoglycanen (GAGs), die op het blaasslijmvlies 
liggen. Deze GAGs dragen bij aan het versterking van de beschermende barrière 
van het blaasslijmvlies. Als laatste ben ik betrokken geweest in een project waarbij 
we een experimenteel model voor de urine blaas hebben ontworpen dat mogelijk 
in de toekomst een alternatief voor proefdieronderzoek kan vormen.
Daar de academische promotie plechtigheid omgeven is van tradities, denk aan 
toga’s en rokkostuums, is het te vermelden waard dat ook de wetenschappelijke 
tijdschriften waarin de hoofdstukken uit dit proefschrift zijn gepubliceerd een 
historisch karakter hebben. Zo is Pflügers Archiv een tijdschrift dat voor het eerst 
in 1868 is uitgegeven door Friedrich Wilhelm Pflüger die het tijdschrift toen nog 
‘Archiv für die gesamte physiologie des Menschen und der Thiere’ noemde. Het 
tijdschrift Acta Physiologica komt voort uit het in 1889 opgerichte tijdschrift 
Skandinavische Archiv für Physiologie. Zelfs het Amerikaanse blad Journal of 
Urology, dat bij alle urologen wel bekend is, komt uit 1917 en heeft dr. Hugh 
Hamptom Young als stamvader. Daarmee wil ik niet insinueren dat dit proefschrift 
nou zo’n historisch werk is, maar ik vind het wel bijzonder dat deze tijdschriften 
de tand des tijd hebben doorstaan en nog steeds impact hebben.  
De kaft van dit proefschrift behoeft ook nog een nadere uitleg. Het is een 
samenvoeging van een oude stadskaart van Nijmegen uit 1567 en een 
microscopische afbeelding gemaakt van een dwarsdoorsnede van het slijmvlies 
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van de urine blaas. Deze laatste afbeelding is gemaakt met een elektronen 
microscoop in het kader van dit proefschrift. De stadskaart heb ik uiteraard 
gebruikt vanwege mijn promotietraject aan de Radboud Universiteit in Nijmegen. 
De kaart was oorspronkelijk een kopergravure die is gemaakt door de Italiaan 
Lodovico Guicciardini. In het kader rechts onderaan staat de Latijnse verwijzing 
naar Noviomagus. Dit is de Romeinse stadsbenaming uit ca. 100 n.Chr. voor 
wat nu Nijmegen is. Bovenaan de pagina staat Wael Flu, wat eveneens een oud 
romeinse benaming is voor rivier de Waal die onlosmakelijk verbonden is met de 
stad Nijmegen. De gravure bevat tevens de basis van wat het huidige stadswapen 
van Nijmegen is (de leeuwen aan de zijkant kwamen later). Het idee van de 
kaft is dat de we in Nederlandse steden en dorpen op een vergelijkbare manier 
omgaan met water zoals we dat doen met onze eigen lichamelijke waterwerken 
zoals de blaas. Men zoekt het water op, maar soms moet je jezelf er ook tegen 
beschermen. De traditionele stadsmuren vertegenwoordigen de beschermende 
laag op het blaasslijmvlies. Dit symboliseert dat onze tweestrijd met water niet 
alleen op stedelijk niveau afspeelt, maar ook op een microscopisch niveau. Ik kon 
het niet laten om ook de bootjes erbij te zetten.
Werken aan dit proefschrift was voor mij een fantastische en ongelooflijk 
leerzame ervaring. Promoveren hoeft helemaal geen bloed-zweet-en-tranen 
traject te zijn en het heeft op mij juist een uiterst positieve en onuitwisbare indruk 
achtergelaten.         
PART 2
Outline of the thesis and general introduction
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Outline of the thesis
The chapters of this thesis are all focused on the functional characteristics of the 
urothelium with a predominant focus on the bladder. The chapters are grouped 
in separated parts that cover a distinct topic in urothelial function and research. 
Part 2. General introduction
Part two (this part) is a general introduction on bladder urothelial function. 
Chapter 1 of this thesis reviews the current evidence on structures and molecules 
in the urothelium that play a part in afferent signaling or barrier function. All 
the work in the other chapters involve basic preclinical research that is done 
for this thesis with the aim to further understand the role of the urothelium in 
sensory (afferent) signaling for bladder filling sensations and the role it plays in 
the protective barrier against the toxins in the urine. These chapters describe 
the function of transient receptor potential vanilloid 4 (TRPV4) channels, bladder 
glycosaminoglycans (GAGs) and the development of an experimental model for 
preclinical research. Each of these topics will be explained in detail below.  
Part 3. The role of TRPV4 channels in the urogenital tract 
Chapters 2, 3 and 4 explore the role of the cation channel TRPV4 in the bladder 
urothelium. The TRPV4 channel is a type of receptor that is located on the cell 
membrane that enables controlled transport of ions across the cell membrane. 
The channels can be activated by mechanical stress (stretch) resulting in an 
influx of calcium ions into the cell. Measuring stretch in the urinary bladder is 
essential for bladder filling sensations and the regulation of the storage-voiding 
cycle. Calcium ions are potent activators in cell physiology and are essential 
for urothelial afferent signaling. Besides these interesting characteristics of the 
TRPV4 channel, we know from experiments by other research groups that have 
studied transgenic TRPV4 knockout mice (mice that are genetically modified so 
they do not have any TRPV4 channels) that these mice have considerable bladder 
dysfunction. This implies that TRPV4 channels are important in the regulation of 
normal lower urinary tract function. 
Chapter 2 describes the outcomes of the research efforts that were aimed to 
locate the TRPV4 channels in the human bladder. A second objective of this study 
was to better understand how TRPV4 channels could be activated by mechanical 
stretch in the urothelium. Based on available literature on TRPV4 channels in other 
organs, we investigated a hypothesis that TRPV4 channels could be effectively 
activated by mechanical stretch if they had a molecular connection with specific
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cell junctions that connect urothelial cells to each other. The experiments in 
this chapter confirm that TRPV4 channels interact with specific proteins of the 
adherence junction in the urothelium. 
In chapter 3, this interaction between TRPV4 channels and adherence junctions 
is further explored in multiple tissues of the urinary tract. This chapter describes 
research done on human kidney, ureter and bladder tissues. Furthermore, we 
used the TRPV4 knockout mouse to investigate cell junction formation in a 
urothelial layer that was devoid of any TRPV4 channels. This was investigated on 
a microscopical and ultrastructeral level using Transmission Electron Microscopy 
(TEM). 
Chapter 4 concerns the scientific experiments that were conducted with the aim 
to better understand the role of bladder TRPV4 channels in afferent signaling. This 
in vivo study used both normal mice and TRPV4 knockout mice for comparison. 
Based on a previous study by another research group that reported that a 
distinct dysfunctional voiding pattern in TRPV4 knockout mice, we initiated this 
study to further clarify the role that TRPV4 plays in afferent signaling. The spinal 
c-fos model was used as a tool to quantify bladder afferent signaling. With the 
application of different pharmacological interventions, this study explored the 
differences in bladder afferent neural signals between normal wild type mice and 
TRPV4 knockout mice. 
Part 4. The function of glycosaminoglycans (GAGs) in the bladder urothelium     
   
A second topic of this thesis concerns the function of glycosaminoglycans (GAGs) 
in the bladder wall defense against toxins in the urine. The apical membrane 
of the urothelial layer of bladder wall is exposed to urine that contains bodily 
waste products and irritants. The urothelium is designed to maximally prevent 
reabsorption of these waste products and irritant through the bladder wall. 
The apical cells of the urothelium produce different molecules and proteins to 
thicken and strengthen the apical membrane. Since decades, there has been a 
hypothesis that there is a layer of hydrophilic GAGs on the apical membrane that 
functions as a buffer between the bladder wall and the urine. GAGs are group of 
polysaccharides. Most of these molecules have sulfate groups and are attached 
to a core protein called a proteoglycan. Combined, this creates a layer with a 
negative electrical charge that can bind a large amount of H2O molecules to form 
a gel-like layer. This is called the bladder GAG layer. In current clinical practice, 
intravesical GAG replenishment instillations are given to restore urothelial barrier 
in patients who suffer from bladder wall inflammatory conditions like Bladder
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pain syndrome (IC/BPS). However, there are still many knowledge gaps on the 
content and importance of this GAG layer for bladder barrier. This is called the 
bladder GAG layer. In current clinical practice, intravesical GAG replenishment 
instillations are given to restore urothelial barrier 
Chapter 5 outlines the study that has been done to investigate the location and 
function of sulfated GAGs in the human and porcine bladder. The goal of this study 
was to clarify which GAG subtypes were part of the so-called GAG layer and to 
test which GAG subtypes actually contribute to the bladder barrier. For the latter, 
a model was used that measured Trans Epithelial Electrical Resistance (TEER) on 
an in vitro urothelial cell culture. Specific enzymes were applied to degrade GAG 
subtypes and to evaluate if these subtypes had an effect on barrier. 
Part 5. Experimental models for preclinical bladder muscosa research
This part concerns the research efforts done to develop and evaluate a preclinical 
research model for the study of the bladder wall. The experimental model was 
developed in collaboration with the tissue engineering research group of our 
department. Preclinical research often involves laboratory animals and uses 
mostly small rodents. This thesis is no exception to that. In vivo animal research 
has considerable ethical downsides, and is therefore appropriately controlled with 
strict legal regulations. This results in high costs and a considerable administrative 
burden. Technology is improving in a matter where the use of laboratory animals 
could become more redundant for experimental research. Tissue engineering, or 
regenerative medicine as it is currently named, has given us tools to keep tissues 
and cells alive outside the body in a controlled laboratory setting. 
The aim of the study as described in chapter 6 was to develop an alternative 
model for experimental urinary bladder research based on two concepts. The 
first was to explore the potential of using bladder biopsies from pigs that were 
recently slaughtered in a commercial abattoir and use it as a biological substrate 
for research purposes. The second concept was the to improve bladder tissue 
viability ex vivo with tissue engineering techniques. The chapter describes the 
experiments that have been done to optimize biopsy viability in a controlled 
reproducible laboratory setting and it describes the applied methods to evaluate 
tissue viability. 
Part 6. Epilogue
Contains a Summary and conclusions of this thesis and a future perspective.

Chapter 1 
Urothelium update. 
How the urothelium becomes impermeable and measures bladder filling
D.A.W. Janssen, J.P.F.A. Heesakkers, J.A. Schalken
Dept. of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
This chapter is an adaptation of two manuscripts for publication.
Urothelium update. How the bladder mucosa measures bladder filling 
Accepted for publication (2016) in ACTA Physiologica
How the urothelium becomes impermeable
Submitted for publication in peer reviewed journal.   
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Abstract
The bladder urothelium has a dual role in barrier and afferent signaling. Bladder 
filling results in continuous changes in bladder wall stretch and exposure to urine. 
Consequently, both barrier and afferent signaling functions in the urothelium 
are constantly adapting to cope with these dynamics. Mechanosignaling is a 
crucial element in the responses to this process and the urothelium host many 
different mechanosensory receptors and pathways that measure the bladder 
filling state. Cumulative evidence shows that there is an evident overlap between 
barrier function and bladder filling signaling. Similar structures, pathways and 
mechanoreceptors are applied in both processes. This review will focus on the 
current evidence on the molecular structures and pathways that are involved in 
bladder barrier and bladder filling sensory signaling and summarizes how both 
these functions potentially overlap in the bladder urothelium. 
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1. Introduction
For a normal urinary bladder to function adequately, there must be a 
well-constructed defensive barrier against toxins in the urine and a balanced 
neuro-muscular control to be able to properly store and expel urine from the 
body when needed. This review focusses on the specific functions of the bladder 
mucosa in the barrier and bladder neural control. 
The bladder wall is composed of distinct tissue layers and each layer contributes 
to the organ-specific functions. From inside out there is the urothelium, the 
submucosa (lamina propria), the detrusor muscle layer and the serosa. The classic 
approach to bladder function was simple. The urothelium was believed to form 
the main barrier. The detrusor muscle layers were needed for bladder emptying 
and elasticity of the bladder wall allowed for the required expansion during filling. 
Finally, nerves were there for the sensory-motor control. We now know this 
sensory-motor control part is far more complex and does not include only nerve 
fibers, but also other cell types and structures that have specific roles in afferent 
and efferent signaling pathways. In searching for new therapies for lower urinary 
tract diseases like overactive bladder syndrome (OAB), there has been a lot of 
attention paid to the bladder urothelium and suburothelium. Research groups 
are interested in these layers, because they contain key structures for afferent 
signaling, including those that are involved in the measurement of bladder wall 
stretch. 
2. Anatomy of urothelium and suburothelium
The urothelium is an epithelial cell layer that grows on top of a basement 
membrane. It is a polarized epithelium that contains three different cell types 
[Yamani 2014] [Castillo-Martin 2010]. These are basal, intermediate and umbrella 
cells. The basal cell layer is a single cell layer that consist of smaller cells that 
are connected to the basal membrane with desmosomes and specific integrins 
[Southgate 1995][Jones 2001]. On top of these are the intermediate urothelium 
cells. This cell type represent the bulk of the cells in the urothelium and thickness 
of this cell layer decreases severely during increased stretch of the bladder wall 
[Yamani 2014].  The final, most apical cell layer consist of umbrella cells (Fig. 1 & 
2CD). These are large interconnecting cells that, like the intermediate cells, still 
have protrusions that connect with the distal urothelial cell layers (Fig. 1 & 2CD)
[Martin 1972]. These specialized cells drastically change shape during bladder 
filling from a more polyhedral shape in the empty bladder to a rectangular shape 
in the full bladder. The umbrella cell has developed unique characteristics to cope 
with the continuous exposure to urine and is therefore the most important cell 
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type in urothelial barrier (Lewis 2000). The umbrella cells are adapted to minimize 
the exposed membrane surface that is exposed to urine (Matthai et al. 2014). 
Basal cells were thought to contain the stem cells from which the other cell 
types grow. This can be seen with a Ki67 immunostaining of the urothelium (Fig. 
2F). However, in the last 6 years there have been studies by Mendelsohn and 
Castillo-Martin that show that the basal layer perhaps has a different origin and 
that it is the intermediate cells that have the stem cells that produce the umbrella 
cell type [Yamani 2014] [Colopy 2014] [Castillo-Martin 2010]. 
The normal urothelium has a slow cellular turnover of 6 months [Lewis 2000] 
[Walker 1960]. This turnover rate is flexible. Damage results in a rapid increase 
in proliferation and migration of cells and a quick production of the essential 
structures to restore barrier properties [Kreft 2005] [Yamani 2014]. Injury of the 
urothelium increases mitotic activity in all urothelial cell layers and induces a 
rapid differentiation of the most apical intermediate cells into umbrella cell type 
[Martin 1972][Khandelwal 2009][Lavelle 2002]. This increased cell proliferation 
and migration is aimed to rapidly produce the essential structures and proteins 
to restore barrier properties [Kreft 2005]. This plasticity of the urothelium can 
be seen in the rapid recovery rate after transurethral surgery of the bladder, 
but also in vitro when terminally differentiated urothelial cell layers in culture 
are damaged with protamine. Protamine causes mild damage to the urothelial 
GAG layer and tight junctions and results in a rapid decrease of trans epithelial 
electrical resistance (TEER). This decrease in TEER fully recovers within 24 hours 
[Janssen 2013]. 
Underneath the urothelium lies the suburothelium, also called the lamina 
propria and together with the urothelium, it is called the bladder mucosa. The 
suburothelium is mainly composed of a collagen type 1 matrix containing different 
tissues. It has a thin layer of connected muscle cells called the muscularis mucosa. 
This layer still has an undetermined function. Furthermore, it hosts important 
structures that support the urothelium in its functions. It has a vast capillary and 
lymphatic network that support the urothelial cells and play an essential role in 
immunological defense responses against pathogens that invade the urine tract. 
The suburothelium also contains nerves and specific cells that facilitate afferent 
signaling and communicate with urothelial cells. These afferent nerves consist of 
unmyelated C-fiber and perhaps even myelated Aδ-nerve fibers. There is evidence 
that these nerves can protrude the urothelial basement membrane and innervate 
the basal cell layer (Fig. 1) [Zagorodnyuk 2006][Gabella 1998]. A large part of the 
C-fibers nerves in the bladder mucosal area are considered silent, because they 
are only activated in abnormal circumstances like noxious bladder distention or 
by inflammatory pathways [Andersson 2002]. Just underneath the basement 
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membrane lies a network of specialized spindle shaped myofibroblast type cells 
called interstitial cells or interstitial cells of Cajal (ICC’s) (Fig 1 & 4C)[Gillespie 2005]
[Groll 2008]. These ICC’s communicate directly with afferent nerve fibers via gap 
junctions [Sui 2002]. 
The different functions of the urothelium related to barrier and afferent signaling 
will be discussed next. 
Figure 1. anatomy of the bladder wall and mucosa. From outside to bladder lumen, there 
is the serosa, detrusor layer, lamina propria / suburothelium and the urothelium. The 
apical cell layer of the urothelium contains umbrella cells that have a specialized apical 
cell membrane containing barrier molecules like proteoglycans and GAGs, uroplakins, and 
mucins and lectins. Below are the intermediate and basal layers that are attached to the 
basement membrane. The basement membrane consist of collagen type IV and laminin, 
but also expresses proteoglycans & GAGs. Below the basement membrane lies the lamina 
propria / suburothelium space. Here lie the stellate shaped ICC’s and the CGRP expressing 
afferent nerves that can penetrate into the urothelium. It also contains the capillaries and 
lymphatic vessels for nourishment and immune defense.
22
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3. Barrier
3.1 Barrier and disease
Leakage of urine through a defective urothelium barrier causes inflammation 
and pain sensations and can even cause electrolyte disturbances [Hurst 2007]
[Tzan 1993]. Clinicians are often confronted with these problems. For instance, 
when they consult Interstitial cystitis / Bladder Pain Syndrome (IC/BPS) patients 
with a leaky urothelium that induces bladder wall inflammation and increased 
sensitivity to potassium in the urine (Fig. 2H)[Parsons 2009]. Or when clinicians 
treat patients that have developed electrolyte disturbances due to an increased 
resorption through the more permeable intestinal epithelium of an ileal conduit 
urinary diversion. This inflammatory response is mediated by the afferent C-nerves 
and ICC’s that, together with the urothelium express many key sensory chemical 
and mechanical receptors that respond to the afferent signaling molecules that 
originate in the bladder wall during inflammatory conditions [Kanai 2014][Ikeda 
2006][Neuhaus 2008][Fry 2007]. The pain and discomfort this causes changes 
a patients voiding behavior. It increases bladder voiding frequency in order to 
reduce bladder capacity. This frequently expels the pathogens from the bladder 
and reduces the bacterial load in the urine tract and inhibits the time that bacteria 
can multiply. It may also prevent further bladder wall damage by reducing the 
amount of urothelial urine exposure and the amount of stress on the bladder 
wall. 
The urine, however, is not only composed of toxins or irritants. It also contains 
defensive mechanisms to protect the bladder wall. It contains proteins like the 
Tamm Horsfall protein that is secreted from the kidneys and can potentially 
neutralize E. Coli bacteria, prevent stone formation and reduce inflammation 
[Säemann 2005][Parsons 2007] [Raffi 2009]. Another example is the excretion of 
the enzyme urokinase by the kidneys that prevents blood clotting in the urinary 
tract. The enzyme is very potent and applied in therapeutic clinical thrombolysis 
procedures for thrombosis and embolisms. The bladder wall also pro-actively 
allows the passage of leucocytes to target the pathogens in the urine, accounting 
for leukocytosis during inflammation and infection.  
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Figure 2. Urothelial anatomy and function. A) Expression of chondroitin sulfate (GAG) on 
both apical membrane of umbrella cells and in suburothelial space of the human bladder. 
B-C) Heparan sulfate (GAG) and Perlecan (proteoglycan) are expressed in the basement 
membrane of the urothelium (orange arrows) and also in the basement membranes of 
capillaries in suburothelium. D) Human umbrella cells immunostained with ZO-1 antibody 
(red) show that umbrella cells have projections toward the basement membrane (blue 
arrow). E) E-cadherin antibody (green) stains adherence junctions that are expressed by 
all urothelial cells, but AJs are not formed between the basement membrane and the basal 
urothelial cells. F) Ki67 immunostaining (cell proliferation) in the porcine bladder show 
that basal cell layer is the dividing cell layer in the normal urothelium. G) Normal healthy 
multilayered human urothelium. H) urothelium in bladder biopsy from patient with IC/BPS 
show only a single layered urothelium and inflammatory cells in the suburothelial space.     
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3.2 Barrier structures and molecules.
So how does the urothelium become impermeable? Some unique adaptations 
in the cells of the urothelium are responsible for this. The umbrella cells for 
instance, adapt to minimize the membrane surface that is exposed to urine in 
two ways [Matthai 2014]. Firstly, it uses a process called vesicular exocytosis to 
constantly decrease or, when mandatory, increase the apical cell membrane. 
Secondly, it strengthens and thickens its apical membrane by depositing a wide 
arrange of specific anti-adhesive and protective molecules (Fig. 1, 4AB, 5AB)
[Levin 1975]. Umbrella cells also prevent leakage through the extracellular route 
by creating hinge areas that seal-off the exposed luminal cell borders [Apodaca 
2004][Lewis 2000]. To be able to accomplish this, there has to be a high degree of 
structural organization of the cells in the urothelium. This is done with different 
interconnecting cell junctions and adhesion molecules (Fig. 4EF, 5C-G). Finally, 
there is a basal membrane that forms the foundation on which the whole 
urothelium grows and this structure also creates a functional barrier for bacteria 
and bladder cancer cells. The currently known barrier structures and processes in 
the urothelium will be discussed next.
3.2.1. Vesicular exocytosis
Vesicular exocytosis is a unique adaptive process that takes place in umbrella 
cells. The attributed goal of this system is to minimize the exposed cell membrane 
surface that is in contact with urine. After voiding, umbrella cells start to cut out 
the excess cell membrane (endocytosis) and store it in intracellular disc shaped / 
fusiform vesicles [Lewis 1982, 1984] [Truschel 2002]. During bladder filling, tension 
increases in the bladder wall and the disc shaped vesicles will be transported back 
to and fuse with the apical membrane (exocytosis) (Fig. 3, 4D)[Khandelwal 2010]
[Lewis 2000] [Minski 1978]. This is not a one-way system, but a dynamic process 
where the balance between endo- and exocytosis continuously shifts to either an 
increase or a decrease of the total exposed membrane surface [Truschel 2002]. This 
process is mechanically achieved through a connection between the disc shaped 
vesicles and the cytoskeleton and moleculary driven by intracellular Ca2+, cyclic 
adenosine monophosphate (cAMP) and protein kinase A (PKA) concentrations 
and epidermal growth factor receptors (EGFr) [Truschel 2002][Wang 2005]
[Balestreire 2007]. The disc shaped vesicles are initially formed in the Golgi 
apparatus of the cell and are transported to the area just underneath the apical 
cell membrane where they are stored [Chen 2003]. Apodaca et al. demonstrated 
that the contents of many of the endocytosed vesicles are degraded by liposomes 
and that this process helps to renew the umbrella cell apical membrane [Apodaca 
2002]. The disc shaped vesicles contain cell membrane molecules, anti-adhesive 
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molecules and membrane bound receptors (Fig. 4D) [Lewis 2000]. This process 
thus regulates receptor expression on the apical cell membrane and as a result 
could influence excitability and signaling behavior of the umbrella cell.
Figure 3. Schematic hypothetical pathways of vesicular endo-/exocytosis in the apical 
membrane of umbrella cells. Left figure displays activating pathways for exocytosis of 
vesicles. Main driving force is stretch on the apical membrane and a resulting intracellular 
calcium increase via release from intracellular stores and activation of mechanosensitive 
cation channels (MR) that are still undetermined. This also involves cAMP and protein 
kinase pathways (PKA). ATP produced upon stretch and excreted via exocytosis. Purinergic 
activation (mainly P2X3 receptors) lead to a positive feedback loop and stimulates further 
exocytosis. Other exocytosis stimulating pathways are adenosin excretion and adenosin 
receptor 1 activation (AR-1) on the apical side of the umbrella cell and Epithelial Growth 
Factor receptor activation by ATP and adenosine. Right figure shows a hypothetical model 
on how apical membrane stretch and basolateral membrane stretch promote either 
exocytosis or endocytosis. New vesicles are formed in the Golgi system. Membrane stretch 
on the apical membrane stimulates transport of new and stored vesicles to the apical 
cell membrane via the cytokeratin filaments, after which they merge with the apical 
membrane (exocytosis). Continuous bladder filling will eventually also increase tension on 
actin filaments of the basolateral membrane and stimulate endocytosis of vesicles via an 
unknown pathway. Endocytosed vesicles are either degraded by liposomes or stored just 
under the apical membrane for recycling.       
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To explain apical membrane increasing and decreasing processes during bladder 
filling and emptying, Khandelwal, Yu and Apodaca proposed a hypothesis by which 
stretch in the apical membrane of the umbrella cell influences the exocytosis 
component of vesicular exocytosis and stretch in the basolateral side of the 
umbrella cell mediates the endocytosis component (Fig 3)[Yu 2009][Khandelwal 
2009]. This hypothesis takes into account 1) the floppiness and folding capacity of 
the mucosa layer compared to the more rigid detrusor layer and 2) that the apical 
cell membrane of the umbrella cell is dynamic due to vesicular exo-/endocytosis, 
but the basolateral membrane is not. Based on their studies, they explain that 
in the initial phase of bladder filling, the urothelium unfolds and predominantly 
bends in the direction of the bladder lumen, resulting in a slight tension increase 
on the apical side of the umbrella cell which then responds by stimulating 
exocytosis of stored vesicles. Rab 11a, Rab8a and Myo5B proteins are involved 
in the regulation of vesicular exocytosis of cell membrane [Khandelwal 2013]. 
After the urothelium in completely unfolded, it will bend in the direction of the 
serosa and tension will also built up in the basolateral side of the umbrella cell. 
This results in a costimulation of endocystosis alongside exocytosis resulting in an 
increase of membrane turnover that could also alter receptor expression on the 
apical membrane. This latter phenomenon was observed by applying stretch to 
the basolateral side of the bladder wall in Ussing chamber experiments [Yu 2009]. 
During and after voiding, endocytosis is regulated with the Myelin-lymphocyte 
(MAL) protein and is the dominant process resulting in a rapidly decrease in the 
total membrane surface to baseline proportions [Truschel 2002] [Zhou 2012] [Yu 
2009]. 
Hence, the umbrella cells are continuously responding to mechanical forces 
inside the bladder wall. Different mechanoreceptors like: Epithelial Sodium 
Channels (ENaCs), Potassium Channels, TRP-channels and other Non-Specific 
Cation Channels (NSCC) are suggested candidates to play a potential role in 
stimulating vesicular exocytosis [Yu 2006]. The umbrella cell cytoskeleton is 
believed to play a crucial role in the transportation of mechanical forces and 
there are indications that the umbrella cells have evolved their cytoskeleton to 
adjust it specifically for vesicular endo- and exocytosis [Romih 1999][Lewis 2000]. 
This means that there is a connection between the disc shaped vesicles and the 
cytokeratin network (intermediate filaments) near the apical cell membrane 
that allegedly forms the transportation network that guides the vesicles to 
and from the apical membrane [Veranic 2001]. On the other side, the actin 
cytoskeleton is predominantly distributed close and parallel to the basolateral 
membrane [Khandelwal 2009]. Both the cytokeratin and actin network are 
able to transport tensile forces between the cell membrane and other parts of 
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the cell, but they also perform this function between different cells since they 
are connected to specific cell junctions on the urothelial cell membrane like 
desmosomes and adherence junctions [Janssen 2011][Goodwin 2004] [Morris 
2001]. Khandelwal et al. showed that pharmacological inhibition of the urothelial 
actin cytoskeleton with cytochalasin D inhibits endocytosis [Khandelwal 2010]. 
How the predominantly basolateral location of the actin cytoskeleton mediates 
vesicular endocytosis on the apical membrane of the umbrella cell is currently 
unknown. But transportation of mechanical forces via the actin cytoskeleton is 
important for afferent mechanosignaling and urothelial ATP excretion [Suzuki 
2003] [Khandelwal 2009].
Vesicular exocytosis is also used as one of the routes for ATP transport outside 
the cell during bladder wall stretch [Wang 2005][Lewis 2006]. ATP released by 
both fusion of intracellular vesicles with the apical membrane and excretion to 
the basolateral side will activate P2X(P2Y) receptors on the urothelial membrane. 
Purinergic receptor activation stimulates further exocytosis by increasing the 
intracellular Ca²⁺ and cAMP concentrations and thereby forming a positive feedback 
loop [Wang 2005]. The Ca²⁺ required comes from the release of intracellular Ca²⁺ 
stores and from extracellular deposits by opening Ca²⁺ sensitive ion channels 
on the cell membrane that are currently unknown [Wang 2005]. Experiments 
by Wang at al. have shown that multiple interventions like blocking urothelial 
calcium channels, P2X receptors and protein kinase A pathways can inhibit 
vesicular exocytosis [Wang 2005][Sarikas 1986]. Ussing chamber experiments 
with bladders from knockout mice like P2X3 -/-, P2X2 -/- and TRPV1 -/- showed 
an an inhibited capability for apical membrane expansion (capacitance) in these 
mice during stretch [Wang 2005][Birder 2002]. 
Adenosin could also have an potentiating effect on vesicular exocytosis [Yu 2006]. 
Adenosin is produced and excreted by the urothelial cells and has two functions 
that seem somewhat conflicting. There is a study by Dunning-Davies et al. that 
demonstrated that adenosine excretion and activation of the AR-1 receptor at the 
serosal side of the urothelium has a inhibitory effect on urothelial ATP excretion 
via the basolateral route [Dunning-Davies 2013]. By contrast, Yu et al. reported 
that excretion of adenosine on the apical side of the urothelium has a stimulating 
effect on vesicular exocytosis. They showed an adenosine increase on primarily the 
apical side of the urothelium during stretch, which activated the AR-1 receptors 
near the urothelial apical membrane, increasing intracellular Ca²⁺-concentrations 
and stimulating vesicular exocytosis (Fig. 3) [Yu 2006]. 
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Figure 4. Ultrastructeral imaging of the urothelium. A&B) Scanning electron microscopy 
(SEM) images at different magnifications show the thick cushion like apical membrane of 
the porcine bladder urothelium with the hexagonal shaped umbrella cells. C) Transmission 
Electron Microscopy (TEM) of mouse bladder showing a densly packed urothelium with 
umbrella cells (u), intermediate cells (i) and basal cells (b). In the suburothelium there are 
the stellate shaped ICC’s that lie close to the basement membrane. D) TEM image at high 
magnification of the apical membrane of mouse bladder umbrella cell showing vesicular 
endo-/exocytosis. Disc shaped vesicles (#) and more oval shaped vesicles (*) lie in close 
proximity to the apical membrane. These vesicles merge with the apical membrane to 
expand the total apical membrane surface and these vesicles contain barrier molecules 
that are specific for the umbrella cells (purple arrows. E) TEM image of a tight junction 
(yellow arrow) F) TEM image of adherence junction (AJ; red arrow) and desmosome 
(orange arrow) that interconnect urothelial cells.      
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3.2.2 Anti-adhesive molecules 
Umbrella cells form thick outer membrane deposits that are also called the 
glycocalix. The structure of the glycocalyx is extensively studied on an ultrastructural 
level using transmission or scanning electron microscopes (Fig. 4) [Cornish 1990]
[Koss 1969][Levin 1975]. Studying the different compounds of the glycocalix has 
identified several molecules that are of interest for barrier. These are uroplakins, 
glycosaminoglycans and proteoglycans (the GAG layer) and different mucins and 
lectins.  
The GAG-layer. 
Glycosaminoglycans (GAGs) are a group of polysaccharides that are negatively 
charged and have the remarkable capacity to bind (lots of) H2O molecules into 
a gel like form[Parsons 1986][Lamberg 1974][Hurst 1994]. The negative charge 
and water binding capacities give the GAG layer anti-adhesive and buffering 
properties and make the GAG layer a first line of defense against toxins and 
solutes in the urine [Parsons 1986] [Lily 1990]. Examples of GAGs are heparin, 
chondroitin sulfate, heparin sulfate, dermatan sulfate and hyaluronic acid. Most 
of them (except hyaluronic acid) are connected to a proteoglycan, which is a 
family of core-proteins of varying size that have many different functions and are 
found in areas throughout the human body like joints, cartilage and extracellular 
matrix [Lamberg 1974]. These proteoglycans can be free floating or bound to 
the cell membrane, depending on their function. It is the combination of the 
proteoglycans and the attached GAGs that form a GAG layer. While there are 
many types of proteoglycans and GAGs located in the bladder wall and even in the 
uroepithelium, but when literature mentions the bladder GAG layer, they refer only 
to the proteoglycans and GAGs that are located on the apical membrane of the 
umbrella cells. Ground breaking work on the function of the GAGs in the urinary 
tract has been done by investigators like Parsons and Hurst. They hypothesized 
that a deficient GAG layer is associated with IC/BPS, and they pioneered in the 
introduction of GAG replenishment therapies with heparin, chondroitin sulfate, 
hyaluronic acid and pentosan polysulfate, that are used widely in clinical practice 
for bladder inflammatory conditions  [Parsons 1982] [Erickson 1997] [Hauser 
2009] [Anderson 2006] [Hurst 1996]. Nonetheless, there is much unknown 
about the content and physiology of the urothelial GAG layer. Only recently, it 
has been demonstrated that chondroitin sulfate is the only GAG on the bladder 
apical membrane that contributes to the epithelial barrier (Fig 5A) [Janssen 2013] 
[Hauser 2009]. The type(s) of proteoglycans that are relevant for the GAG layer 
and bladder barrier are largely unclear [Lamberg 1974]. There is evidence that 
proteoglycans like syndecan, biglycan and decorin are present in the urothelium, 
30
Urothelium updateChapter 1
but it is not known if they take part in the urothelial barrier [Hauser 2008]. The 
normal turnover rate and the role of the GAG layer in bladder wall repair is also 
largely unknown, but there are some clues that can be found from a study by 
our group on differentiated urothelial cell layers using TEER measurements. 
Protamine and GAG digesting enzymes were used to digest or destroy the GAG 
layer and the results from this study demonstrated that after damaging the GAG 
layer, it takes approximately 24 hours for the GAG layer and epithelial resistance 
to recover [Janssen 2013].
Uroplakins
Uroplakins are dense crystalline proteins that are deposited on the apical surface 
of the umbrella cells. The group of Sun et al. has done extensive research on 
bladder uroplakins and they identified 4 subtypes (Ia, Ib, II and III) that are present 
in the bladders of a wide range of mammals [Wu 2009] (Fig 5B). Combined in 
a specific arrangement, these uroplakins form the 0.3–1 µm thick crystalline 
plaques that are called the asymmetric unit membrane (AUM) which has a 
typical appearance on an ultrastructeral level. If the urothelium is not terminally 
differentiated, it will not have an umbrella cell layer that expresses this AUM 
and consequently, the bladder wall will be more exposed to toxins in the urine. 
Uroplakins are deposited on the apical cell membrane via vesicular exocytosis (Fig 
4D) [Wu 2009]. Uroplakins are believed to strengthen the urothelium during large 
volume expansion and it could also be an additional layer to protect the umbrella 
cell membrane. The density and content of uroplakins on the urothelium differs 
between bladder, ureter and kidney [Liang 2005]. The effect of uroplakins on 
barrier has been investigated using a knockout mouse model of UPIII [Hu 2000, 
2002]. Hu et al. observed an increased permeability of the urothelium and the 
emergence of vesico-urethral reflux in these mice [Hu 2000]. The latter suggests 
that uroplakins could be important for coaptation of the mucosal wall in the 
ureter and perhaps the urethra too. Despite the evident advantages, the uroplakin 
layer does contain a weakness, since it there is evidence that E. Coli bacteria use 
uroplakin proteins as attachment sites for the bladder wall [Zhou 2001].  
Mucins and Lectins
The role of mucins and lectins of the AUM are poorly studied in the bladder. These 
molecules are also called glycoconjugates and have a water binding capacity that 
resembles GAGs. Mucins and lectins are found on every wet mucosal surface 
of the body like in the trachea, mouth and intestines. Studies by Buckley et. 
al. demonstrated that in the rabbit bladder, there were at least 13 different 
glycoconjugates associated with the urothelium of which at least 3 (two lectins ; 
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Jacalin, DSL one mucin; MAL-II) were specific for the apical membrane and were 
found in large quantities [Buckley 2000]. There were also glycoconjugates that 
were detected in other sites of the urothelium like the basement membrane or 
the lectin called UEA-II that was specific for the basal cell layer. Furthermore, they 
showed that the concentrations of these glycoconjugates in the urothelium was 
higher compared to the glycosaminoglycans. No studies have yet been conducted 
to the role of mucins and lectins in bladder barrier, but in potential, these could 
be as important as the GAG layer and might offer new potential therapies.  
3.2.3 Cell junctions
To decrease intercellular space and interconnect cells with each other, urothelial 
cells form a vast number of cell junctions that all have specific functions (Fig. 4EF, 
5C-G). There are for example: gap junctions for intercellular communication, tight 
functions (TJs) for barrier function and integrins for the connection of urothelial 
cells to the basal membrane. For many different cell junctions, like adherence 
junctions, desmosomes and integrins, it is not fully understood what their actual 
contribution to the bladder barrier is. However, they do all play an important role 
in maintaining the structural integrity of the urothelium and are therefore directly 
or indirectly involved in barrier. From what we currently know, the TJ (also called 
zona occludens) is the most important cell junction for the urothelial barrier. 
Tight junctions (TJs)
TJs connect the apical cell membranes of neighboring umbrella cells [Rickard 
08]. It uses internal ZO-1 and external claudin, JAM-1 and occludin proteins that 
work like a zipper that closes the intracellular space (Fig 4E.). TJs can be detected 
with occludin or claudin immunostainings and with TEM microscopy. In the 
urothelium, TJs are umbrella cell specific and are therefore used as a histological 
marker for the terminally differentiated urothelium (Fig. 5CD). In cell culture, the 
appearance of tight junctions coincides with a dramatic increase in TEER [Janssen 
2013]. Barrier studies investigating the TEER of different epithelia, demonstrated 
TEER values in the urothelium of approximately 75.000 Ω.cm², which is higher 
than any other epithelia in the body, including the blood-brain barrier [Lewis 
2000]. These extreme TEER rises coincide with TJ formation and therefore, the 
TJs are considered to be one of the most vital structures for impermeability of the 
urothelium. Because of their impermeability for electrolytes and their location 
on the apical side of the urothelium, the tight junctions are also important for 
upholding the cell polarity in the urothelium that is crucial for normal functioning 
of the urothelial layer as a whole. The permeability of the tight junction ring could 
be more fluctuant than previously thought. There is evidence that stress alters 
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the tight junctions function [Carattino 2013]. Carratino et al evaluated rat bladder 
tissues in Ussing chamber experiments and demonstrated that stretch on mucosa 
tissues drastically decreases urothelial thickness, increases the tight junction 
ring and decreases barrier function. What the consequences are of this more 
permeable urothelium on afferent signaling is still not clear, but in theory it could 
lead to increased excitability during bladder filling [Carattino 2013]. Damage or 
dysfunction of the umbrella cell layer also makes the urothelium more permeable 
and fragile [Sewada 2003]. Loss of TJ’s is seen in diseases that are characterized by 
increased bladder wall permeability like IC/BPS [Lavelle 2000].  
Adherence junctions (AJs)
The AJs are found throughout the urothelium but always distally from the tight 
junctions. The extracellular connections between neighboring cells are formed with 
E-cadherin proteins (Fig. 4F, 5E) and the intracellular component of the AJ consist 
of α-, β- and γ-catenins that connects to the actin cytoskeleton. The E-cadherin 
binding of the AJ’s is Ca²⁺ dependent and together with desmosomes, they are 
believed to form the basis for epithelial structure and organization [Jost 1989]. 
This structure and organization is lost during carcinogenisis of the urothelium 
which is characterized by a progressive loss of AJs, which can subsequently lead 
to increased cell migration and invasion capabilities of cancer cells [Bussemakers 
1996][Koga 2003]. The Ca²⁺ dependency of the AJs are also used in cell culturing 
techniques. EDTA is applied for depletion of extracellular calcium and this disrupts 
the E-cadherin binding of the AJs and promotes cell detachment. 
The actual qualitative contribution of AJs to the urothelial barrier is unknown, 
because other cell junctions, like the TJs, are dependent on the presence of AJs. 
This makes it impossible to measure the effects on barrier of AJ’s alone with TEER 
or permeability experiments. Because the AJs form the bridge between the actin 
cytoskeleton and the cell membranes of adjacent cells, they are considered as 
one of the important structures for transportation of mechanical forces across the 
urothelium [Goodwin 2004][Janssen 2011].   
Desmosomes  
Desmosomes are smaller type junctions that are also called macula adherens 
(Fig. 4F). They are present on the cell membranes of different epithelia, but also 
in muscle tissues [Jost 1989]. The junction consist of intracellular desmoplakin 
proteins that are attached to the keratin cytoskeleton on one side and on the 
other side to plakoglobin and plakophillin proteins (Fig. 5F). The latter two 
proteins connect to the extracellular part of the cell junction that consists of 
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desmoglein and desmocollin proteins. Like the AJs, the extracellular connections 
of the desmosomes are Ca²⁺ dependent and the main functions of desmosomes 
in the urothelium is cell adhesion and epithelial organization [Jones 2001]. 
Pathological disruption of desmosomes is the cause of rare types of blistering 
diseases in skin. But currently, we do not know of any bladder diseases associated 
with desmosome dysfunction. The only observation of involvement of desmosomes 
in urothelial disease was done by Veranic et al. who reported that desquamation 
of the urothelium caused by chronic damage or inflammatory stress resulted in a 
successive disruption of TJs, AJs and desmosomes [Veranic 2001]. There is no data 
on the isolated contribution of desmosomes to the bladder barrier.  
Integrins
Integrins are not considered true cell junctions, but more focal adhesion molecules. 
Integrins have many isoforms and are known to play a part in connecting the 
intracellular cytoskeleton to the extracellular matrix [Katsumi 2004]. It is one 
of the main cell signaling routes to which the cell receives information from its 
surroundings [Katsumi 2004]. This regulates mechanotransduction, cell growth, 
differentiation, migration and apoptosis [Bussemakers 1996]. The bladder 
urothelium contains α2-β1 and α3-β1 integrins throughout the urothelium, 
but some integrins like α6-β4 and α5-β4 integrins are more specific for the 
attachment of the basal cell layer to the urothelial basement membrane (Fig. 
5G) [Southgate 1995]. The effect of integrins on barrier is unclear. Kanasaki et 
al. studied the effects of β1 type integrins in a knockout mouse model and found 
no abnormalities in bladder wall permeability [Kanasaki 2013]. He did however 
detect increased bladder capacities and detrusor hyperactivity that suggest that 
integrins could play a role in mechanotransduction in the urothelium. 
3.2.4. Basement Membrane (BM)
Few attention is given to the urothelial basement membrane (Fig. 2BC). It is a 
thin layer consisting of mostly collagen type IV and laminin molecules and 
functions as an anchoring platform for the urothelial cell layers and to connect 
the urothelium to the suburothelium. It has an inner and an outer layer for its two 
main attachment sites. The anchoring of the basal urothelial cells is done with 
desmosomes and specific integrins (Fig 5FG). Not many structures penetrate the 
BM, but branches from afferent nerves that are located in the suburothelium are 
able to penetrate the membrane to allow for the innervation of the urothelium 
(Fig. 1, 7CD)[Gabella 1998] [Hawthorn 2000]. Currently, there is not much known 
about the involvement of the BM in urothelial health, barrier and disease. This 
lack of attention is somewhat strange considering that the BM is the foundation 
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on which the entire urothelium grows and could therefore be vital for normal 
urothelial development and repair. In our own study of the urothelial BM, we 
detected high expressions in the basement membrane of the heparan sulfate 
binding proteoglycan perlecan, and potentially also other sulfated GAGs like 
chondroitin sulfate (Fig. 2A-C). Proteoglycans are found in many different types of 
BMs and are thought to sustain layer polarity that is important for cell attachment 
and to form a barrier for proteins and electrolytes [Abrahamson 1986][Lamberg 
1974]. Heparan sulfate is also associated with diverse biologic processes like 
growth factor binding (Fig. 2B) [Hauser 2009] [Lamberg 1974]. The potential role 
of the BM in bladder disease is of interest. The BM of epithelia from other organs 
is affected by diseases like diabetes mellitus or different autoimmune diseases like 
Goodpasture syndrome (kidney & lung) or epidermolysis bullosa acquisita (skin) 
[Abrahamson 1986]. We know from other organs that the BM forms a functional 
barrier for (cancer) cells and bacteria [Abrahamson 1986]. Bacteria like E. Coli and 
Pseaudomonas aeruginosa, but also invasive cancer cells need to actively secrete 
enzymes like elastase to dissolve the collagen type IV in order to pass the BM 
[Abrahamson 1986]. There is also an interesting study in the bladder by Wilson 
at al. who reported a reduction of collagen type IV in the urothelial BM of IC/BPS 
patients [Wilson 1995]. 
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Figure 5. Immunohistochemistry results of stainings for barrier molecules and cell 
junctions in the urothelium. A) Chondroitin sulfate (GAG) (green) is expressed at the apical 
membrane of the human umbrella cells. B) Image of an uroplakin (brown) immunostaining 
of the porcine bladder. Uroplakins coat the apical membrane of umbrella cells C) 
Immunostaining of tight junctions (TJs; green) in mouse bladder show that TJs exclusively 
formed at the most apical membrane cell connections of neighboring umbrella cells. D) 
Tight junction expression (brown) in cultured porcine urothelial cells. Tight junctions are 
only formed when cultured cells are terminally differentiated and seal of the intercellular 
spaces. Only then does TEER significantly rise. E-G) Adherence junctions (E; green), 
desmosomes (F; red) and integrins (G; green) are formed throughout the urothelium of 
the human bladder. Image D was published in Janssen et al. 2013.
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4. Mechanosensation
4.1 Bladder neural control
The control over the urinary bladder is different from any other organ in the 
human body. The bladder wall has differently orientated muscle fiber layers that, 
when activated, contract to expel all or most off the urine inside the bladder. One 
can also sense the fullness of the bladder in various states, leading to changes 
in perceived necessity to void and thereby behavior. The bladder mucosa and 
specifically, the urothelium play an essential role in this stretch (mechano) 
signaling [Lewis 1984] [Fergusson 1997] [Fowler 2008] [Andersson 2002]. Bladder 
strip experiments with and without mucosa showed that the bladder detrusor 
muscle fiber excitability is diminished when the urothelial layer is removed 
[Ferguson  2015] [Chaiyaprasithi 2003] [Akino 2006]. Besides this, experiments 
on cultured urothelial cell monolayers show excretion of (neuro)transmitters 
after stretch [Charrua 2009] [Birder 2001].  But to understand the role of the 
urothelium in neural control and the pathophysiology behind overactive bladder 
syndrome (OAB) and detrusor overactivity (DO), we must also know how we 
normally control our bladder. 
What makes bladder control so different from other organs is that it is a 
semi-autonomous organ. That means that the rate the bladder expands and the 
force by which it expels urine (bladder contraction) is not under conscious control, 
but the initiation of voiding is. The bladder wall is innervated with parasympathic 
(cholinergic) nerve fibers from the sacral and pudendal nerve and with sympathic 
(adrenergic) nerve fibers from the hypogastric nerve. These cholinergic and 
adrenergic nerve fibers are located in the mucosal, detrusor and serosal areas 
and all contain efferent and afferent fibers [Andersson 2004]. It is believed that 
the afferent nerve fibers continuously convey the state of bladder filling, urethral 
stretch and flow and essential chemosensitive information such as inflammation 
and tissue damage [de Groat 2015]. Afferent nerves are not distributed 
equally across the bladder. The trigonal area, which originates from a different 
embryological structure, has a higher density of afferent nerves compared to the 
bladder dome [Spradling 2015] [Andersson 2002]. For voiding, we use cholinergic 
motor (efferent) nerves that innervate the detrusor and bladder neck area that, 
when activated: 1) contract the detrusor smooth muscle and 2) relax the bladder 
neck (internal sphincter) (Fig. 6, 7F) [Andersson 2004]. Impulses from afferent and 
efferent cholinergic nerves both travel through the parasympathic sacral nervous 
plexus that is located in the small pelvis and enter and exit the spinal cord at 
level S2-S4 (Fig. 6, 7F) [Fowler 2008] [Araki 1996]. Also located in the lower sacral 
area of the spinal cord is a group of motor nerves called Onuf’s nucleus. This 
37
Urothelium update Chapter 1
nucleus is located in the ventral horns of the sacral spinal cord and gives rise to 
the pudendal nerve that controls the striated muscles of the external urethral 
and anal sphincters. This is a somatic nerve, which means that these sphincters 
are under direct conscious control. It uses predominantly nicotine receptors for 
sphincter activation [Thor 1989] [Chancellor 2004]. The pudendal nerve also has 
afferent fibers and nerve density in the proximal urethra and external sphincter 
region is high (Fig. 6, 7E) [Andersson 2002]. 
Figure 6. Schematic figure, neural control of the urinary bladder. The bladder, bladder 
neck and urethra (external urethral sphincter; EUS) are innervated with parasympathic 
(Sarcral N. Plexus and N. Pudendus) and sympathic (N. Hypogasticus) nerves. All have 
afferent and efferent branches. Sacral nerves promote detrusor contractions via 
acetylcholine (ACh) and primarily M3 receptor activation, while the N. Hypogasticus 
inhibits detrusor contractions via stimulation β3 receptors with primarily noradrenalin 
(NE). The N. Hypogastricus also stimulates the striated muscles of the internal sphincter 
in the bladderneck with α1 receptors. The N. Pudendus innervates the EUS and contracts 
striated muscles by activating Nicotine (N) receptors. The N. Pudendus is under voluntary 
control. For coordination between bladder (detrusor), bladder neck (internal sphincter) 
and EUS, there is communication between these nerves on spinal cord level. The main 
control over these spinal cord reflexes is located in the pontine micturation center (PMC) 
in the brain stem. The PMC is our storage/void switch. The PMC is under the influence 
of the periaqueductal grey (PAG) center that receives the sensory information from the 
afferent nerves of the lower urinary tract. All 3 nerves that innervate the bladder and 
urethra have afferent nerve fibers that signal sensory information like bladder filling and / 
or urethral stretch. The PAG communicates with the higher brain centers (cortex and limbic 
system) and through this connection, we can consciously intervene in the storage voiding 
pathways and initiate voiding.         
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To inhibit spontaneous bladder contractions, we use another nerve, called 
the hypogastric nerve (Fig. 6). This sympathetic nerve descends from of the 
thoracolumbar area (Th11-L2) of the spinal cord and infiltrates the bladder 
wall [Janig 1991]. It uses noradrenalin to inhibit the detrusor muscle fibers by 
stimulating the β3-receptors in the bladder dome, but excites the internal 
sphincter muscle fibers in the bladder neck area using α1-receptor stimulation 
(Fig. 6) [de Groat 2015] [Andersson 2002] [Janig 1991] [Kadow 2016].
Before entering the spinal cord, afferent impulses travel through dorsal root ganglia 
at the designated spinal cord levels (Fig. 6). Much of this anatomical mapping in 
the spinal cord has been done by quantifying nuclei of activated neurons that 
express c-fos (Fig. 7G-I) [de Groat 2015]. 
It is believed that sensation of bladder fullness comes from predominantly 
the sacral nerve afferents, but sensations that occur during a full bladder and 
imminent voiding also uses afferents from the pudendal nerve [Andersson 2002]. 
Besides this, there is convincing evidence that the afferents of the hypogastric 
nerve in the bladder dome and bladder neck are also activated during bladder 
filling [Moss 1997] [Gosling 1999]. Moss et al. demonstrated in a rat model that 
both sacral and hypogastric afferents are activated by bladder filling, but the 
hypogastric nerve has afferents that are more sensitive to chemical stimuli [Moss 
1997].  
The first step in bladder neural control is to interpret the mechanosensory 
information that originates from the receptors in the bladder wall (Fig. 7AB, 8). 
The afferent signals from sacral, pudendal and hypogastric nerves travel from 
the bladder wall and enter the spinal cord at different levels to progress to the 
designated areas of the central nervous system (periaqueductal grey, pontine 
micturition center, limbic system and cortex)(Fig. 6) [Fowler 2008]. Signaling could 
also be mediated through intramural cholinergic and adrenergic ganglia that have 
been identified in the human bladder body, trigone and bladder neck [Dixon 1983 
and 1996]. The pontine micturition center (PMC) is located in the brain stem and 
functions as our voiding switch [de Groat 2015]. The PMC is under the influence 
of the periaqueductal grey and higher brain centers and it is the site where our 
conscious decisions can influence the spinal reflexes. The PMC is designed to 
1) organize coordinated storage (bladder relaxation/urethral contraction) and 
voiding (bladder contraction/urethral relaxation) and 2) control the start and 
end of voiding by controlling the detrusor excitability and efferent (motor) sacral 
nerves that initiate detrusor contractions. 
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Only by voluntary relaxing our external urethral sphincter through the pudendal 
nerve and by releasing of the inhibition through the hypogastric nerve, do we give 
back the control to the activating bladder reflexes and start voiding [Andersson 
2002]. This means that sacral nerve causes: 1) the internal sphincter to relax, and 
2) the detrusor muscle fibers to contract. After voiding, the hypogastric nerve 
is reactivated via the PMC and the storage phase starts again. Learning to fully 
control your bladder is one of the most difficult tasks in children’s development. 
Neural control over the motor function of the bladder only makes sense when 
there is appropriate information about the filling state of the bladder. Bladder filling 
sensation is measured in the bladder wall and is dependent on mechanoreceptors 
on afferent nerves or other cell types like urothelial cells and ICC’s [Zagorodnyuk 
2006]. Shae et al. and Zagordnyuk et al. have done detailed work on the different 
type of afferents that innervate the bladder. Shea at al. studied the rat bladder 
afferents with electrophysiological recordings and reported that approximately 
60% of bladder afferent nerve fibers are sensitive to slow volume increases with a 
low threshold of 10cmH2O and that the majority was located in the bladder body 
and not the base. The other afferents consisted of either high threshold near the 
uretho-vesical junctions and of chemosensitive fibers [Shae 2000]. The results of 
this study did not find a real pattern of c-fiber specific chemoactivation and Aδ 
specific mechanosensation, since they discovered that in their samples, there were 
many c-fibers that also responded to slow bladder volume increases. Zagorodnyuk 
et al. suggested that depending on the location of the mechanoreceptor, they 
can either directly (receptor located on nerve) activate afferent nerves, or 
chemically activate them using (neuro)transmitters (receptor located on other 
cell type) [Zagorodnyuk 2006 and 2007]. There are multiple hypothesis where 
and how the increase in stretch of the bladder wall is measured. Experiments 
with bladder strips with and without mucosa, showed that there is evidence for 
mucosa independent and mucosa dependent mechanosignaling in the bladder 
wall [Chaiyaprasithi 2003] [Nguyen 2000] [Andersson 2002] [Birder 2013] [de 
Groat 2015]. This statement is based on the identification and characterization 
of at least four different types of afferent nerves in the bladder that have 
mechanosensory properties [Zagorodnyuk 2007] [de Groat 2015]. These are: 1) 
Muscle stretch-sensitive mechanoreceptors, 2) Muscle-Mucosal stretch-sensitive 
mechanoreceptors, 3) Mucosal high-responding mechanoreceptors and 4) 
Mucosal low-responding mechanoreceptors. The first two respond to bladder 
wall stretch, the latter two respond to mucosal stroking (Zagorodnyuk et al. 
2007) (de Groat et al. 2015). To further facilitate mechanosignaling, there is an 
additional hypothesis that rhythmic microcontractions occur in the bladder wall 
that help to continuously measure the fullness of bladder, like one would do when 
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probing the fullness of an air-filled balloon by gently squeezing it [Drake 2003] 
[Sibley 1984] [Fry 2007]. Non-voiding contractions are however normally seen 
in rodent cystometry measurements, but are not observed in normal human 
urodynamics. The large network of ICC’s in the bladder may help to regulate 
these microcontractions using interconnecting gap junctions and NO and cGMP 
signaling [Kanai 2014][Ikeda 2006][Gillespie 2005] [Juszczak 2014]. 
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Figure 7. Afferent signaling in the bladder. A & B) immunofluorescence stainings of the 
mechanosensory cation channel TRPV4 (A; green) and the capsaicin sensitive channel 
TRPV1 (B; green) in the rat urothelium. Urothelium host many different receptors that 
play an important role in normal bladder filling sensation and afferent signaling during 
inflammation. C & D) CGRP expressing nerves (green) in the mouse bladder are located in 
the suburothelial space, but also seem to penetrate into the urothelium (yellow arrows). E) 
CGRP expressing nerves (green) in the mouse bladder are located in the proximal urethra, 
but also at the nervous plexus (ganglia can be seen in grey) located adjacent to the 
proximal urethra outside the bladder (red arrows). F) The ganglia in the same area as seen 
in E, express Vesicular AcetylCholine transporter (VACht; green) (blue arrows), implying 
cholinergic signaling. G) Transection of a mouse sacral spinal cord segment (L6-S1). 
Afferent information from the bladder enters the dorsal horn area (DH) via the dorsal 
root ganglia. H) shows immunohistochemical staining of c-fos + nuclei (arrow) in the DH 
of L6-S1 spinal cord region in mouse. This mouse is treated with noxious distention of the 
bladder after which c-fos is produced in nuclei of neurons in mostly the superficial lamina 
of the DH in the L6-S1 spinal cord region. The amount of C-fos + nuclei corresponds to the 
amount of afferent signal and is applied as marker for afferent signaling  I) shows a similar 
image of a DH of the L6-S1 spinal cord level, but in a LPS treated mice, causing bladder 
inflammation. Arrows show a distinct increase in c-fos + nuclei in the superficial lamina 
of the L6-S1 DH in a mouse with bladder inflammation compared to the non-inflamed 
bladder (H). Images A-F unpublished material. G-I unpublished images from Janssen et al. 
[Janssen 2016]
4.2 The involvement of the mucosa in bladder neural control
So what is the exact role of the bladder mucosa in afferent signaling? For long, it 
is known that the urothelium is packed with sensory receptors including chemical, 
mechanosensory and even thermal receptors [Andersson 2002][Charrua 2009]. 
Examples of these are: Muscarinic receptors, Epithelial Sodium channels, 
TRP-channels, Purinergic receptors, Prostaglandin receptors and Growth Factor 
receptors [Andersson 2002] [Rong 2002] [Everaerts 2010] [Lewis 1984] [Kullmann 
2008]. Besides this, urothelial cells are also capable of releasing multiple signaling 
molecules, some of which were previously thought that they could only be 
secreted by nerve cells [Andersson 2002] [Birder 2013]. Examples of these are 
acetylcholine (ACh), nitric oxide (NO) and ATP. Central in afferent signaling is 
cellular calcium ion (Ca²⁺) movements. All pathways in afferent signaling directly 
or indirectly intervene in the concentration of Ca²⁺ in the cytoplasm of the 
urothelial cells [Andersson 2002]. Basic research has shown that there are afferent 
nerve fibers that protrude the urothelial basal membrane and that the lack of an 
urothelial layer, severely inhibits the afferent signal that is essential for normal 
bladder sensation (Fig. 7CD)  [Gabella 1998][Hawthorn 2000]. Bladder filling 
creates tension in urothelial cell layers. This tension is distributed between the 
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cell membrane, cell junctions and the intracellular cytoskeleton [Veranic  2001]
[Goodwin 2004]. Applying stretch to mucosal side of bladder tissues in Ussing 
chamber experiments, showed that the apical cell membranes of the umbrella 
cell adapt to increasing tension by increasing surface with vesicular exocytosis 
and they detected that this discoid vesicle transport is guided by the intracellular 
cytokeratin network [Yu 2009] [Khandelwal 2010] [Veranic 2001] [Wang 2005] 
[Lewis  2006]. This does affect the mucosa as a mechanosensory layer Studies 
from Lewis et al., Yu et al. and Khandelwal et al. showed that different types of 
stretch influence ATP dynamics in the urothelium [Yu 2009] [Khandelwal 2010].   
There are also signs that the urothelium has an neuroendocrine function. 
Hanna-Mitchel et al. identified corticotropin excreting urothelial cells in an feline 
interstitial cystitis model and suggested that these cells could play a role in altered 
urothelial function in bladder pain syndrome [Hanna-Mitchel 2014]. Birder et 
al. also described increased NGF and substance P in the same feline model and 
suggested this could be the cause of the enlargement of the DRG ganglia seen in 
the feline interstitial cystitis [Birder 2010].
The receptors found on the urothelium are also believed to be involved in 
diseases like OAB [de Groat  2004][Fowler 2008]. The basic hypothesis is that 
under normal conditions, afferent signaling is almost exclusively dependent 
on mechanoreceptors. However, during situations like urothelial damage, 
inflammation or other chemosensory abnormalities, the afferent signal is 
potentiated by the activation of chemoreceptors and mechanoreceptors on 
additional, normally silent or high threshold afferent nerves (predominantly 
the unmyelated C-nerve fibers). An overexpression of specific receptors or 
abnormalities in (neuro)transmitter excretion in the urothelium is thought to 
be one of the causes behind OAB and urgency sensations [Andersson 2004] [De 
Groat 2004]. This makes the urothelium a therapeutic target in the development 
of OAB treatments. 
This strategy is based on the idea that inhibition of normal mechanoreceptors 
or abnormally expressed mechano- and chemoreceptors, could both reduce 
urgency sensations and inhibit the motor excitability part of the bladder sacral 
reflex to prevent DO. This idea is supported by bladder strip experiments with and 
without urothelium from Chaiyaprasithi et al. that showed that contractility of 
the detrusor muscles is inhibited in absence of an urothelial layer [Chaiyaprasithi 
2003]. This part of the review focuses on the mucosal pathways and the role of 
urothelium in bladder filling mechanosignaling because it is essential that we 
understand the normal physiology behind bladder mechanosensation and current 
evidence shows that this topic is complex. Sadly, also in the urothelium, there is no 
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exclusive stretch receptor that is responsible for bladder filling sensation. Evidence 
puts forward that urothelial mechanosensation involves at least two dominant 
pathways and multiple receptors. The next section explains the evidence of these 
signaling pathways, the involved mechanoreceptors and their interactions. 
4.3 Signaling pathways and molecules
Adenosine Triphosphate (ATP) pathway
ATP is the vital energy transportation molecule in living cells. During the glycolysis 
and citric acid cycle, low energy containing adenosine diphosphate (ADP) is 
converted into the high energy molecule ATP. Considering that energy storage 
is crucial for survival, it is quite remarkable that ATP is also actively excreted by 
urothelial cells during bladder wall stretch and that it is one of the most important 
afferent signaling molecules in the bladder [Lewis 2006][Ferguson 1997]. Different 
studies have investigated ATP excretion physiology in bladder stretch experiments 
on mostly rodent models, but also on cultured urothelial cell layers [Ferguson 
1997 and 2015] [Vlaskovska 2001]. These studies demonstrated and increase of 
ATP excretion during bladder stretch. ATP excretion by the urothelium goes by 
the means of two routes: 1) the apical route that is thought to be the driver of 
vesicular exocytosis which is a dynamic process that takes place in the umbrella 
cell apical membrane that modulates cell membrane turnover and is important 
for barrier function, 2) a basolateral route that is important for ATP driven 
afferent signaling [Wang 2005][Lewis 2006]. Fusion of membrane bound discoid 
vesicles in vesicular exocytosis is mechanically achieved through a connection 
between the disc shaped vesicles and the cytoskeleton and molecularly driven 
by intracellular Ca2+, cyclic adenosine monophosphate (cAMP), protein kinase 
A (PKA) concentrations and epidermal growth factor receptors (EGFr) [Truschel 
2002] [Wang  2005] [Balestreire 2007]. ATP excretion in both apical and basolateral 
routes correlate to the amount of bladder wall stretch [Lewis 2006]. Besides this, 
exposure to hypo-osmotic solutions (cell swelling) can also trigger ATP release 
by the urothelium (cell swelling) and could be important in chemoreception 
during bladder inflammation [Lewis 2006]. In the apical route, ATP is (partly) 
excreted via exocytosis and activates purinergic (P2X3/P2Y) receptors on the 
luminal cell membrane [Wang 2005]. This stimulates further vesicular exocytosis 
and is believed to form a positive feedback loop. For the basolateral route, ATP 
activates purinergic receptors on afferent nerves and ICC’s in the mucosal area 
and could potentially even directly affect the nerves, ICC’s and smooth muscle 
cells in the detrusor layers [Elneil 2001][Lewis 2000]. Basolateral excreted ATP 
can be controlled with ecto- and endonucleotidases on the cell membranes and 
it is suggested that this process can modulate the afferent ATP signal [Yu 2006]
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[Lewis 2006]. Adenosin is a breakdown product of ATP and forms a negative 
feedback loop for afferent ATP signaling [Dunning-Davies 2013]. Dunning-Davies 
et al. demonstrated that the application of adenosin to the urothelial basolateral 
side inhibitis basolateral ATP excretion. Studying the effects of botulinum toxin 
A on urothelium cell cultures revealed a function of SNARE proteins in urothelial 
ATP excretion. Hanna Mitchel et al. discovered that botulinum toxin A exposure 
inhibits SNAP23 and SNAP25 in urothelial cells [Hanna-Mitchell 2015]. ATP is 
currently used in many preclinical in vitro and in vivo bladder models as a good 
marker for increased afferent signaling and mechanosignaling [Lewis 2006]. 
There are multiple hypothesis on receptors that trigger or influence the increase 
of intracellular ATP in the urothelium during stretch. Most investigated are 1) 
the Epithelial Sodium Channel (ENaC), 2) Purinergic receptors 3) the Transient 
Receptor Potential Vanilloid subtypes 4 (TRPV4) and 1 (TRPV1) 4) the Muscarinic 
(M3) and Nicotinergic receptors (Fig 7AB, 8). Their modes of action will be 
discussed separately.    
Cholinergic pathway.
The paraympatic nerve system, including the sacral nerves that innervate the 
bladder, use acetylcholine (ACh) as neurotransmitter (Fig. 6, 7F). ACh is mostly 
known as the neurotransmitter that activates muscle fibers [Dixon 2000]. ACh is 
excreted by parasympathic nerves in the neuromuscular junction and activates the 
muscarinic (mostly M3) receptors on the membrane of the smooth muscle cells, 
after which the muscle fibers contract [Fowler 2008]. This was used as a principle 
behind the use of M3 blockage with anticholinergics and intradetrusor botulinum 
toxin infections to combat detrusor overactivity in OAB [Chapple 2015]. Only later, 
it was discovered that ACh plays a much bigger role in the bladder and that it was 
also involved in afferent signaling (Fig. 8)[Yamaguchi 2010]. It was demonstrated 
that urothelial cells can produce and excrete ACh and that there are M3 and 
Nicotine receptors expressed on the urothelial cell membranes [Zarghooni 2007] 
[Beckel 2006] [Mansfield 2005] [Hanna-Mitchel 2007]. Immunohistochemistry 
and PCR techniques also helped to identify other muscarinic receptor subtypes 
in the human bladder urothelium which has opened the idea that cholinergic 
signaling in the urothelium is more complex than previously thought [Bschleipfer 
2007] [Mukerji 2006]. Bschleipfer et al. showed that all 5 muscarinic receptor 
subtypes are found in the urothelium and that it is actually the M2 receptor that 
has the highest expression. M2 receptors are localized in the umbrella cells and 
M3, M4 and M5 are also abundant throughout all layers, whilst M1 receptors 
seem to be confined to the basal cell layers [Bschleipfer 2007]. Besides this, 
muscarinic receptors are expressed by afferent nerves (M3) and ICC’s (M2,M3) 
in the suburothelium [Yoshida 2006]. The importance of ACh in afferent 
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signaling can also be observed in the urological clinic, because we now know 
that anticholinergics and even intradetrusor Botulinim toxin injections also have 
significant positive effects on urgency symptoms of OAB dry patients that do not 
have detrusor overactivity [Rovner 2011].      
How the intracellular ACh concentration increases during bladder stretch is still 
not clear. But after ACh is formed, it is excreted by the urothelial cell where 
it is believed to activate M2 and M3 receptors on afferent nerve fibers and 
ICC’s in the suburothelium [Zarghooni 2007]. Kullmann et al. showed in a rat 
model that stimulating rat bladder with the muscarinic agonist oxotremorine 
methiodide resulted in increased excitation of the bladder that could be abolished 
by using the antimuscarinic atropine [Kullmann 2008]. They also showed increased 
ATP excretion and intracellular Ca²⁺ release in urothelial cell cultures after 
oxotremorine methiodide  exposure [Kullmann 2008]. This study also showed 
that only M1, M2 and M3 receptors activation stimulate ATP excretion. Birder 
et al. suggested that ACh exposure also induced a potential negative feedback 
loop. They showed that activated M3 and Nicotinergic receptors in urothelial cells 
stimulate not only intracellular Ca²⁺-influx and ATP secretion, but also increases 
NO which is believed to be an inhibiting transmitter for ATP production (Fig. 8) 
[Birder 2013].    
Other pathways for mechanosignaling
The pathways for mechanosignaling that have been discussed are involved in 
direct bladder filling sensation. These systems can however be affected indirectly 
through other pathways (Fig. 8). There are for instance the much studied effects 
of neurotrophins like NGF and BDNF that modulate the excitation levels of bladder 
muscles and afferent nerves [Cruz 2014] [Ochodnicky 2012]. There is also an 
autocrine pathway for mechanosignaling in umbrella cells through the Epidermal 
Growth Factor Receptor (EGFr) / tyrosine kinase pathway [Balestreire 2007]. 
From all the evidence of receptors involved in afferent signaling, we can 
conclude that there is much overlap in bladder afferent mechanosignaling and 
chemosignaling. Many receptors and pathways like tachykinin, TRPV1, Bradykinin 
or prostaglandin signaling pathways are believed to act as pain or tissue 
damage modulators, but many of these receptors also potentiate the afferent 
mechanosignal in pathological conditions. Nonetheless, there is evidence that 
some of these receptors could also mediate in normal stretch responses [Charrua 
2009][Birder 1998] [Rahnama’I 2010] [Chopra 2005] [Andersson  2002]. For 
example, Chopra et al. identified bradykinin receptor subtype 2 in the normal 
rat bladder, but in the cyclophosphamide inflamed rat bladder, upregulation of 
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the bradykinin receptor subtype 1 was also detected. Exposing the rat bladder 
to bradykinin increased bladder reflex activity that could be inhibited with the 
B1 antagonist des-Arg(10)-Hoe-140 or the B2 antagonist Hoe-140 [Chopra 2005]. 
Similar effect are described for the role of Nitric Oxide (NO) in mechanosensation. 
NO in is produced by the urothelium by the enzyme Nitric Oxide Synthase (NOS), 
that has different isoforms (Birder et al. 2002₂ and 1998). It is also believed to 
play a crucial role in chemosensation in inflammation using prostaglandine 
and bradykinin pathways [Rahnama’I 2010] [Chopra 2005]. But contrary to the 
previously mentioned pathways, there is evidence that urothelial NO has an 
inhibitory effect on the ATP pathway for afferent mechanosignaling [Munoz 2011] 
[Andersson 2002] [Mumtaz 2000). NOS and NO are produced by stimulating 
β3-adrenoreceptors on urothelial cells with β-adrenoreceptor agonists (Fig. 
8) [Masanuga 2010] [Birder 1998, 2002₂] [Harmon 2005]. Increasing NO in the 
urothelium could therefore potentially reduce OAB symptoms and clinically used 
β3 receptor agonists may also have a beneficial impact on urothelial sensory 
pathways and urgency symptoms. 
4.4 Mechanoreceptors
Purinergic receptors
There are multiple purinergic receptors expressed in the bladder mucosal area 
(P2X and P2Y isoforms) [Elneil 2001] [Cockanye 2005] [Chen 2010] [Birder 2004]. 
They were initially thought of as receptors that were only involved in inflammatory 
responses and urgency sensation [Tempest 2004]. For afferent signaling, the most 
investigated receptors are the P2X3 and P2X2/3 receptors that were located on 
urothelial cell membrane and in afferent nerve fibers [Birder 2004] [Wang 2005] 
[Vlaskovska 2001]. Even ICC’s express purinergic receptors [Vial 2000]. We know 
now that these purinergic receptors are important for normal bladder filling 
signaling and for vesicular endo-/exocytosis (Fig. 8) [Ford  2011] [Wang 2005]. 
Purinergic receptors are activated by ATP and activation of purinergic receptors 
on afferent nerves can evoke a neural discharge [Rong 2002]. Much of what we 
know about P2X receptor function in the bladder comes from studying knockout 
mice models. Vlavoska reported for instance, that the P2X3 knockout mouse 
phenotype is less responsive to bladder wall stretch, despite normal urothelial 
ATP production in these mice [Vlaskovska 2001]. Ferguson et al. demonstrated in 
mice that removal of the urothelium augments the contractile bladder response 
to purinergic activation by ATP [Ferguson  2015]. Both P2X2 and P2X3 receptors 
expression patterns appear to be altered in IC/BPS and OAB patients implying an 
involvement of these channels in pathophysiology [Tempest 2004][Birder 2004]
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[Moore 2001]. The non-afferent signaling pathway in which purinergic receptors 
play a role is the previously mentioned vesicular endo-/exocytosis process in 
umbrella cells. P2X receptor and possibly P2Y activation on the umbrella cell 
membrane is crucial for maintaining ATP driven vesicular exocytosis and Wang et 
al. showed that this process is inhibited in P2X3 and P2X2 knockout mice [Wang 
2005]. It is currently not clear what impact the vesicular endo-/exocytosis process 
has on mechanoreceptor expression on the umbrella cell apical membrane, 
but there is a chance that this process could help to modulate purinergic-ATP 
mechanosignaling in the urothelium (Fig. 8).         
Epithelial Sodium Channel (ENaC). 
The bladder wall upholds a negative electrical potential difference (also called 
transepithelial potential). This is done by active sodium transport from the 
mucosal side to the serosal side of the bladder wall [Smith 1998] [Ferguson 1997]. 
The Epithelial sodium channels (ENaC) are predominantly responsible for this 
transport. ENaCs belong to the degenerin /ENaC gene family and are present in 
the bladder urothelium and consist of alpha-, beta- and gamma subunits [Garty 
1997]. It is believed that there are amiloride dependent and amiloride independent 
ENACs [Fergusson 1997]. Lewis et al. already investigated these channels in the 
rabbit bladder in the 1980’s and showed that stimulating ENAC’s with aldosterone 
increases sodium uptake by urothelial cells which also had a stimulating effect 
on vesicular exocytosis [Lewis 1984 ₁ ₂, 1985]. Ussing chamber experiments by 
Ferguson et al. showed that small pressure changes in the rabbit bladder evoke 
potential changes that can be inhibited with the specific ENaC blocker amiloride 
[Ferguson 1997]. They also confirmed that ENaC stimulation with hydrodistention 
corresponds with mucosal ATP release towards the basal / serosal side of the 
bladder wall and that this process could be reduced with amiloride, implying that 
ENaCs are important mechanoreceptors for mechanosensation and drivers of the 
ATP pathway. These results were verified with Ussing chamber tests on rat bladders 
by Wang et al. who demonstrated that during stretch, Na⁺ is taken up by ENaCs 
and K⁺ and Cl⁻ is excreted by urothelial cells. This sodium uptake is maintained by 
Na⁺-K⁺-ATPase, K⁺-channels and Cl⁻ channels to maintain this continuous electrical 
gradient that potentially mediates in Ca²⁺ and ATP movements [Wang 2003]. It 
appears that the processes of vesicular exocytosis is not influenced by amiloride 
[Lewis 1991]. This further enhances the hypothesis that apical and basolateral 
routes of ATP excretion contribute to different functions in the urothelium (Fig 8). 
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TRPV1 & TRPV4
TRPV1 and TRPV4 are both part of a family of non-selective Ca²⁺-permeable 
cation channels that are activated by a wide variety of stimuli [Everaerts 2008]. 
This large family of ion channels has many diverse functions in the body. Both 
TRPV1 and TRPV4 are located on the cell membranes of urothelial cells in humans 
and many other mammals (Fig. 7AB) [Everaerts 2008][Everaerts 2010₁]. But PCR 
experiments also demonstrated that other TRP-channels like TRPV2, TRPM8 and 
TRPA1 are also present in the bladder urothelium of which the latter is involved in 
cold signaling [Everaerts 2010₂]. Activation opens TRPV1 and TRPV4 channels and 
causes an influx of Ca²⁺ into the cell. Interest in the potential role of TRP-channels 
in bladder function started after first discovering the capsaicin sensitive TRPV1 
channel in the urogential tract. TRPV1 channels are activated by temperature and 
chemical stimulation [Charrua 2009]. TRPV1 was first considered to be a receptor 
for inflammatory and pain responses [Birder 2002₁] [Charrua 2006]. This was 
because TRPV1 channels were thought to be specific for silent (noxious) afferent 
C-fibers. TRPV1 channels are however also expressed by urothelial cells (Fig. 7B) 
[Birder 2001]. Birder et al. studied the TRPV1 channel in a TRPV1 knockout (-/-) 
mouse model and detected an increased bladder capacity and a decrease in ATP 
excretion during bladder distention, implying that the TRPV1 receptors may also 
regulate normal bladder filling mechanosignaling [Birder 2002₁]. Charrua et al. 
confirmed these results by detecting an increase in urothelial ATP excretion after 
TRPV1 activation [Charrua 2009] [Matos 2016]. OAB is associated with C-fiber 
activation and bladder instillation with TRPV1 agonists like capsaicin or the 
superagonist resiniferatoxin have been clinically applied in humans to desensitize 
these normally silent nerves to reduce the symptoms of OAB. 
The presence of TRPV4 was later discovered to be the most abundant TRP channel 
in the urothelium (Fig. 7A) [Mochizuki 2009] [Everaerts 2010₁]. TRPV4 channels 
are found throughout the body and are involved in mechanosensation, but also 
other processes like heat-cold detection, hearing, pain and vision [Everaerts 
2008] [Suzuki 2003₂]. A TRPV4 knockout mouse was developed that had a 
remarkable phenotype with severe bladder dysfunction [Gevaert 2007] [Janssen 
2016]. Gevaert et al. studied the phenotype and discovered that these mice had 
a incontinent like voiding pattern, a late cystometric response to bladder filling 
and reduction of stretch induced ATP excretion by urothelial cells [Gevaert  2007] 
[Everaerts 2010₂] [Mochizuki 2009]. Alterations in bladder afferent signaling 
could be seen on spinal cord level in a TRPV4 knockout mouse model that was 
investigated by Janssen et al. (Janssen 2016). Evidence from a study on TRPV4 
channels in the (flow sensitive) epithelial cells of the distal nefron in the kidney 
revealed that after activation of TRPV4 channels, ATP and purinergic signaling 
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further stimulates TRPV4 channels to maintain a continuous Ca²⁺-plateau in these 
cells and that this is inhibited by with blocking TRPV channels with ruthenium red 
or TRPV4 knock-down [Mamenko 2011]. Together this led to the hypothesis that 
TRPV4 is involved in bladder mechanosensation. How TRPV4 measures urothelial 
stretch in a very flexible organ was unclear. Research on TRPV4 locations in 
epithelial layers led to the discovery that TRPV4 channels are connected to the 
intracellular actin cytoskeleton. Janssen et al. demonstrated that there were 
specific connections between TRPV4 channels and the adherence junctions 
on the cell membranes in the urothelium [Janssen 2011]. These rigid junctions 
provide the anchoring points between adjacent urothelial cells and are connected 
to the actin cytoskeleton that can transmit the mechanical forces within the cell 
[Goodwin 2004]. Suzuki et al. demonstrated that TRPV4 channels are linked to 
the actin cytoskeleton by MAP proteins and that this connection enhances the 
stretch activation responses of the TRPV4 channel [Suzuki 2003₁]. We previously 
mentioned that the actin cytoskeleton is also involved in the vesicular endo-/
exocytosis processes in the umbrella cell, but we do not know if TRPV4 channels 
mediate in this process. TRPV4 antagonists and agonists have been developed 
and tested in vivo [Everaerts 2010₂] [Thorneloe 2008]. These experiments 
demonstrated that inhibiting TRPV4 channels with antagonist in mice showed a 
clear reduction in bladder filling responses and inhibited ATP responses [Everaerts 
2010₂]. Human trials with TRPV4 antagonist, have so far not been reported. 
Other potential receptors in mechanosignaling
There are multiple other receptors that could contribute to mechanosensation 
in the urothelium, albeit they have been studies less compared to the previously 
mentioned receptors. Another candidate receptor for mechanosensation is 
a group of potassium channels. Wang et al. studied the presence and role of 
different potassium channels in umbrella cells of mouse bladders and discovered 
the presence of multiple channels in the basolateral side of the umbrella cell 
and that stretch does evoke a K+ dependant signal in these cells [Ferguson 1997] 
[Wang 2003]. Finally, there are mechanoreceptor candidates that are of interest 
like the mechanosensitive ion channel (MSC or MscL), Pannexin-1 channels or 
the Piezo-1 receptors. All these receptors are present in the urothelium and 
have stretch evoked responses (Fig. 8) [Olsen 2011] [Beckel 2015] [Negoro 2014] 
[Volkers 2015] [Miyamoto 2014].   
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Figure 8. Hypothetical model of sensory pathways for urothelial afferent signaling. 
ATP pathway via the basolateral route is activated by mechanical stretch which activates 
mechanoreceptors (multiple candidates) on the cell membrane. This promotes increase of 
intracellular Ca2+ from extracellular (cation channel activation) and intracellular stores via 
protein kinase A (PKA) pathways and cAMP. ATP is produced and excreted by the urothelial 
cell and activates purinergic receptors (P2X / P2Y) on afferent nerves and ICC’s that are 
located in the suburothelium / lamina propria (or nerve endings in the urothelial layer). 
EGFr receptor activation also promotes ATP excretion. Extracellular ATP can be converted 
to adenosine at the basolateral side and adenosine activates the adenosine receptor-1 
(AR-1), which inhibits the ATP pathway by inhibiting PKA. In the cholinergic pathway, ACh 
is produced by the urothelium during stretch. The driving mechanism is unknown. ACh 
is excreted outside the cell and activate prodominantly M3 receptors and perhaps M2 
receptors on Afferent nerves and ICC’s. There is an feedback loop where ACh activates M3 
and Nicotine receptors on the urothelial cell membrane which increase or modulates ATP 
production. The Adrenergic/ NO pathway is more inhibitory. Like detrusor muscle fibers, 
the urothelial cells also contain β3 adrenal receptors. Noradrenalin (from perhaps neural 
origin) promotes NO synthesis in the urothelial cell via the enzyme NOS. Excretion of NO 
inhibits ATP pathways and therefore inhibits afferent signaling. Other pathways include 
noxious pathways that can potentiate the afferent signal. Inflammation causes activation 
of chemoreceptors on the urothelium, the ICCs and on the normally silent high threshold 
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C-fiber nerves. These latter nerves will activate and initiate noxious afferent signaling. Also 
noxious stretch (overdistention) activates high threshold mechanoreceptors on normal Aδ 
and silent C-fibers and potentiate the afferent (noxious) signal. NGF is believed to modulate 
afferent nerve signaling on different levels by modulating afferent receptor expression on 
urothelial cells and nerves. Finally, the process of vesicular endo-/exocytosis may perhaps 
also modulate afferent receptor expression on the apical membrane of umbrella cells. It is 
still unknown if this has an impact on total afferent signaling.
5 Summary
The key structures that make the urothelium so impermeable have largely been 
identified and some of them thoroughly investigated. There are however still 
many unknowns about the roles of different proteins on the apical umbrella 
cell membrane like the mucins, lectins and proteoglycans that need further 
studying. What we currently know is that barrier function in the urothelium is 
not a static, but a very dynamic process. Especially in the apical cell membrane 
of the umbrella cells. There are difficulties in this type of research. In many cases 
like cell junction formation, the epithelial barrier function of these juctions runs 
parallel with epithelial structure and organization functions. Different types 
of cell junctions therefore interact and this makes it difficult to single out the 
individual role in barrier function for each type of cell junction. Therapies, like 
GAG replenishment therapies that aim to strengthen the bladder barrier seem to 
help IC/BPS patients, but do not produce any satisfying long term clinical results. 
The disease and economic burden of bladder inflammatory diseases and urine 
tract infections is very high and antibiotic resistance is becoming an increasingly 
difficult problem. There is therefore a real clinical demand to create new and 
better therapies that increase or restore the natural bladder barrier. The focus 
of future research should be to improve the understanding on how individual 
components of the urothelial barrier interact in this dynamic process to create 
the most impermeable epithelium in the human body and to investigate how 
these processes are mediated during urothelial injury and disease. 
The role of the urothelium in afferent mechanosignaling is evident, but 
complex. We know that mechanosignaling in the bladder wall is processed in 
different layers. There is convincing evidence that there is interaction between 
these different layers and that the urothelium plays a crucial role in afferent 
mechanosignaling. The role of the umbrella cell is by far the most studied, but 
there is a need to figure out what the contribution of the basal and intermediate 
cells are in mechanosignaling. Many different pathways and receptors have been 
investigated and compounds have been tested in vitro and in vivo to see if they 
are suitable for OAB treatments. The fact that this has currently not produced a 
52
Urothelium updateChapter 1
large collection of effective and specific drug treatments, is a clue that we still do 
not know enough of the complete physiology of mechanosignaling in the bladder. 
The more we know about normal mechanosignaling in the bladder, the more likely 
we are able to find successful therapies for when the process is disturbed. Like in 
barrier function, the biggest challenge in bladder mechanosignaling research is 
to understand how different pathways and receptors interact to create afferent 
mechanosignals in health and disease.
Barrier function and afferent mechanosignaling are not separated processes. 
From what we currently understand is that there is a very large overlap between 
both functions in the urothelium. For instance, vesicular exocytosis is driven by 
mechanical forces and mechanoreceptors. And we know that cell junctions are 
essential to create a functional barrier, but combined with their intracellular 
connections to the cytoskeleton, they are also a crucial focus of mechanical force 
distribution throughout the urothelial layers. This is supported by evidence that 
disrupting the actin cytoskeleton impairs afferent mechanosignaling and vesicular 
endocytosis [Suzuki 2003] [Khandelwal 2010]. The overlap between barrier and 
mechanosignaling functions in the urothelium is reflected by the shared (neuro)
transmitters and receptors that are essential in both processes. The big influence 
of ATP and purinergic receptors in barrier function and afferent signaling are good 
examples of this. This overlap in functions could also mean that when we target 
mechanosignaling with drug therapies, we may also affect barrier and vice versa. 
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Abstract
Purpose: The Transient Receptor Potential Vanilloid 4 channel (TRPV4) is a 
non-selective cation channel that is involved in different sensory functions. It has 
recently been implicated in bladder mechanosensation. 
We investigated the cellular location of TRPV4 in the bladder urothelium. In this 
study, a molecular connection between TRPV4 and urothelial adherence junctions 
(AJ’s) was explored. 
Materials and Methods: Healthy tissues sections from human cystectomies (3 
cancerous; 2 non-cancerous) were obtained. Besides human biopsies, tissues from 
normal mouse (n=7), TRPV4-/-mice (n=7) and the urothelial cell line RT4 were 
also used for the experiments. Experiments were conducted with an antibody 
against TRPV4 (polyclonal, against N-terminus of rat-TRPV4; ref: D’hoedt et al. J 
Biol Chem, 7;283(10):6272-80, 2008).
A molecular connection between TRPV4 and different components of 
the AJ was investigated using immunofluorescence, Western blotting and 
immunoprecipitation techniques. 
Results: Results demonstrate that TRPV4 is located on the membranes of 
urothelial cells near the AJ’s. Results between urothelial cell line, human and 
mouse bladders were comparable. Subsequent immunopecipitation experiments 
established a molecular connection of TRPV4 to α-catenin, an integral part of the 
AJ that catenates E-cadherin to the actin-microfilamental network. 
Conclusions: Our investigation provided evidence for the location of TRPV4 in 
the human bladder urothelium. TRPV4 is molecularly connected to adherence 
junctions on the urothelial cell membrane. The coupling of TRPV4 to a rigid intra- 
and intercellular structural network would be in agreement with the hypothesis 
that TRPV4 can be activated by bladder stretch.
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Introduction 
In the search for new therapeutic targets for Overactive Bladder Syndrome (OAB), 
most research is currently concentrating on understanding the sensory role of 
the urothelium. Urothelium is transitional and contains a basal, an intermediate 
and a specialized umbrella cell layer. These cells express multiple receptors and 
cation-channels that are involved in chemo- or mechanosensation. Urothelial 
cells are able to release signaling molecules like adenosine triphosphate (ATP), 
acetylcholine (ACh) and nitric oxide (NO), that are capable of mediating the 
afferent nerves of the bladder [1]. The family of transient receptor potential (TRP) 
proteins consist of a family of sensory cation channels that are involved in diverse 
cell processes. A number of these TRP channels are expressed in urothelial cells 
and afferent nerve fibers of the bladder (TRPV1, TRPV4, TRPV2, TRPM7, TRPM8, 
TRPA1) [2][3][4] and have been associated with normal and pathological functions 
[5]. In this regard, vanilloid receptors; especially TRPV1, have been studied in 
great extent [6][7][8]. TRPV4 (also known as VRL-2, OTRPC4, VR-OAC and TRP12) 
is another member of the vanilloid TRP channel family. This membrane associated 
non-selective cation channel can be activated by stretch, temperature change, 
osmosis, low pH and specific proteins (eg. cannabinoids) [9][10][11] and uses 
distinct pathways for these different stimuli [12].
Activation of TRPV4 causes a calcium-influx in the cell, which triggers local sensory 
transmitter molecules like ATP [13][14]. The exact sensory functions of TRPV4 
are still not clear. In circumventricular organs, TRPV4 is thought to take part in 
mechanosensation [13][14][10].
TRPV4 was detected in urothelial cell membranes of rat, mice and guinea pig 
bladders [15][16]. Recent mRNA quantification experiments on primary urothelial 
cell cultures from mouse bladders, revealed that TRPV4 is the most common 
vanilloid receptor in urothelial cells [3]. TRPV4 could, therefore, be involved in 
bladder filling sensation. In vivo experiments demonstrated that instilling agonists 
or antagonists for TRPV4 in the bladder, respectively provoked or diminished 
bladder hyperactivity [17][18][19]. This implies that TRPV4 is a promising target 
for pharmacological therapy for OAB.
The exact mechanism of stretch activation via TRPV4 channels is still not fully 
understood. We hypothesized that if TRPV4 is able to be activated by stretch in 
the urothelium, it could be connected to structures that can transmit mechanical 
forces that arise from bladder filling. Cell junctions, especially anchoring cell 
junctions like adherence junctions (AJ’s), tight junctions or desmosomes, are 
the best candidates for this, because they are located on the cell membrane and 
they connect neighboring epithelial cells, thereby creating a dynamic intercellular 
network. Beside this essential barrier function, these cell junctions can also 
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mediate the tensile forces, since they are linked intracellularly to the cytoskeleton 
[20][21]. Both inter- and intracellular structures are able to transmit the previously 
mentioned mechanical forces. A molecular relation between TRPV4 and the 
actin-cytoskeleton has already been suggested [22][23][24][25]. Adherence 
junctions (AJ’s) are intracellularly bound to the actin-cytoskeleton. Consequently, 
a connection between TRPV4 and AJ’s is a valid model that should be tested. 
The aim of our study is to investigate the cellular localization of TRPV4 in the 
human bladder urothelium.
Materials & Methods
Tissue and cells
For the experiments we obtained non-tumorous tissue (pathologist controlled) 
from human bladders from patients who underwent a cystectomy (three for 
bladder cancer, one for locally advancing cervixcarcinoma without bladder 
infiltration, one for severe stress incontinence). Mice bladders and kidneys were 
harvested from C57BI 6J mice (TRPV4 +/+) and TRPV4 knockout-mice (TRPV4 
-/-). TRPV4 -/- mice were donated by Suzuki et al. [23] and housed in our central 
animal facility. A well-differentiated urothelial bladder cancer cell line ‘RT4’ (origin 
ATCC, HTB-2) was also used. RT4 cells were cultured for 1 week in a CO2-incubator 
with 5% v/v CO2 (37°C). All tissues were obtained with approval of the human 
(CMO Arnhem-Nijmegen) and animal (RUDEC) ethical committees affiliated to the 
Radboud University Medical Center.
Immunofluorescence
Human bladder biopsies were embedded in Tissue-Tek (O.C.T.®) and snap frozen 
in isopentane. Bladders from TRPV4 +/+ (n=4) and TRPV4 -/- mice (n=4) were 
treated similarly and used as respectively positive- and negative controls. The 
urothelial cell line RT4 was used as in vitro model for well-differentiated urothelial 
cells. From frozen tissue, 4µM sections were cut in a cryostat microtome (Microm, 
Heidelberg) and air dried for 2 hours. RT4 urothelial cells were cultured on glass 
slides. Next, sections were fixated with 3% v/v paraformaldehyde (10 min), 
following rinsing (3 times) with Tris-Buffered Saline with 0,05% v/v Tween solution 
(TBS-T) and blocking with 20% v/v goat-serum in TBS-T. After this, sections were 
incubated overnight (4°C) with antibodies against TRPV4 (polyclonal, raised against 
amino acids 1–233 from the amino terminus of rat TRPV4; donated by Dept. of 
Otolaryngology, Stanford University School of Medicine, Stanford, California 
94305, USA) [26] and two against E-cadherin (Takara bio inc. & Sigma). Alexa’s 
488 & 594 (Invitrogen) labeled secondary antibodies were used. DAPI (Merck) 
was applied for nuclei-staining. Sections were analyzed by using epifluorescent 
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binocular-(Leica DMR®) and confocal laser scanning microscope (Olympus FV1000; 
16 cross sections per 4µM). Images were processed with ImageJ 1.41o software. 
Western blotting
Kidney samples from TRPV4 +/+ and TRPV4 -/- mice were used to assess the 
specificity of the TRPV4 antibody. After this, we investigated the expression of 
TRPV4 in the bladder urothelium. For this we used TRPV4 +/+ mice bladders 
and RT4 cells. After rinsing (saline), tissues were mechanically homogenized 
with a polytron (IKA-analyze). Both RT4-cells and tissues were transferred to an 
extraction buffer containing 300mM sucrose, 1mM EGTA, 5mM EDTA, 25mM 
imidazole and protease inhibitors. The samples were centrifuged at 100g (4°C) 
for 2 min. Protein concentrations of supernatants were determined with a BioRad 
protein-assay. 10µg of each samples was then loaded on a 10% w/v SDS gel 
and transferred to a PVDF-membrane (GE healthcare). The Western blots were 
analyzed with antibodies against TRPV4 (described above), E-cadherin (described 
above) that is an integral part of AJ’s and also α-catenin (Sigma) and β-catenin (BD 
Transduction Laboratories) for the intracellular proteins catenating E-cadherin to 
the actin-microfilamental network. Also antibodies against tubulin (Molecular 
probes) and Epidermal Growth Factor-receptor (EGF-R; Santa-Cruz) were 
used. Images of Western blots were acquired using the Biorad GS-690 Imaging 
Densitometer. 
Immunoprecipitation
Molecular interactions between TRPV4 and components of the AJ’s, particularly 
α- and β-catenin, were examined using the RT4 cells. Cells were rinsed twice 
with saline and solubilized with a lysis buffer containing: 0.5% v/v NP40, 10mM 
Tris (pH 7,4 adjusted with HCl), 140mM NaCl and a protease inhibitor cocktail 
tablet (Roche; 1 tablet/10ml). The lysates were centrifuged (4°C) and 100µl of the 
cleared supernatant was incubated for 2 hours with 5µl of the previously described 
antibodies for α-catenin, β-catenin and the negative controls tubulin and EGF-R. 
Then, 25µl protein G plus Agarose (Calbiochem) was added for an overnight 
incubation at 4°C. The immunocomplexes were centrifuged at 7,000g (4°C) for 5 
min and washed 3x with the lysis buffer, after which it was boiled in 100µl of Laemli 
sample buffer for 5 min. 10µl was loaded on 10% w/v SDS-gels and transferred 
to a PVDF-membrane (GE healthcare). The precipitates were analyzed with the 
previously described antibodies (TRPV4, E-cadherin, α- and β-catenin, tubulin, 
EGF-R). As reference markers, previously described protein lysates from RT4 and 
different tissue samples that were used in the Western blotting experiments, were 
loaded on the adjacent slots. Images of the immunoprecipitates were acquired 
using the Biorad GS-690 Imaging Densitometer. 
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Results
Immunofluorescence; TRPV4 co-localizes with the AJ’s
Specificity of the antibody for TRPV4 was confirmed by comparing bladder 
of TRPV4 +/+ and  -/- mice (fig 1). Antibodies against E-cadherin were used to 
mark the AJ’s in the urothelium. The urothelium of human and mouse bladders 
and in RT4 cells were investigated. The bladders of TRPV4 +/+ mice showed 
immunoreactivity for TRPV4 on cell membranes throughout all layers of the 
urothelium. In the E-cadherin stainings on the human bladder (fig 2), AJ’s were 
observed as dot-like structures between the cell-membranes of two adjacent 
umbrella-cells. Simultaneous incubation with the TRPV4 antibody revealed that 
these ‘dots’ or ‘puncta’ had a distinct immunoreactivity for TRPV4 as well. This 
precise co-localization was confirmed with confocal laser scanning microscopy (fig 
2). 
Figure 1. a & b) Immunofluorescence on bladders from TRPV4 +/+ and TRPV4 -/- mice. The 
white arrows mark the urothelium. Note the expression of TRPV4 (green) in the urothelium 
in TRPV4 +/+  mouse and no signal in the TRPV4 -/-. There is some expression of TRPV4 
in bloodvessels (orange arrows) and in sporadic cells in the detrusor layer (red arrows). 
Pictures taken with (a) CLSM (16 cross-sections per 4 µM at 10x) and b) epifluorescent 
microscopy (at 63x) c) Western blotting on TRPV4 +/+ (bladder & kidney) and TRPV4 -/- 
(kidney) mice. Note the TRPV4 expression (95-100 kDa) in the TRPV4 +/+ mouse and no 
signal in the TRPV4 -/- . 
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Figure 2. Immunofluorescence analysis on bladder urothelium from human, wildtype 
(TRPV4 +/+) mice and urothelial cell line RT4 with antibodies for TRPV4 and E-cadherin 
(adherence junctions; AJ’s) and DAPI for nuclei staining. TRPV4 and E-cadherin 
immunofluorescence was detected on the membranes of urothelial cells. The dotted 
white line marks the urothelium-lumen border. AJ’s (E-cadherin) in the human bladder 
are observed on urothelial cell membranes with a distinct expression at the ‘kissing 
points’ between connecting umbrella cells (arrows). These topographical sites also stain 
for TRPV4 (merged images). This co-localization between TRPV4 and E-cadherin is also 
observed in the mouse urothelium and the RT4 urothelial cell line (arrows). TRPV4 in the 
mouse bladder appears to be located more in the basal and intermediate layers of the 
urothelium. The TRPV4 immunofluorescence in some nuclei (mostly umbrella cells) is 
also detected in mouse, but not in TRPV4 -/- mice and could be caused by processing of 
TRPV4 protein near the nucleus. Pictures taken at 60x enlargement with CLSM (human; 16 
cross-sections per 4 µM) and epifluorescent microscopy (mouse, RT4).
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The RT4 urothelial cell line grows in a clustered way and clearly showed both 
E-cadherin and TRPV4 immunoreactivity on the cell membranes (fig 2). In both 
TRPV4 +/+ mice (urothelium) and RT4 cells, the topographical relationship between 
TRPV4 and AJ’s was clearly detectable and similar to the human urothelium (fig 2). 
No differences in immunoreactivity for TRPV4 were observed between different 
human specimens. TRPV4 immunofluorescence was predominant in the 
urothelium. However, some immunoreactivity was noticed in other parts of the 
bladder wall, in among others the walls of blood vessels and sporadic cells in the 
suburothelium and detrusor-layer (fig 1). 
Figure 3. Immunoprecipitation (IP) experiments on RT4 urothelial cell lystate to evaluate 
sensitivity and specificity of the IP’s. Precipitates from IP’s from 3 different proteins of 
AJ’s were used to evaluate the connection between α-catenin (α-cat), β-catenin (β-cat) 
& E-cadherin (E-cad). IP’s using antibodies for α-tubulin and Epidermal Growth Factor 
receptor (EGF-r) were used as negative controls. Besides the IP’s, Western blotting 
experiments on RT4 protein lysates (WB: RT4) were also evaluated with antibodies for 
α-catenin, β-catenin, E-cad, α-tubulin and EGF-r. These 5 proteins were all detected in 
‘WB: RT4’. All 3 AJ proteins were detected in the precipitates of ‘IP: α-cat’ & ‘IP: β-cat’, 
but none were detected in the negative controls. Therefore, the IP’s were able to keep the 
molecular connections between AJ proteins intact, but were also specific enough to rule 
out false positives.
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Western blotting experiments
The specificity of the TRPV4 antibody was confirmed by comparing kidneys from 
TRPV4 +/+ and -/- mice; a double band in the 95-100 kDa range in the kidneys 
of TRPV4 +/+ mice was detected that was absent in TRPV4 -/- mice kidneys (fig 
1c). A similar band was observed in bladders from TRPV4 +/+ mice. Experiments 
confirmed the expression of TRPV4, E-cadherin, β- and α-catenin, tubulin and 
EGF-R in RT4 cells (fig 3 & 4).
Figure 4. Top: Western blotting (WB) and immunoprecipitation (IP) experiments to 
investigate biomolecular connections between TRPV4 and β- or α-catenin. WB on RT4 
urothelial cell line and wild type mouse (TRPV4 +/+) demonstrate TRPV4 expression levels 
(95-100 kDa). TRPV4 expression is absent in the TRPV4 -/- mouse. For the IP experiments we 
used a lysate of RT4 urothelial cell line and antibodies for β-catenin, α-catenin (both part of 
intracellular complex of AJ’s) and negative controls α-tubulin and EGF-r for the precipitation. 
We investigated the precipitates for the presence of TRPV4 in the immunocomplex. TRPV4 
was detected in the immunocomplex of α-catenin (IP: α-cat). The immunocomplexes of 
β-catenin (IP: β-cat), α-tubulin and EGF-r (EGF-r results in supplemental figure) showed 
no signal for TRPV4. Bottom: Western blotting (WB) and immunoprecipitation (IP) on RT4 
urothelial cell line. No TRPV4 was detected in the immunocomplexes of the precipitations 
with antibodies EGF-r and α-tubulin (negative controls). Western blot of RT4 whole cell 
lysate (WB: RT4) was used as a positive control.
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Immunoprecipitations;
Molecular connection between TRPV4 and components of the AJ
In order to study the biomolecular connection between TRPV4 and AJ proteins, 
immunoprecipitation experiments on RT4 cells were performed. Because TRPV4 
is located in the cell membrane, only antibodies against the membrane associated 
proteins from the AJ (β- and α-catenin) were used for these experiments. First, 
experiments were evaluated by analyzing the precipitates for the presence of 
different AJ-proteins (E-cadherin, β-catenin, α-catenin), using tubulin and EGF-R 
as negative controls. All three AJ-proteins were detected in the immunocomplexes 
of the β- and α-catenin precipitations, but none were observed in negative 
controls (fig 3). Secondly,  a possible connection between TRPV4 and different 
AJ-components was investigated by examining the presence of TRPV4 in the β- 
and α-catenin precipitates (immunocomplexes), also using the same negative 
controls (fig 4). This demonstrated a strong expression of TRPV4 in the α-catenin 
immunocomplex and none in the immunocomplexes from β-catenin or negative 
controls. The intensity of the TRPV4 expression in the α-catenin immunoprecipitate 
was higher compared to the expression in the protein-lysates from RT4 and TRPV4 
+/+ kidney samples (fig 4).
Discussion 
We investigated the cellular location of TRPV4 in the bladder urothelium and 
tested the biomolecular connection between TRPV4 and different proteins that 
are part of the AJ. 
TRPV4 co-localizes with AJ’s in the urothelium. 
Results from the immunofluorescence experiments on human bladder tissue 
provided evidence for a co-localization between TRPV4 and E-cadherin, an integral 
part of the AJ. This co-localization was also observed in the mouse bladder and in 
RT4 cells. Subsequent confocal laser scanning microscopy was applied for a more 
detailed assessment. The location of TRPV4 immunofluorescence on urothelial 
cell membranes in the mouse bladder, was previously described by other groups 
[14]. Wissenbach et al. reported on TRPV4 expression in the walls of blood vessels 
and Thorneloe et al. discribed TRPV4 expression in spindle like cells in the detrusor 
layer [27][17]. Our results support these observations. Nonetheless, the precise 
origin of this latter cell type still requires further examination.
TRPV4 is connected to the intracellular domain of the AJ. 
The immunofluorescence data are indicative, albeit not sufficient to prove 
that there is a physical link between TRPV4 and components of the AJ. In 
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order to study the biomolecular connection between TRPV4 and AJ proteins, 
we performed immunoprecipitation experiments on the RT4 cells. These 
experiments demonstrated a specific molecular connection to α-catenin, the 
domain that connects the AJ to the actin-filaments. Hence, TRPV4 may function 
as a mechanoreceptor through its interaction with the tensile network in- and 
between cells, via the adherence junctions. In accordance with these results, 
in vitro experiments from Becker et al. demonstrated that TRPV4 interacts with 
actin-filaments. However, their immunoprecipitation experiments failed to detect 
a direct molecular connection between the two [24]. The α-catenin protein can 
be the critical biomolecular link between both structures.
Our experiments focused on the cellular localization of TRPV4 in the urothelium 
that may be crucial for its function as a mechanosensor. This latter statement 
requires additional dynamic studies. The hypothesis that TRPV4 is an important 
mechanoreceptor in the bladder is speculated in two publications. First, knocking 
out the TRPV4 gene (TRPV4 -/-) in mice, results in a phenotype that has bladder 
function disorders. The symptoms include an enlarged bladder capacity and 
uncontrolled voiding. This latter symptom can be observed as out of the corner 
voiding behavior that is uncommon in mice [13]. Secondly, stretch experiments on 
bladder tissue and cell cultures derived from TRPV4 -/- mice, revealed a diminished 
ATP production and cellular Ca2+ influx during stretch [13][14]. Altogether, this is 
in agreement with a model that these mice have a reduced capability to detect 
mechanical stretch in the urinary bladder and that TRPV4 influences the sensory 
signaling pathway by mediating ATP-release in the urothelium.
A link between TRPV4 and the intracellular domain of AJ’s means that the 
channel is connected close to the structural network that incorporates the 
intracellular actin-filaments (cytoskeleton) and anchoring cell-junctions. This 
network is essential to keep urothelial impermeability intact and it probably 
is the major determinant to equally divide mechanical force (eg. stretch) over 
large surfaces of the urothelium. Suzuki et al. reported on an association 
between microtubule-associated protein 7 (MAP7), a protein bound to the 
actin-cytoskeleton, and the C-terminus of the TRPV4 channel [22][25]. In a cell 
culture, co-transfection of MAP7 revealed a higher membrane expression of 
TRPV4-protein and resulted in a more potent stretch response by these cells. 
This response was abolished by the application of actin-freezing agents, further 
proving that TRPV4 needs a connection to the actin-cytoskeleton to be able to 
be activated by stretch. This supports the hypothesis that TRPV4 channels are 
dependent on a connection with AJ’s to accurately measure quantitative amounts 
of stretch (bladder filling) (fig 5). 
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Figure 5. Hypothesized model explaining mechanosignaling characteristics of TRPV4. 
TRPV4 is connected, via its C-terminal to AJ’s. Mechanical forces derived from stretch 
during bladder filling, travel through the actin cytoskeleton and AJ’s. This activates TRPV4, 
causing a Ca²⁺-influx in the cell that evokes the production of the neurotransmitter ATP. 
ATP will stimulate afferent nerve fibers in the urothelium and suburothelium. 
Stretching of the urothelium can lead to activation of TRPV4 channels and cause 
a Ca2+ influx in urothelial cells [11][14]. This Ca2+ influx will trigger the release of 
ATP from urothelial cells [14]. There is evidence that ATP is capable of stimulating 
afferent nerve fibers in the urothelium and suburothelium [13][28]. These nerves 
express purinergic receptors (P2X, P2Y) that respond to ATP [29]. Interestingly, 
the enlarged bladder capacities that are observed in the TRPV4 -/- mouse 
phenotype, are also seen in P2X3 -/- mice [30]. The difference between these 
two mice strains is that bladders of P2X3 -/- mice still have a normal urothelial 
ATP release, but the response to ATP is augmented, while TRPV4 -/- mice have a 
diminished urothelial ATP release and probably a normal response to ATP. Though 
this might implicate that TRPV4 exerts its action by mediating purinergic receptors 
on afferent nerve fibers, additional research is required to study this interaction. 
Interactions between TRPV4 and other members of the TRP channel superfamily 
may be possible. TRPV1, for instance, is also associated with mechanosensation 
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in the bladder and also mediates ATP signaling [7]. Potential roles for TRPV4 in 
other sensation pathways (thermal, chemical) [12] or pathological involvement 
go beyond the scope of this investigation.
An inhibited ability to sense bladder stretch in transgenic TRPV4 -/- mice, could 
reduce central nervous control of the bladder and cause frequent overfilling of 
the bladder. This may explain the development of enlarged bladder capacities 
and the out of corner voiding behavior in these mice.  The abundance of TRPV4 
channels in the urothelium, indicates that it might be a promising target for 
pharmacological intervention. This concept is further supported by a previous 
report from Thorneloe et al. who discribed a potent effect on bladder activity 
through pharmacological activation of TRPV4 in mice [17][18].
Altering the connection between TRPV4 and α-catenin, might selectively alter 
the mechanosensory properties of TRPV4 and consequently, influence bladder 
sensation pathways. 
Conclusion
We have provided evidence for  a biomolecular connection of TRPV4 and α-catenin, 
an integral part of the adherence junctions in the human bladder urothelium. The 
coupling of TRPV4 to a rigid intra- and intercellular structural network would be 
in agreement with the hypothesis that TRPV4 can be activated by bladder stretch. 
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Abstract
Aim: The molecular interactions between Transient Receptor Potential Vanilloid 
subtype 4 channels (TRPV4) and cell junction formation were investigated in the 
human and mouse urogenital tract.
Materials and Methods: A qualitative study was performed to investigate TRPV4 
channels, adherence junctions (AJ’s) and tight junctions (TJ’s) in kidney, ureter 
and bladder tissues from humans and wild type and transgenic TRPV4 knockout 
(-/-) mice with immunohistochemistry, western blotting, immunoprecipitation 
and reverse-trasnscription-PCR. Cell junction formation in the wild type and 
TRPV4 knockout (-/-) mouse was evaluated with immunohistochemistry and 
Transmission Electron Microscope (TEM) techniques.
Results: TRPV4 channels are predominantly located in membranes of epithelial 
cells of the bladder, ureter and the collecting ducts of the kidney. There is a 
molecular connection between the TRPV4 channel and the AJ. TEM evaluation 
showed that AJ formation is disrupted in the TRPV4 -/- mouse resulting in deficient 
intercellular connections and integrity of the epithelium. 
Conclusions: TRPV4 is believed to be a mechanoreceptor in the bladder. This 
study demonstrates that TRPV4 is also involved in intercellular connectivity and 
structural integrity of the epithelium.
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Introduction
This study investigates the interactions between the cation channel Transient 
Receptor Potential Vanilloid subtype 4 (TRPV4) and cell junctions in urinary 
epithelia. 
TRPV4 is a non-selective Ca²⁺-permeable cation channel that is part of the 
TRP-channel family that is involved in diverse physiological processes like heat-cold 
detection, vision, mechanosensation, pain and hearing [Nilius B et al., 2003] 
[Nilius B et al., 2004] [Everaerts W et al., 2008] [Nilius B et al., 2005]. The TRPV4 
channels are formed by six membrane spanning helices and a cytoplasmic located 
N- and C-terminus and are expressed predominantly in epithelial cells [Nilius B et 
al., 2003] [Everaerts W et al., 2008] [Mochizuki T et al., 2009]. Besides this, there 
is evidence that TRPV4 channels are present in specific neurons [Vriens J et al., 
2004] [Cao D et al., 2009]. The TRPV4 channel can be activated by mechanical 
stretch, shear stress (flow), temperature differences and specific chemical stimuli 
[Vriens J et al., 2004] [Cao D et al., 2009]. The modes of activation occurs through 
different pathways [Vriens J et al., 2004]. Their gating function is dependent on 
intra- and extracellular Ca²⁺ concentrations [Nilius B et al., 2003].
In the urogenital tract, TRPV4 channels are located in the epithelial lining of 
the connecting tubule/collecting duct cells of the kidney, and the epithelia of 
the ureter, bladder and urethra [Berrout J et al., 2012] [Birder L et al., 2007] 
[Gevaert T et al., 2010] [Everaerts W et al., 2010] [Everaerts W et al., 2008]. In 
the bladder, TRPV4 channels are investigated for mechanosensory properties and 
its involvement in bladder filling sensations [Mochizuki T et al., 2009] [Gevaert T 
et al., 2010]. Reduced mechanosensation was observed in the transgenic TRPV4 
knockout (-/-) mouse [Gevaert T et al., 2010]. The phenotype is characterized 
by bladder dysfunction with an increased bladder capacity and altered voiding 
behavior [Gevaert T et al., 2010]. A lack of TRPV4 channels inhibits afferent 
signaling by reducing ATP excretion in the urothelium [Mochizuki T et al., 2009] 
[Gevaert T et al., 2010]. There are also reports that showed TRPV4 localization on 
nerves in dorsal root ganglia and dorsal horns, which might also influence bladder 
function [Cao D et al., 2009]. 
According to the location of TPRV4 channels in the kidney, it is believed that TRPV4 
is either involved in regulation of osmosis, or as a flow receptor in the distal tubuli 
or collecting ducts [Berrout J et al., 2012]. TRPV4 is expressed in aldosterone 
sensitive cells containing Aquaporin 2 receptors in the kidney [Galizia L et al., 
2012]. Both flow and water uptake are regulated in these nephron segments. The 
exact function of TRPV4 channels in the kidney is however, still not fully clarified.
Mechanoactivation of TRPV4 channels is thought to occur via an distinct 
pathway in which cell swelling activates phospholipase A2 which induces P450 
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epoxygenase dependant arachidonic acid metabolite formation [Vriens J et al., 
2004]. The latter being the endogenous agonist that activates the channel [Vriens 
J et al., 2004]. There is evidence that TRPV4 channels are connected to adherence 
junctions (AJ’s) and the actin cytoskeleton [Janssen D et al., 2011] [Becker D et 
al., 2009] [Sokabe T et al., 2010] [Goswami C et al., 2010]. The AJ is a rigid cell 
junction that plays a vital role in maintenance of the epithelial barrier and helps to 
provide structure and organization in epithelial and endothelial tissues [Goodwin 
M et al., 2007] [van Roy F et al., 2008]. The extracellular component of the AJ 
consists of E-cadherin dimers are essential for the intercellular connections. 
The intracellular component consist of β-, γ- and α-catenins of which the latter 
is connected to the actin cytoskeleton [Goodwin M et al., 2007] [van Roy F et 
al., 2008]. This rigid intercellular network is capable of transporting mechanical 
forces across neighboring cells and may enable the activation of TRPV4 channels. 
Previous research in bladder urothelial cells demonstrated a distinct molecular 
connection between TRPV4 channels and the intracellular α-catenin complex of 
the adherence junction [Janssen D et al., 2011]. Besides this, there is evidence 
from different organ systems that TRPV4 deficiency impairs barrier and cell 
junction formation [Sokabe T et al., 2010] [Willette R et al., 2008]. 
The objective of this study was to explore the location and molecular interaction 
of TRPV4 channels and barrier forming cell junctions in the human and mouse 
urogenital tract.
Materials and Methods
Tissue and cells
The local human and animal ethical committees of the Radboud University Medical 
Center approved the use of patient and animal materials. We obtained pathology 
verified, non-tumorous tissue from human bladders (n=6), kidneys (n=2) and 
ureters (n=1). For RNA isolations from human bladders, we used cold cup biopsies 
(n=3) that were taken from patients treated for pure stress incontinence. Mice 
bladders and kidneys were harvested from C57BI 6J mice (TRPV4 +/+)(8 bladders, 
5 kidneys from individual mice) and transgenic TRPV4 knockout-mice (TRPV4 -/-) 
with a C57BI 6J background (8 bladders, 5 kidneys from individual mice). TRPV4 
-/- mice were generously provided by Suzuki et al. and housed and bred in our 
central animal facility [Suzuki M. et al., 2003].  
Immunofluorescence 
Immunofluorescence (IF) assays were performed to investigate the location 
of TRPV4 channels and the relation with AJ’s in the urogenital tract of humans 
and mice. A table of all antibodies used is included in the supplemental data. 
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Tissues were embedded in Tissue-Tek® O.C.T. (Sakura Finetek) and snap frozen in 
isopentane. From frozen tissue, 4 µm sections were cut in a cryostat microtome 
(Microm) and air dried. Sections were fixed with 3% v/v paraformaldehyde (10 
min), following rinsing (3 times) with Tris-Buffered Saline with 0,05% v/v Tween 
solution (TBS-T) and blocking with 20% v/v goat-serum in TBS-T. After this, 
sections were incubated overnight (4°C) with primary antibodies against TRPV4 
(polyclonal, donated by Department of Otolaryngology, Stanford University 
School of Medicine) [22], two against E-cadherin (Takara bio inc. & Sigma) and 
an occludin (Invitrogen) antibody for tight junction evaluation. Alexa’s 488 & 594 
(Invitrogen) labeled antibodies were used as secondary antibodies, and DAPI 
(Merck) was used for visualizing nuclei. Omission of the first antibody was taken 
as a control. Sections were analyzed by using epifluorescent binocular microscope 
(Leica DMR®). Images were processed with Image J 1.41o software.
Immunohistochemistry
Tight junctions expression in the wild type and TRPV4 -/- mouse were also 
investigated with immunohistochemistry. For this, the occludin antibody 
(Invitrogen) was used. Procedures were comparable to the IF assays. Differences 
were that Poly-HRP-α-RA/Rb/Mo IgG (Immunologic) was used as secondary 
antibody and bound antibodies were visualized by DAB (Immunologic). No DAPI 
was used. Sections were analyzed by using normal binocular microscope (Leica 
DMR®). 
Western blotting
Kidney samples from humans, wild type and TRPV4 -/- mice were used to 
investigate the expression of TRPV4 in the kidney tissue and to assess the specificity 
of the TRPV4 antibody. Tissues were rinsed twice with saline and mechanically 
homogenized with a polytron (IKA-analyze). After this, samples were transferred 
to an extraction buffer containing 300 mM sucrose, 1 mM EGTA, 5 mM EDTA, 25 
mM imidazole and protease inhibitors. The samples were centrifuged at 100 g 
(4°C) for 2 mins. Protein concentrations of the supernatants of the specimens 
were determined with the BioRad protein assay. After this, 10 µg of each samples 
was loaded on a 10% w/v SDS gel and transferred to a PVDF membrane (GE 
healthcare). The Western blots were analyzed with antibodies against TRPV4 
(described above), E-cadherin (Takara bio inc. & Sigma), α-catenin (Sigma) and 
β-catenin (BD Transduction Laboratories). Images of Western blots were acquired 
using the Biorad GS-690 Imaging Densitometer. 
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Immunoprecipitation
Immunoprecipitation experiments were performed to examine possible 
molecular connections between TRPV4 and components of the AJ’s, particularly 
α-, β-catenin and E-cadherin. Normal human kidney tissue was used for analysis 
(n=1). After rinsing (saline), tissues were mechanically homogenized with a 
polytron (IKA-analyze). Tissues were solubilized with a lysis buffer containing: 0.5% 
v/v NP40, 10 mM Tris (pH 7,4 adjusted with HCl), 140 mM NaCl and a protease 
inhibitor cocktail tablet (Roche; 1 tablet/10 ml). The lysates were centrifuged 
(4°C) and 100 µl of the cleared supernatant was incubated for 2 hrs with 5 µl 
the previously described TRPV4 antibody. Then, 25 µl protein G plus Agarose 
(Calbiochem) was added for incubation (overnight, 4°C). The immunocomplexes 
were centrifuged at 7,000 g (4°C) for 5 mins and washed 3x with the lysis buffer, 
after which they were boiled in 100 µl of Laemli sample buffer (5 mins). 10 µl was 
loaded on 10% w/v SDS gels and transferred to a PVDF membrane (GE healthcare). 
Precipitates were analysed with the previously described antibodies for TRPV4, 
E-cadherin, α- and β-catenin to determine if these proteins could be detected in 
the immunocomplexes. Images of the immunoprecipitates were acquired using 
the Biorad GS-690 Imaging Densitometer.       
Real-time RT-PCR
Real-time RT-PCR was performed to investigate the presence and location 
of TRPV4 channels in the human bladder. Cold cup biopsies were snap frozen 
in liquid nitrogen and processed by step sectioning. Bladder biopsies were 
immunohistochemicaly evaluated for presence of urothelial layer with a standard 
hemotoxylin-eosin staining. We included three histological normal looking 
biopsies of which two had a normal urothelial layer present and 1 without any 
urothelium present (Fig. 1A). Total RNA from 6 x 20µm cold cup biopsy sections 
per sample were isolated using Trizol reagent, according to the manufacturer’s 
instructions (Invitrogen). Concentration and purity of the RNA was determined on 
a Nanodrop-1000 spectrophotometer (Thermo Scientific).
Total RNA (400ng) was DNase-I-treated (Invitrogen) and cDNA was synthesized 
using random hexamer primers and SuperScript II-MMLV reverse transcriptase 
(Invitrogen). The RT-reaction was diluted 3 times in PCR grade H2O. Gene expression 
was determined by SYBR Green qPCR, using SYBR Green PCR mix (Roche) and 2µl 
cDNA as a template. RNA not subjected to reverse transcriptase was used as a negative 
control. Gene-specific primers, including urothelium specific and smooth muscle 
specific primers, are listed in the Supplementary Table 1. qPCR was performed on a 
LightCycler480 instrument (Roche), using the following amplification conditions: 5 
min. 95oC, followed by cycles of 10 sec. 95°C, 20 sec. 60°C, 20 sec. 72°C. Cp values 
were determined using the LC480 SW1.5 software (Roche). 
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Transmission electron microscopy (TEM)
TEM was used to investigate cell junction formation in the TRPV4 -/- mouse 
on an ultrastructural level. For this, bladders from wild type (n=2) and TRPV4 
-/- mice (n=2) were removed. Tissues were fixed in 2% (v/v) glutaraldehyde in 
0.1 m phosphate buffer (pH 7.4) for 12 h at 4°C, and post fixed with 1% (w/v) 
osmium tetroxide in 0.1 m phosphate buffer (pH 7.4) for 1 h. After a rinsing period 
of 3 h with 0.1 m phosphate buffer (pH 7.4), the samples were dehydrated in 
an ascending series of ethanols and embedded in Epon 812. Ultrathin sections 
(60 nm) were picked up on formvar-coated grids, post stained with lead citrate 
and uranyl acetate, and examined in a JEOL 1010 electron microscope.
Results
The light micrographs and electron micrographs shown should be considered as 
typical examples of the evaluated sectioned material.
Location of TRPV4 channels in the urogenital tract.
Specificity of the antibody for TRPV4 was confirmed by comparing kidneys of 
wild type (TRPV4 +/+) and TRPV4 -/- mice. No signal was detected in TRPV4 -/- 
mouse tissues in both immunofluorescence assays (Fig. 1C, 3F) and western 
blotting experiments (Fig. 1D) [Janssen D et el., 2011]. Immunofluorescence 
assays demonstrated that TRPV4 channels in the human bladder and ureter are 
expressed on the cell membranes of urothelial cells, with a distinct co localization 
with E-cadherin molecules that form the AJ’s (Fig. 2). AJ’s were clearly visible as 
dot-like structures between the cell-membranes of two adjacent umbrella-cells. 
Simultaneous incubation with the TRPV4 antibody revealed that these ‘dots’ or 
‘puncta’ showed distinct co localization with TRPV4 (Fig. 2). TRPV4 expression 
in lower urothelial layers was observed in the human bladder and ureter, but 
the signal was less pronounced (Fig. 2). In the mice bladders, the TRPV4 signal 
was seen more  equally distributed throughout the urothelium (Fig. 3). With IF, 
no signal of TRPV4 expression was seen in the deeper layers of the bladders of 
human specimens (lamina propria and detrusor layers). 
Expression of TRPV4 in the human kidney was confirmed with Western blotting 
experiments and immunofluorescence assays (Fig. 1C & 2). The immunofluorescent 
signal for TRPV4 was stronger in the kidneys compared to the human bladder and 
ureter. TRPV4 was clearly visible on the epithelial cell membranes of the collecting 
tubules, with also a co localization with AJ’s (Fig. 2). Besides these areas, there 
were also sections of the kidney tubuli that either solitary expressed AJ’s or TRPV4 
(Fig. 2).
92
TRPV4 channels in the human urogenital tract play a role in cell junction formation and epithelial barrierChapter 3
Figure 1. RT-PCR and immunoprecipitation experiments on location and molecular 
connections of TRPV4 and adherence junctions in the urogenital tract epithelium. 
Gene expression in cold cup human bladder biopsy samples with (n=2; red bracket) and 
without urothelium (n=1) (A). Total RNA was isolated from tissue sections, and analyzed 
by qPCR as described in Materials and Methods (B) and supplementary table 1. Gene 
expression levels were normalized to the amount of RNA (per mg). TRPV4 mRNA is 
predominantly expressed in the urothelium containing biopsies that specifically express 
CDH1, FGFR3(IIIb), and KRT20. Hardly any TRPV4 is detected (100- fold less) in the biopsy 
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without urothelium and urothelium specific transcripts.  Immunofluorescence experiments 
on TRPV4 in mouse kidneys from wildtype (n=3) and transgenic TRPV4 -/- mice (n=3) show 
presence of TRPV4 channels in kidney epithelium, with complete absence of TRPV4 in the 
TRPV4 -/- mouse (C). Immunoprecipitation and western blotting experiments on human 
(n=1), mouse (n=1) and transgenic TRPV4-/- mouse (n=1) kidneys show presence of TRPV4 
protein in both human and mouse kidneys and absence of TRPV4 in the TRPV4 -/- (D). 
Immunoprecipitation experiments on human kidney tissue show a molecular connection 
between TRPV4 proteins and adherence junction proteins α catenin (grey arrow), β 
catenin and E cadherin with subsequent decreasing concentrations in the precipitate. 
The cytoskeleton related protein α tubulin was used as a negative control and it was not 
detected in the precipitate, which indicates that the IP was specific enough to show a 
protein–protein interaction between TRPV4 and AJ related proteins. 
TRPV4 mRNA expression in bladder urothelial cells
We analyzed TRPV4 mRNA expression in cold cup bladder biopsy specimens 
by real-time RT-PCR. In the sample that had no urothelium (Fig. 1A), only the 
HPRT house-keeping gene, and the smooth muscle-specific transcript ACTB were 
expressed (Fig. 1B). In the two specimens containing a healthy urothelial layer on 
standard HE staining, the urothelium-specific transcripts, CDH1, FGFR3(IIIb), and 
KRT20 were detected. In the latter samples, ACTB was also expressed, since these 
specimens all contained a smooth muscle cell component. TRPV4 expression 
was found in the CDH1/FGFR3/KRT20 positive samples and hardly in the sample 
without urothelium (approximately a 100 fold higher expression in urothelium 
enriched samples), indicating that TRPV4 expression is predominantly restricted 
to urothelial cells (Fig. 1B).
Molecular connection between TRPV4 channels and AJ’s
With immunoprecipitation (IP) experiments on human kidney tissue, we 
investigated potential molecular interactions between TRPV4 and AJ proteins 
(Fig. 1D). The TRPV4 antibody was used for the pull down experiment and the 
immunoprecipitates were investigated for the presence of E-cadherin, α- and 
β-catenin proteins. The negative control α-tubulin was not present in the TRPV4 
precipitate (supplemental data). Results confirmed that TPRV4 has a molecular 
connection to α-catenin, the intracellular AJ protein that is connected to the 
actin cytoskeleton. Lower concentrations of β-catenin and E-cadherin were also 
detected in the precipitate in respectively decreasing concentrations, confirming 
that TRPV4 channels are connected to AJ’s.
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Figure 2. immunofluorescence experiments on presence and co localization of TRPV4 
channels and AJ’s in the urogenital tract epithelium. TRPV4 channels and the AJ 
specific molecule E cadherin were investigated in human bladder (n=6) (A-C), ureter 
(n=1) (D-F) and kidney (n=2) (G-L). AJ’s were clearly visible as dot-like structures between 
the cell-membranes of two adjacent umbrella-cells. Simultaneous incubation with the 
TRPV4 antibody revealed that these ‘dots’ or ‘puncta’ (white arrows) had a distinct 
immunoreactivity for TRPV4. TRPV4 was clearly visible on the epithelial cell membranes 
of the collecting tubules, with also a distinct co-localization with AJ’s. Besides these areas, 
there were also sections of the kidney tubuli that either solitary expressed AJ’s (orange 
arrows) or TRPV4 (red arrows).
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Figure 3. immunofluorescence experiments on TRPV4 and adherence junction formation 
in wildtype and transgenic TRPV4 -/- mice in the urogenital tract epithelium. TRPV4 
channels were located in bladder urothelium in wild type (WT; n=3) (image A-D) and co 
localized with the AJ specific protein E-cadherin (image C). In the transgenic TRPV4 -/- 
mouse bladder (n=3) (image E-H), no signal for TRPV4 was detected. AJ’s were continuously 
formed at the epithelial cell borders in wild type mouse bladders (image B and enlarged 
in D) and kidneys (image I) (white arrows). In contrast, in the TRPV4 -/- bladder (image 
E and enlarged in G) and kidney (image J), AJ’s in the epithelial cell borders had notable 
interrupted areas between adjacent cells (white arrows).  
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Figure 4. Tight junction formation in the mouse urogenital tract epithelium. 
Immunohistochemical (images A,B) and immunofluorescence (IF) (images C-F) 
investigations on wild type (WT)(images A,C,E)  and transgenic TRPV4 -/- mouse (images 
B,D,F) bladders. Tight junctions were visualized with an occludin immunostaining and are 
highlighted in the images with black and white arrows. Tight junctions in the WT bladders 
(n=3) are formed in the luminal umbrella cell type urothelial cells. In the TRPV4 -/- mouse 
bladder (n=3), adjacent urothelial cells have enlarged intercellular spaces (B), compared 
to the WT mouse (A).  Tight junctions also appear the be less frequently visible in the 
TRPV4-/- mouse bladder compared to the WT on immunohistochemistry experiments. 
However, this difference could not be confirmed with IF (image D). In the kidney, there is 
a similar expression of tight junctions between WT (n=2) and TRPV4 -/- mice (n=2) in the 
luminal epithelial cells.    
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Interaction between TRPV4 channels and AJ’s. Disturbed AJ formation in 
TRPV4 -/- mice
To study the interaction of TRPV4 channels and AJ’s in the urogenital tract, cell 
junction formation was investigated in the urogenital tract of the TRPV4 -/- 
mouse using IF and immunohistochemistry experiments and also evaluated on 
an ultra-structural level with TEM. The results from the IF experiments confirmed 
a similar co localization between TRPV4 channels and AJ’s in mice bladders 
and kidneys (Fig. 3). AJ formation in the wild type mouse bladders resembled 
the human bladder with clearly visible narrow cell junction ridges between 
neighboring urothelial cells. AJ formation in the TRPV4 -/- mouse bladders differed 
from this with less pronounced intercellular ridges that appeared interrupted. 
Similar observations were done in the collecting ducts of TRPV4 -/- mice kidneys. 
Tight junction formation was investigated with occludin immunostainings. The 
results showed that tight junctions were still formed in both bladders and kidneys 
from TRPV4 -/- mice (Fig. 4) 
On an ultrastructral level, evaluation of wild type and TRPV4 -/- bladders with 
TEM revealed clear urothelial abnormalities in the TRPV4 -/- mice (Fig. 5). This 
included enlarged intercellular spaces between urothelial cells, which were 
hardly detectable in the wild type mouse. When looking at cell junction formation 
in the urothelium in higher detail, tight junctions and desmosomes were clearly 
detectable in both wild type and TRPV4 -/- mice. However, no adherence junctions 
were detected in the TRPV4 -/- mouse urothelium, while they were clearly 
distinguishable in the wild type. 
Besides these abnormalities, we also detected abnormal vesicular exocytosis in 
the TRPV4 -/- mouse bladder umbrella cells. Intracellular vesicles in the umbrella 
cell type were much larger compared to wild types and also contained large 
amounts of clearly visible material that was expelled into the bladder lumen after 
fusion of the vesicles with the outer cell membrane (Fig. 4). 
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Figure 5. Transmission Electron Microscopy (TEM) evaluation of cell junction formation 
of the wild type (WT) and transgenic TRPV4 -/- mouse bladder. WT (n=2) (images A-C, 
G-I) and transgenic TRPV4 -/- mouse (n=2) (images D-F, J-L) bladders were investigated 
on ultrastructural level with TEM. In the WT urothelium, adjacent cells were tightly 
packed with hardly any distinguishable cell borders (image A and I ;blue arrow). Tight 
junctions (red arrows) were visible between the most luminal cell borders of neighboring 
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umbrella cells (B). AJ’s (yellow arrows) and desmosomes (orange arrows) were detectable 
between adjacent urothelial cell membranes (image C). In the TRPV4 -/- bladder, adjacent 
urothelial cells have enlarged intercellular spaces (blue arrows) (image D and L), and 
absent AJ formation (image F). Tight junctions (red arrow) image E) and desmosomes 
(orange arrow) (image F) were still present.  Vesicular exocytosis was detected in both 
WT (image G and H) and TRPV4 -/- mice (image J and K) umbrella cells and seen as the 
fusion of vesicles with the luminal membrane (pink arrows). The intracellular vesicles in 
the TRPV4 -/- umbrella cells were enlarged (purple arrows) and contained more proteins 
compared to the WT (image J and K). 
Discussion
A qualitative evaluation was performed to localize TRPV4 channels in the urogenital 
tract and investigate the interaction between TRPV4 and epithelial cell junctions 
in humans and mice. Our results demonstrate that TRPV4 is predominantly 
located on epithelial cells of the bladder, ureters and in the collecting ducts of the 
kidney. There is a distinct co localization between TRPV4 channels and AJ’s in the 
investigated epithelial cell layers. Subsequent immunoprecipitation experiments 
demonstrated that there is a molecular interaction between TRPV4 and α-catenin, 
which is the intracellular complex of the AJ that connects to the actin cytoskeleton. 
We used transgenic TRPV4 -/- mouse to study the interaction between TRPV4 
channels and AJ’s. Immunofluorescence assays and TEM evaluation on bladder 
tissue showed a disruption in AJ formation in the TRPV4 -/- phenotype, resulting 
in a decrease in epithelial integrity. 
The TRPV4 -/- mice that was used is a well investigated strain [Suzuki M. et al., 
2003] [Janssen D et al., 2011]. There are other transgenic TRPV4 -/- mouse strains 
to we did not have access for confirmation of our experiments [Gevaert T et al., 
2007]. For the TEM experiments, only bladder tissue was chosen, because not 
all epithelial linings in kidney tissues express TRPV4 channels, making it far less 
suitable for comparative evaluation. 
The function of TRPV4 in the kidney is still unclear. The TRPV4 -/- mouse phenotype 
has distinct abnormalities in osmolar balance [Everaerts W et al., 2010]. It has 
therefore been suggested that the lack of TRPV4 channels in the kidney may be 
responsible for this, since TRPV4 channels are located in the aldosterone-sensitive 
cells of the distal nephron [Berrout J et al., 2012] [Galizia L et al., 2012]. There 
is however, convincing evidence that shows that the osmolar disturbance in the 
TRPV4 -/- is actually caused by a lack of TRPV4 channels in the brain ventricula 
[Mamenko M et al., 2011]. There is evidence that water absorption in the collecting 
ducts occurs via transmembrane transport via activated aquaporin-2 channels in 
the principal cells and not through extracellular transport [Galizia L et al., 2012]. 
There are some indications that kidney TRPV4 channels regulate water absorption 
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indirectly by regulating K⁺ and Na⁺ uptake in the collecting ducts [Mamenko M 
et al., 2011]. A regulatory function in cell junctions formation by TRPV4 channels 
would be interesting for kidney function.
The results from our RT-PCR and immunofluorescence experiments demonstrate 
that TRPV4 channels are predominantly located in epithelial layers. No study 
was performed on TRPV4 channels in other urogenital organs like the prostate 
or urethra. The latter region is of interest, since the urethra is also exposed to 
flow and stretch and humans are able to sense urethral flow. Different groups 
have investigated the location of TRPV4 channels in the urogenital tract with 
comparable results [Berrout J et al., 2012] [Birder L et al., 2007] [Everaerts W et 
al., 2008] [Everaerts W et al., 2010] [Gevaert T et al., 2007] [Galizia L et al., 2012]. 
Besides in the epithelium, Gevaert et al. and other groups also reported on TRPV4 
expression in the walls of blood vessels [Gevaert T et al., 2007] [Wissenback U et 
a;., 2000]. Thorneloe et al. described TRPV4 expression in spindle like cells in the 
detrusor layer [Thorneloe K et al., 2008]. 
Cystometry experiments by other groups demonstrated that mechanical activation 
of TRPV4 channels is important for bladder afferent signaling [Birder L et al., 
2007] [Gevaert T et al., 2007] [Mochizuki T et al., 2009]. Stretch activates TRPV4 
channels independently from heat or agonists like 4α-phorbol 12,13-didecanoate 
[Vriens J et al., 2004]. The interaction between TRPV4 channels and the tensile 
network that consist of AJ’s and the actin cytoskeleton appears to be important 
for TRPV4 functioning. This is supported by investigations by Becker et al, who 
demonstrated that TRPV4 is connected to actin-filaments [Becker D et al., 2009] 
[Goswami C et al., 2010]. Additionally, Suzuki et al. reported that stretch activation 
of TRPV4 was abolished by the application of actin-freezing agents [Suzuki M et 
al., 2003].
The results from the ultra structural investigation of the TRPV4 -/- mouse 
bladder, imply that a lack of TRPV4 channels is responsible for the formation of 
enlarged vesicles with the congestion of cell material and membrane proteins 
in the umbrella cells. Vesicular endo- and exocytosis is an adaptation in bladder 
umbrella cells that minimizes the exposure of the outer cell membranes to urine 
[Hoduklin S et al., 2012]. Vesicles with membrane proteins are stored intracellular 
and merge with the outer membrane during stretch of the bladder wall and a 
reverse process takes place after bladder emptying. Transport of these vesicles 
is dependent on the actin cytoskeleton and is directly influenced by mechanical 
strain. This process could also be important for secretion of ATP for afferent 
signaling, although there is contrasting evidence that urothelial ATP excretion 
does not occur though vesical excretion [Ferguson D et al., 1997] [Lewis S et al., 
2006]. The abnormal vesicle formation could be caused by the absent interaction 
between TRPV4 channels and the actin cytoskeleton. Additionally, Cuajungco et al. 
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demonstrated that TRPV4 interacts with PACSIN 3 [Cuajungco M et al., 2006]. The 
latter is a cytoskeleton protein that is involved in vesicular membrane transport 
and endocytosis. To our knowledge, there are no reports on PACSIN 3 proteins 
in the bladder urothelium [Modregger J et al., 2000]. Our results are however 
indicative that TRPV4 has a role in vesicular endo- and exocytosis in the bladder 
urothelium, which could influence bladder sensory pathways. The content of the 
cell material in the vesicles needs further study.
The relation between TRPV4 and barrier forming cell junctions has been 
investigated in other organs like skin and lung tissue. In lung, applying a TRPV4 
antagonist in high doses induces severe barrier failure in pulmonal microvessels 
[Willette R et al., 2008]. In skin, TRPV4 reduces tight junction formation and 
causes an impairment in epithelial barrier [Sokabe T et al., 2010]. Reduced tight 
junction formation was not observed in our study and we haven’t performed 
functional assays to measure epithelial resistance. New studies also show that 
TRPV4 influences both cellular migration and fixation in tissues [Mrkonjic S et al., 
2015]. How TRPV4 exactly mediates cell junction formation in epithelia and the 
degree it contributes to epithelial resistance still requires further study. Even so, 
there appears to be a mutual dependence, which suggests that there is a bridge 
between the two classical functions in epithelia being 1) barrier formation and 2) 
sensory function.
Summarized we can say that although the interaction between TRPV4 channels 
and cell junction formation in the epithelia of the urogenital tract generates 
plausible hypothesis. Further study is mandated to clarify the physiological 
implications for this in different organ systems. 
Conclusion
This study has demonstrated an important role for TRPV4 channels in cell junction 
formation in the urogenital tract. A lack of TRPV4 impairs the ability to construct 
a sufficient coherent epithelial barrier, implying that in the epithelium, there is an 
association between barrier function and afferent signaling.
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Supplemental data
Supplementary Table 1. Antibody specifications
Supplementary Table 2. Sequences of primers used in this study
*, This variant, also known as isoform IIIb, contains alternatively spliced exon 8 but lacks 
exon 9. The resulting protein (isoform 3) has the IIIb-type C-terminal half of the IgIII domain.
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Abstract
Introduction: The role of TRPV4 channels in urinary bladder afferent neural 
pathways was investigated using spinal c-fos measurements in mice.
Material & Methods: Anesthetized wild type and TRPV4 knockout(-/-) mice 
underwent noxious bladder distention and treatment with either intravesical 
instillation with lipopolysaccharide (LPS), or the TRPV1 agonist resiniferatoxin 
(RTX), vehicle or an intraperitoneal injected TRPV4 antagonist (HC067047). Mice 
underwent paraformaldehyde perfusion for rapid fixation and L6-S1 spinal cord 
sections were removed followed by immunohistochemical staining for c-fos. 
Theory/Calculation: Number of c-fos expressing neurons in the dorsal horns of 
L6-S1 spinal cord transections were quantified. Groups were compared using 
univariate ANOVA.
Results: Even with absence of bladder inflammation on H&E, the TRPV4 -/- mice 
still have a significant two-fold higher c-fos expression (n=39, SD 2) after noxious 
bladder distention compared to wild type mice (n=20, SD 3). A two-fold increase 
in c-fos expression was observed after LPS treatment in wild types (n=42, SD 5), 
but no increase was seen in TRPV4 -/- mice (n=42, SD 2). After desensitization 
of primary afferent C-nerve fibers with RTX, c-fos expression in TRPV4-/- mice 
decreased significantly (three-fold) (n=12, SD 4). 
Conclusions: Results imply that TRPV4 channels are important for bladder afferent 
signaling. TRPV4-/- mice bladders generate more noxious sensory output, which 
is predominantly mediated through TRPV1 expressing high threshold nerve fibers. 
This study reveals TRPV1 related adaptive changes in afferent pathways of the 
TRPV4 -/- mouse. We propose that this effect is caused by a congenital impairment 
of low threshold nerves that mediate normal bladder filling sensations. 
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Introduction
Transient Receptor Potential Vanilloid subtype 4 (TRPV4) is a non-selective 
Ca²⁺-permeable cation channel that is located on the membranes of urinary bladder 
epithelial cells [20,19,9,14]. TRPV4 is part of the large family of TRP-channels that 
are involved in a wide range of physiological processes and is the most abundantly 
expressed TRP-channel in the urinary bladder [9,21,8]. TRPV4 channels are of 
interest because the channel is activated by mechanical stretch and therefore 
could participate in bladder filling sensory pathways [8,24,17,11]. 
Under physiological conditions, stretch in the urothelium causes a TRPV4 mediated 
Ca²⁺ influx into the cell which triggers the release of ATP, a potent activator of 
afferent nerve fibers in the bladder [8,24,17,11]. These afferents contain low and 
high threshold nerve fibers, that mostly consist of myelinated Aδ fibers, and a 
group of silent fibers that consist of unmyelinated C nerve fibers [17,11,15,28]. 
Low threshold fibers are important for normal bladder filling sensations and 
respond to low bladder pressures. High threshold fibers are only activated during 
high pressures (>20 cmH2O) and silent fibers are activated during chemical 
irritation after which they also become mechanosensitive. The high threshold 
fibers express TRPV1 receptors and are important for inflammatory responses 
and pain [28]. 
A considerable number of publications suggest that TRPV4 channels are involved 
in bladder afferent pathways [17,11,10,2]. The phenotype of transgenic TRPV4 -/- 
mice is marked by an enlarged bladder capacity, diminished voiding contractions 
and a reduced ATP response to urothelial stretch [17,11]. This body of evidence 
implies that TRPV4 -/- mice have inadequate bladder filling sensations which 
mostly occurs through low threshold afferents [28].
These characteristics make TRPV4 channels an interesting target for pharmacological 
intervention for conditions like overactive bladder syndrome (OAB) or Bladder 
Pain Syndrome (BPS). Evidence from in vitro and in vivo experiments confirm that 
the pharmacological blocking and stimulating of TRPV4 channels can mediate a 
local response in the bladder [10,2,25,26]. Investigating the sensory function of 
TRPV4 channels higher up in the afferent neural tract could give more insight 
in the function of these channels in the lower urinary tract. To gain this insight, 
neural sensory information needs to be quantified.  
The spinal c-fos experimental model is an in vivo model that enables us to 
quantify afferent signaling [13,2,5]. After stimulation, c-fos mRNA is transcribed 
in the nuclei of sensory neurons [18,7]. In mice, the afferent signals that originate 
in the bladder travel via the dorsal root ganglia and enters the spinal cord at the 
superficial dorsal horn area of the spinal cord segment L6-S1 [1,3]. Noxious stimuli 
in the bladder results in the transcription of c-fos in three main areas of the L6-S1 
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segment that are important in bladder afferent signaling. These are: the dorsal 
horns (DH)(laminea I,II,V), sacral parasympathetic nuclei (SPN), and the dorsal 
commissure [13,1,3,27]. 
The aim of this study was to investigate the contribution of TRPV4 channels in 
bladder afferent signaling by quantifying c-fos positive nuclei in sensory regions of 
the L6-S1 spinal cord segment of normal wild type and transgenic TRPV4 -/- mice. 
Materials methods
Animal experiment
Our animal experiments were conducted with approval of our regional animal 
ethical committee Radboud University Medical Center (CDL). Wild type mice 
(C57BL/6UJ) (n=16) and TRPV4 -/- (n=16) females of 25 grams were used for 
experiments. TRPV4 -/- mice (n=16) were generously made available by Suzuki et. 
al. [23]. Knock out of TRPV4 in TRPV4 -/- mice was validated by Western blotting 
and immunohistochemistry experiments [14]. The experimental procedure went 
as followed. On day one, mice were anesthetized with isoflurane inhalation (1,5%) 
and catheterized using a thin PET tube (PE10; Intramedic Sparks, USA) and gel 
lubrication. Bladders were emptied. 
Four different experimental groups were created. 1) A control group (TRPV4 -/- 
n=4, wild type n=4) received a bladder installation of 0,1ml of normal saline for 
10 min. 2) A bladder inflammation group (TRPV4 -/- n=4, wild type n=4) received 
an installation of 0,1 ml Lipopolysaccharide (LPS, 5mg/ml) (Sigma-Aldrich, St 
Louis, USA) in the bladder for 10 min. 3) A resiniferatoxin (RTX) group (TRPV4 -/- 
n=4, wild type n=4) received a bladder instillation of 0,1ml RTX (1nM dissolved in 
DMSO)(Tocris Bioscience, Bristol, UK) for 30min to desensitize TRPV1 expressing 
high threshold and silent afferent C-fibers. 4) A TRPV4 antagonist group (TRPV4 
-/- n=4, wild type n=4) received an installation of 0,1ml of normal saline at day one 
followed by an intraperitoneal (ip) injection of the TRPV4 antagonist HC 067047 
(10mg/kg)(Tocris Bioscience, Bristol, UK) 15 min prior to the surgical intervention 
at day two.
At day two (24 hours later), mice from all groups were anesthetized with urethane 
ip (2g/kg). The abdomen was surgically opened and an infusion needle was 
inserted in the bladder dome. Bladder contractions and voiding was still possible. 
The bladder was then continuously infused with normal saline at 23 cmH2O 
(noxious distention) for 60 minutes (37°C) (Fig. 1). 
After this, the thorax was quickly opened. A needle was inserted first in the portal 
vein and secondly through the left cardiac ventricle, after which the blood supply 
was drained by flushing the circulatory system with phosphate buffered saline (PBS)
(0,4M pH 7,2). Immediately after this,  the mice underwent a perfusion fixation 
111
TRPV4 mediates afferent pathways in the urinary bladder. A spinal c-fos study Chapter 4
procedure by flushing the circulatory system with 4% (v/v) paraformaldehyde in 
0,1M PBS (pH 7,2), until paws and tail stiffened up. Mice were then placed in flasks 
containing 4% (v/v) paraformaldehyde in 0,1M PBS (pH 7,2) and transported to 
the lab for tissue preparation.
Figure 1. Applied experimental spinal c-fos in vivo mouse model for bladder afferent 
signaling. Bladder distension is achieved via normal saline infusion through a small 
syringe inserted into the bladder dome. LPS, RTX or vehicle was instilled in the bladder 
via catherisation. Bladders were able to empty during noxious distension (23cmH2O). 
During stimulation, afferent nerves (Aδ and C-fibers) are activated, and an afferent 
signal travels through the sacral nerves, cross the dorsal root ganglia (DRG) and enter 
the superficial dorsal horn (SDH) areas of the L6-S1 spinal cord segment, where nuclei 
of afferent nerves start producing c-fos in three main areas: the dorsal horn (DH & SDH), 
sacral parasympathetic nuclei (SPN), and the dorsal commissure (DCM). The bottom right 
image shows a c-fos immunostaining of a L6-S1 spinal cord transection of a TRPV4 -/- 
mouse that has underwent a bladder distention. Black dots are c-fos expressing nuclei. VH 
= ventral horn.
Tissue preparation
Spinal cords including dorsal roots ganglia were surgically removed using a 
dissection microscope (Zeiss, Göttingen, Germany) and microscopic surgery 
tweezers and cutting scissors and subsequently fixated one night in 4% (v/v) 
paraformaldehyde and 24 hours in a 30% (v/v) sucrose in 0,1M PBS solution. 
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The L6-S1 spinal cord segment was isolated and imbedded separately with 
Tissue-Tek® O.C.T. (Sakura Finetek, Japan) and snap frozen in isopentane on dry 
ice and stored at -80°C. 35 mu thick sections were cut with a freezing microtome 
(Microm, Heidelberg, Germany) and collected in free floating staining cups that 
were placed in 12 well plates (Millipore Corporation, Billerica, USA) containing 
0,1M PBS solution (pH 7,3). Rat spinal cord cross sections that had received a 
similar fixation protocol were used as positive controls. Also urinary bladders were 
removed and immediately snap frozen in isopentane on dry ice and cut in 4 mu 
sections with a freezing microtome and placed on glass slides (Superfrost®plus, 
Thermo-Scientific, Waltham, USA). 
Immunohistochemistry    
Bladder tissue was analyzed for signs of inflammation with standard HE-staining. 
Free floating immunohistochemistry was performed for spinal cord c-fos 
experiments. Tissue was rinsed with 0,1M PBS solution containing 0,1% (v/v) 
Bovine Serum Albumin and 0,3% (v/v) Triton-X-100 (PBS-BT). Tissue was 
incubated overnight with a c-fos (4) antibody (c-fos (4) sc-52 rabbit-polyclonal Lot 
# L 1809, Santa Cruz®, Santa Cruz, USA) dissolved in PBS-BT at room temperature. 
We used 0,1M PBS pH 7,3 for further rinsing steps. Tissue was incubated with 
a donkey-a-rabbit IgG biotin conjugated secondary antibody (Jackson Imm 
Research®, West Grove, USA) in PBS-BT for 90 min, following incubation with 
Vector ABC elite® (Vector, Burlingame, USA) for 90 minutes. Tissue was incubated 
using a DAB solution containing 10 µl DAB (Sigma Aldrich, St Louis, USA) and 
150mg Ammonium-Nickel-Sulphate dissolved in 50ml 0,05M Tris buffered saline 
for 10 min, followed by a 10 min incubation with the same DAB-Nickel solution 
with the addition of perhydrol (5µl in 25ml DAB-Nickel solution). Tissue was 
mounted on objects glasses coated with gelatin and dried overnight at 37°C, 
then dehydrated with ethanol and xylene and mounted with Permount® (Thermo 
Fisher Scientific, Waltham, USA). Sections were analyzed by using binocular (Leica 
DMR®) microscope and processed with Image J 1.41o® software. 
Theory/ Calculation
Quantitative analyses was performed in triplo and blinded by quantifying the 
c-fos positive nuclei in the (unilateral) dorsal horn area of intact 35 mu thick L6-S1 
spinal cord transections. For each individual animal, multiple transections were 
counted this way and the median number of c-fos positive nuclei per L6-S1 dorsal 
horn / transection / per animal was calculated. From these medians, the average 
number of c-fos positive nuclei per L6-S1 dorsal horn / transection / per group 
was calculated (this will be referred to as ‘the number of c-fos + cells’). Groups 
were compared using univariate ANOVA.
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Results
A total of 26 out of 32 individual animals were included in the evaluation. Two 
animals died prematurely (5 and 15 minutes before end of distention) during 
the experiment. In four animals, L6-S1 segments were unfit for evaluation. This 
diminished sample sizes in the RTX groups (n=3, n=3) and TRPV4 antagonist groups 
(n=2, n=2). The TRPV4 antagonist groups were omitted from statistical evaluation 
because of low number of animals. Univariate ANOVA showed statistical significant 
differences between groups (Between-Subject effects). 
Immunohistochemical staining for c-fos were performed on L6-S1 spinal cord 
segments. Lower sacral and higher lumbar and thoracic spinal cord segments 
were also dissected and stained and were clearly distinguishable in size and 
shape from the L6-S1 spinal cord transections (Fig. 2a). IHC experiments showed 
that only nuclei with c-fos immunoreactivity were detectable and had a clear 
oval aspect. These c-fos positive nuclei of different sizes were clearly detectable 
in the designated areas of the spinal cord sections (DH, SPN, DCM) of mice and 
in rat spinal cord and brain transections with hardly any background (Fig 2). 
The DAB-Nickel immunostaining improved the contrast and detection of c-fos 
expressing nuclei. The majority of c-fos expressing cells in the dorsal horn region 
were detected in the superficial dorsal horn area (SDH) followed by the lower 
(anterior) laminae V area (Fig. 2b). The number of c-fos expressing nuclei in the 
L6-S1 dorsal horn were counted and compared between groups. In some cases, 
there were considerable variances observed in the number of c-fos expressing 
nuclei even between two intact dorsal horns from the same tissue transection. As 
a result, the experiment used all suitable transections for analysis with an average 
of 6 representative L6-S1 transections included for each individual animal. 
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Figure 2. Displays the mouse spinal cord along with the cross sections at different levels 
showing distinct differences in size and shape for each level (A). The dorsal horns (DH) 
of the L6-S1 segment were used for the experiments. (B) Detail of c-fos expression in the 
dorsal horn (DH) area of a L6-S1 spinal cord segments in wild type (upper image) and 
TRPV4 -/- (lower image) mouse after bladder distension. C-fos expressing nuclei are seen 
as black dots (blue arrows). After bladder stimulation, the majority of c-fos expressing cells 
in the DH area were seen in the superficial dorsal horn area (SDH). Other sensory areas like 
the sacral parasympathetic nuclei (SPN) and the dorsal commissure (DCM) also showed 
increased numbers of c-fos expressing nuclei. TRPV4 -/- mice had more c-fos expressing 
nuclei after bladder distension compared to wild type mice.
Bladder distention
Distending the bladder with 23 cmH2O resulted in a large difference in c-fos 
expression between wild type (n = 4) and TRPV4 -/- mice (n = 4) (Fig. 3). Dorsal 
horn regions contained a two-fold higher number of c-fos positive nuclei in the 
TRPV4 -/- mouse (39 + cells, SD 2) compared to wild type mouse (20 + cells, SD 
3) (p < 0,001) (Fig. 3). The bladders were evaluated after the experiment with a 
standard H&E staining. No signs of inflammation or bladder wall damage after 
bladder distention were observed in the  TRPV4 -/- or the wild types (Fig. 4a,b).
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Figure 3. The results of mouse spinal c-fos measurements in L6-S1 dorsal horns after 
noxious bladder distention (23 cmH2O). C-fos expression was calculated as the average 
number c-fos expressing cells (nuclei) per L6-S1 dorsal horn / 35mu transection / group. 
Graph shows that after bladder distention, there was a significant (*)(p<0,001) 2-fold 
higher c-fos expression in the L6-S1 dorsal horns of TRPV4 -/- mouse (39 + cells, SD 2) 
compared to wild type mouse (20 + cells, SD 3) (p<0,001). 
Bladder inflammation
Inducing bladder inflammation with LPS resulted in inflammatory changes which 
was evaluated by bladder H&E staining and revealed a damaged umbrella cell 
layer, hemorrhage within the bladder wall and bladder wall edema (Fig. 4c, 
supplemental figure 3). Cystitis increased the number of c-fos expressing cells 
significantly (two-fold) in the wild type mice (n = 4) (42 + cells, SD 5) compared 
to controls (n=4) (20 + cells, SD 3) (p<0,001) (Fig. 4d). Induction of cystitis in the 
TRPV4 -/- mice  (n = 4) (42 + cells, SD 2) however, did not result in any difference 
in c-fos expression when comparing them to controls (n = 4) (39 + cells,  SD 2) (Fig. 
4d). 
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Figure 4. Results of the Resiniferatoxin (RTX) and Lipopolysaccharide (LPS) experiments. 
Image A and B shows typical HE staining of WT mouse (A) and TRPV4 -/- (B) after bladder 
distention (23 cmH2O). Image C shows a WT mouse bladder after LPS treatment + 
distention. No signs of bladder wall damage or inflammation characteristics were observed 
in the TRPV4 -/- mice and the WT mice after distention. The LPS treated bladders did show 
histochemical inflammation characteristics with a disrupted urothelial layer (orange 
arrow), Hemorrhage (blue arrow) and submucosal edema (green arrow) (C). Graph D 
shows results of the spinal c-fos quantification from LPS and RTX experiments. TRPV4 
-/- and wild type mice received a combination of bladder distention (23 cmH2O) + LPS 
instillation (bladder inflammation) (WT n = 4 , TRPV4-/- n = 4) or a distention (23 cmH2O) 
+ RTX instillation (desensitizes afferent C-fibers) (WT n = 3, TRPV4-/- n = 3). Treatment 
groups were compared to bladder distention alone ( = baseline). C-fos expression was 
calculated as the average number of c-fos expressing cells (nuclei) per L6-S1 dorsal horn 
/ 35mu transection / group.  Results are displayed as % increase or decrease compared 
to baseline and upper and lower limits display the variation within each group. After LPS 
treatment there is a significant (*) 120% increase in c-fos expression in the wild type mice 
(42 + cells, SD 5) (p<0,001). By contrast, only a non-significant 17% increase was seen 
in the TRPV4 -/- mice after LPS treatment (42 + cells, SD 2). After RTX treatment, c-fos 
expression was significantly (*) reduced in both wild type (46%,  11 + cells, SD 2) (p=0,02) 
, and even more profound in TRPV4 -/- mice (69%,  12 + cells, SD 4) (p<0,001) compared 
to controls.    
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RTX treatment
Desensitizing the bladder afferent c-fibers with RTX, an ultrapotent TRPV1 agonist, 
induced a 3-fold decrease of c-fos activity in the TRPV4 -/- mice (n = 3) (12 + cells, 
SD 4) compared to controls (n = 4) (39 , SD 2) (p < 0,001) (Fig. 4D). In the wild type 
mouse, a significant decrease in c-fos expression was also seen (n = 3) (11 + cells, 
SD 2) compared to the non-treated controls (n = 4) (20 + cells SD 3) (p = 0,02)(Fig. 
4d). This difference was relatively lower compared to the TRPV4 -/- mice. 
TRPV4 antagonist HC 067047
Fall out in both TRPV4 -/- and wild types resulted in 2 mice per treatment 
group. Outcomes of statistics in these low numbers of specimens are therefore 
problematic and therefore omitted. Results of c-fos activity within each group 
were very comparable in all groups. A decrease in c-fos expression was observed 
in the wild type treated group (15 + cells, SD 1) compared to untreated wild types 
(20 + cells, SD 3). A relatively smaller decrease was also observed in the HC067047 
treated TRPV4 -/- group (32 + cells, SD 2) compared to untreated TRPV4 -/- (39 + 
cells, SD 1).
Discussion
The spinal c-fos in vivo model was used to investigate the role of TRPV4 channels 
in bladder afferent signaling during noxious stretch and bladder inflammation. 
Results of this study demonstrate that the TRPV4 -/- phenotype has disturbed 
signaling during noxious stimulation of the bladder. Compared to normal mice, 
there was a two-fold higher c-fos expression in the dorsal horns of TRPV4 -/- mice 
during noxious stretch. This difference was unexpected, since we had hypothesized 
a decrease of c-fos activity in the TRPV4 -/- mouse. Further experiments were 
conducted to investigate this afferent signaling paradox. An expected doubling 
of c-fos expression was seen in normal mice during bladder inflammation. By 
contrast, no increase in c-fos expression was seen in the TRPV4 -/- mice. The high 
c-fos counts in the TRPV4 -/- dorsal horns were however, significantly reduced to 
low levels by desensitizing primary afferent nerve fibers with the the ultrapotent 
TRPV1 agonist RTX. Our results confirm that TRPV4 is an important mediator in 
bladder filling sensory pathways, but other receptors of redundant pathways are 
likely implicated in the TRPV4 -/- mice.
Treatment with the selective TRPV4 antagonist HC 067047 did show homogenous 
results within each group, but there was considerable fall out of specimens in 
both treatment groups resulting in small numbers per group (n=2) that were too 
low for representative statistical analysis. Results are therefore only indicative for 
future studies. Compared to the controls, the treated wild type group showed 
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a decrease in c-fos expression. This difference was relatively larger compared 
to the treated TRPV4 -/- mice group. The same antagonist was used previously 
in bladder in vivo cystometry experiments by Gevaert et al. [11]. Their results 
demonstrated a significant decrease in the frequency of bladder contractions in 
the inflamed wild type mouse bladder. Although we used a similar concentration 
and administrative route in our experiment, we used the TRPV4 -/- antagonist 
in non-inflamed mouse bladders. The results from this latter study and our own 
results give an indication that it is worthwhile to further investigate the effects of 
HC 067047 and other TRPV4 antagonists on bladder afferent signaling pathways. 
Spinal c-fos measurement is an established experimental in vivo model for 
quantifying afferent neural signaling [5]. C-fos is a proto-oncogene that regulates 
cell differentiation and proliferation [13,4,5]. Quantifying afferent neural signals is 
difficult. The amount of c-fos positive nuclei in designated areas of the spinal cord, 
highly corresponds to the intensity of the nociceptive afferent stimulus, and can 
therefore be used for comparative quantitative analysis [13,7,1]. This model has 
been used for mapping neural pathways and to evaluate the effects of different 
noxious stimuli and pharmacological interventions on bladder sensory pathways 
[7,1,3]. The only alternative model is electrophysiological recording. There are 
some differences between these two models. Electrophysiological recordings 
measure a more direct and continuous afferent signal, while the spinal c-fos model 
traps a moment in time. Upside of this is that c-fos stains nuclei in specific anatomic 
areas of the dorsal horns that are very suited for neural mapping, quantification 
and statistical analysis [13]. Other areas with increased c-fos expression like the 
sacral parasympathetic nucleus, and the dorsal commissure were also detected in 
our experiments. These areas were not used in our evaluation because isolating 
these two areas anatomically is more arbitrary compared to the dorsal horn. 
A drawback of the c-fos model is the relatively high threshold for detection, 
since it requires a noxious stimulus for a prolonged time to achieve high enough 
c-fos concentrations for detection on immunohistochemistry [13]. A stimulus of 
just over 20cmH2O during 1 hour was chosen for two reasons. The first is the 
requirement of a noxious, but non-traumatic stimulus for spinal c-fos expression. 
The second was because other groups have demonstrated that a stimulation 
durance of 1-2 hour gives the highest number of c-fos expressing nuclei [1]. 
Urethane anesthesia was chosen because unlike other forms of anesthesia it does 
not alter spinal c-fos expression [1]. Both the c-fos model and electrophysiological 
recordings have great additional value in relation to organ confined measurements 
like bladder cystometry for understanding the complete afferent pathway of a 
sensory receptor.
The spinal c-fos model has helped to understand neurologic bladder dysfunction 
due to spinal cord lesions and was used to investigate the function of sensory 
receptors like TRPV1 channels and P2X receptors in the urinary bladder [7,3,16]. 
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TRPV1 channels are located on bladder afferents and urothelial cells and are 
involved in pain and inflammatory sensory pathways. The TRPV1 -/- mouse 
phenotype shows mild voiding abnormalities under normal conditions and shows 
a decreased spinal c-fos activity during bladder distention and inflammatory 
conditions [7,3]. In contrast, the TRPV4 -/- mice phenotype is characterized by 
an abnormal voiding behavior and a reduced voiding contraction frequency 
under normal conditions [11]. This suggests that TRPV4 channels are important 
for normal bladder filling sensations that are largely dependent on low threshold 
(Aδ) nerve fibers [28]. We expected lower c-fos activity during bladder distention 
in these knockout mice. Results of this study revealed the opposite meaning 
that the number c-fos expressing nuclei was equivalent to cystitis conditions in 
the wild type mouse. During the bladder distention in our experiments, mice 
were still able to void. As a result, the TRPV4 -/- mice may have received more 
noxious input during the experiments then the wild type mice, because their 
bladders maybe responded less to filling and had delayed voiding reflexes and 
therefore received prolonged periods of bladder wall stretch. This would give 
some explanation for higher c-fos activity in the knockout. However, it is unlikely 
that this would fully explain for the very large difference in c-fos expression 
that were observed in this study. The TRPV4 -/- also responded different to the 
manipulation of noxious c-fibers compared to the wild types. The LPS experiments 
demonstrated that bladder inflammation did not cause an expected further rise 
in c-fos activity in the knockout mice and the RTX instillations decreased the high 
baseline c-fos expression to a degree that was comparable wild type animals. This 
relative reduction in c-fos activity was far greater in the TRPV4 -/- mice. RTX is 
a super analog of capsaicin and targets and incapacitates specifically the TRPV1 
expressing noxious c-fibers and does not affect the low threshold Aδ fibers that 
are responsible for normal bladder filling sensations [8]. Although the experiments 
cannot differentiate if the remaining c-fos expression after the RTX treatment 
originates from residual c-fiber signaling or from Aδ signaling. By evaluating the 
results from the RTX and LPS experiments, we can still discriminate that bladder 
filling signaling in the TRPV4 -/- mouse is different compared to wild types and is 
primarily mediated through the noxious, high threshold nerve fibers that express 
TRPV1 receptors. 
The TRPV4 -/- mouse phenotype is remarkable in that is has severe bladder 
dysfunction with increased micturition intervals, soiling, but normal voiding 
contractions [11]. TRPV4 channels are located on urothelial cells and upon 
activation by mechanical stretch trigger the urothelial ATP signaling pathway [24]. 
Activation of urothelial TRPV4 channels by mechanical stretch most likely occurs 
through an interaction between TRPV4 channels and a network with the actin 
cytoskeleton and adherence junctions [14,22,12]. 
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To date, four different types of afferent nerve fibers that are involved in bladder 
mechanosensation have been identified. Some of these are located in the bladder 
mucosal area and are be part of the urothelial afferent signaling pathway [6]. The 
TRPV4 knockout phenotype has an abnormal lower urinary tract function and has 
altered responses to noxious stimuli in the bladder. This is most likely caused by 
an adaptation to a congenital impairment of low threshold nerve fiber signaling 
(Fig. 5). This has to be taken into account when investigating the function of TRPV4 
channels in knockout models.  
Figure 5. Describing the proposed dysfunctional bladder afferent signaling in the TRPV4 
-/- mice. Upper figure shows normal afferent signaling during noxious bladder distention 
in the wild type mouse and the resulting c-fos expression in the sensory regions: Dorsal 
horns (DH; including superficial dorsal horn (SDH) areas), Sacral parasympathetic nuclei 
(SPN), and the Dorsal commissure (DCM). Both normal low threshold Aδ (normal bladder 
filling sensation) and high threshold (noxious) C-fiber afferent nerves are activated during 
bladder distension giving a mixed afferent signal through the sacral nerves into the sensory 
areas of the L6-S1 spinal region. C-fos is activated only through noxious stimuli from 
high threshold nerve fibers, leading to a normal rise in c-fos expression. The lower figure 
displays the proposed altered bladder afferent signaling in the TRPV4 -/- mice. Based on 
our results we suggest that normal low threshold Aδ nerve signaling for normal bladder 
mechanoreception (filling sensation) is (partly) impaired and results in a compensatory 
stronger afferent signal through high threshold noxious C-nerve fibers. As a result, more 
c-fos (two-fold) is expressed in the designated sensory areas of the L6-S1 spinal segment. 
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Conclusions
TRPV4 channels in the bladder are involved in bladder afferent signaling. Bladder 
filling signaling function in the TRPV4 -/- mice phenotype is more dependent on 
noxious, high threshold nerves that express TRPV1 receptors.
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Abstract
Purpose: Glycosaminoglycan (GAG) replenishment therapies are commonly 
applied for the treatment of bladder inflammatory conditions, such as Bladder 
Pain Syndrome (BPS/IC). Although there is evidence that these therapies are 
clinically effective, much is still unknown about the location and function of 
different types of GAGs in the bladder. The aim of this study was to investigate 
the location of sulphated GAGs in the bladder and to evaluate their contribution 
to the urothelial barrier.  
Materials and Methods:  Location of different GAGs (heparan sulphate, 
chondroitin sulphate, dermatan sulphate) in the human and porcine bladder were 
investigated with immunofluorescence stainings and by isolation of GAGs with 
selective urothelial sampling techniques. Barrier function was evaluated with 
Trans Epithelial Electrical Resistance (TEER, Ω.cm2) measurements on primary 
porcine urothelial cell cultures. The contribution of different GAGs to the bladder 
barrier was investigated with specific GAG-digesting enzymes and protamine. 
Results: High concentrations of GAGs are located around the urothelial basal 
membrane and at the urothelial luminal surface. After removing the GAG layer, 
the permeability of the urothelium increases. The natural recovery of the GAG 
layer takes less than twenty-four hours. Chondroitin sulphate was the only 
sulphated GAG that was located on the urothelial luminal surface and it was the 
only sulphated GAG that contributed to urothelial barrier function.
Conclusions: This study revealed an important role for chondroitin sulphate in 
bladder barrier function. Therapies aiming at restoring the luminal GAG layer in 
pathologies like BPS/IC are based on a sound principle.
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Introduction
Bladder inflammatory conditions are associated with a malfunctioning of the 
protective barrier of the bladder. The bladder predominantly functions as a 
short term storage organ and as a result is subjected to large volume changes. 
In order to cope with these continuous volume changes, the bladder wall has a 
high degree of flexibility and is able to prevent the re-entering of urotoxins into 
the body. The urothelium is the first cell layer to be exposed to urine and is also 
the primary tissue that forms the protective barrier [1][2]. Different studies have 
demonstrated that a defective barrier leads to an increased risk for developing 
conditions like interstitial cystitis (BPS/IC) and cystolithiasis [3-6]. Restoring 
or improving the protective bladder barrier has therefore been adopted as a 
strategy to treat diseases [7]. Examples of these are oral pentosan polysulphate 
and bladder instillations with hyaluronic acid, chondroitin sulphate and heparin. 
All these treatments claim to restore the bladder glycosaminoglycan (GAG) layer. 
Some of these have recently been demonstrated to be clinically efficacious [8-11]. 
Despite of these positive results, it is still not fully clear what the exact function 
of individual GAGs is in protecting the bladder and how they are distributed [1].    
The most superficial cell layer of the urothelium is composed of umbrella cells 
that are highly specialized. The luminal surface of the umbrella cell membrane 
is covered with a specialized asymmetric unit membrane (AUM), which consist 
of several uroplakins, lectins and the GAG layer [1][12][13]. Combined, this layer 
is referred to as the glycocalix. Together with the occluding cell junctions (tight 
and adherence junctions), the glycocalix constitutes the primary barrier forming 
structure of the urothelium [1][14][30].  
The GAG layer consists of negatively charged sulphated polysaccharides (the GAGs) 
that are bound to core-proteins that also have a negative charge due to n-terminal 
sialic moieties [4]. Together they form a proteoglycan. The GAG layer binds water 
into a gel-form via a process called electrostatic entrapment. This creates a 
buffer between the irritants in the urine and the urothelial cell membrane. As a 
result, the GAG layer is believed to be the first line of defence. This implies that 
a defective GAG layer is thought to contribute or even cause diseases like BPS/
IC [5]. The GAGs that are associated with the bladder are heparan sulphate (HS), 
chondroitin sulphate (CS), dermatan sulphate (DS) and hyaluronic acid (the latter 
is not bound to a core-protein and unsulphated) [2][15].
The aim of this study is to investigate the distribution of different GAGs in the 
bladder and to evaluate their contribution to the urothelial barrier.
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Materials & Methods
Tissues and cells
Non-tumorous human bladder tissue (pathologist controlled) was obtained 
from cystectomies (three bladder cancer, one locally advancing cervixcarcinoma 
without bladder infiltration, one severe stress incontinence). Freshly dissected 
porcine bladders were provided by the abattoir (Nijmegen) stored on ice and 
processed within 2h. Primary urothelial cell cultures were also obtained from 
these porcine bladders and cultured in keratinocyte serum free medium (cKFSM) 
containing cholera toxin, bovine pituitary extract, 1% P/S (Invitrogen, Gibco). 
Details for the methods applied are in the supplements. All tissues were obtained 
with approval of the human ethical committee (CMO Arnhem-Nijmegen) affiliated 
to the Radboud University Medical Center.  
GAG isolations and silver staining
GAG isolations of specific regions of the porcine bladder were conducted to 
evaluate the distribution of different GAGs (HS, CS and DS). After opening the 
porcine bladders (n=4) under sterile conditions, samples were taken in three 
different methods: 1) For the urothelial mucous layer, a sample of the luminal 
surface of the urothelium was harvested by gently scraping of a 5cm² surface 
using a small blunt spatula (avoiding cutting edges). 2) A complete urothelium 
sample (incl. urothelial basal membrane) was harvested by gently scraping a 5cm² 
surface with a microtome blade and 3) a full thickness biopsy of the bladder wall 
was taken (also human bladder biopsy). Multiple tissue biopsies were taken as 
a histochemical control and processed for standard hematoxylin-eosin-staining 
(HE). 
Detailed descriptions for GAG isolations and silver staining are described in 
the supplements. GAGs were separated from proteins by first applying 10U of 
papain/l digestion buffer/250g , following Trichloro acetic acid precipitation and 
two centrifugation steps (20-30min,4°C, 10.000g). Supernatant containing GAGs 
was diluted 5 times and loaded (0.5ml) on pre treated (10mM TrisHCl, pH 6.8) 
IVSS Vivapure spin columns (Q mini M)(Sigma-Aldrich) and centrifuged (1min, 
10.000g) to bind the GAGs to the column. A 50µl 2M NaCl in 10mM TrisHCl(pH 
6.8) solution was used to release and isolate the GAGs. GAGs were separated 
by thin layer agarose gel electrophoresis. A standardized solution containing 
20ng CS, 20ng DS and 40ng HS was loaded into the slots of the outer lanes to 
be  used as reference. GAGs were visualized with a silver staining using a fixative 
(50% methanol, 10% acetic acid), followed by adding 5%(w/v) Na2CO3 and silver 
staining solution; 0.2%(w/v) ammonium nitrate, 0.2%(w/v) silver nitrate, 1%(w/v) 
silicotungstic acid (Fluka). 0.036% (v/v) Formaldehyde was added to initiate 
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staining and 25%(v/v) and acetic acid was used to terminate it. Fresh 5%(w/v) 
Na2CO3 was added to intensify the gels. Gels were dried and scanned.
Immunofluorescence 
Human and porcine bladder biopsies were embedded in Tissue-Tek (O.C.T.®), 
snap frozen and cut into 4µm sections. Primary urothelial cells were cultured on 
glass slides (1wk). Sections were fixated with 3%(v/v) paraformaldehyde (10min), 
following rinsing (3x) with Tris-Buffered Saline with 0.05%(v/v) Tween solution 
(TBS-T). Sections were blocked with 20%(v/v) goat serum before incubation with 
primary antibodies (overnight, 4°C) against CS: IO3H10 [16](predominantly CS 
6-sulphate) & CS56 (Abcam)(CS 4 & 6-sulphate), HS: AO4B08 [17] & HS4C3 [18] 
and DS: GD3A12 [19]. For the samples stained with the IO3H10, AO4B08, HS4C3 
& GD3A12 antibodies, an incubation step with an anti-VSV-G antibody (P5D4)
(30min) was included after the primary antibody incubation step. Alexa’s 488 
& 594 (Invitrogen) labeled secondary antibodies were used. DAPI (Merck) was 
applied for nuclei staining. Omission of the first antibody was taken as a control. 
Epifluorescent binocular microscopy (Leica DMR®) and ImageJ 1.41o software 
was used for analysis. 
Immunohistochemistry
Samples included urothelial cells cultured on glass slides (1wk) and 4µm 
deparaffinised porcine bladder sections. Sections were fixated using 3% (v/v) 
paraformaldehyde (10min, pH7.4) and air dried (2h), following 3%(v/v) hydrogen 
peroxidase (Merck) treatment and blocking with 5%(v/v) normal goat serum 
(Merck). Primary antibody against Occludin (tight junctions; Invitrogen) was used. 
Poly-HRP-α-RA/Rb/Mo IgG (Immunologic) was used as secondary antibody. Bound 
antibodies were visualized by DAB (Immunologic). Omission of the first antibody 
was taken as a control. Images were processed with ImageJ 1.41o software.
In vitro urothelial barrier model
Primary urothelial cells (10⁵ per well) were seeded into 24-well cell culture 
inserts (Millicell, Hanging Cell Culture Insert, polyethylene terephthalate, 0.4 µm, 
PIHT12R48) contained in 24-well plates. Cells were cultured (1wk, 37°C, 5% CO2) 
until confluency reached. Volumes between samples were equalized. 
Barrier was assessed by TEER measurement and performed using a voltohmmeter 
(EVOM2, WPI). Further details are included in the supplements. In short, samples 
were included if they had a TEER >500 Ω.cm2. The contribution of CS and HS on 
urothelial TEER was investigated by applying chondroitin ABCase (Sigma, C3667) 
or heparinase III (IBEX Pharmaceuticals Inc) on the cell monolayer. Protamine 
treatment (protaminehydrochloride, 1000IE/ml; Meda) and untreated samples 
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were used as controls. TEER measurements were conducted at baseline and 
at regular intervals. A two-tailed Student’s t-test was performed for statistical 
evaluation.
Results
Similar distribution of different GAG’s in the human and porcine bladder
All tissue samples had normal urothelial morphology and there were no 
differences observed in expression of GAGs between different human or porcine 
biopsy specimens. GAG isolations of full thickness human and porcine bladder 
biopsies, demonstrated a high amount of DS in deeper laying bladder structures 
(fig 1). GAG isolations from selective samples revealed that the mucous layer on 
top the luminal side of the urothelium contains predominantly CS and very low 
amounts of HS. Both CS and HS were found in similar concentrations in the deeper 
layers of the urothelium (fig 1). Consecutive immunfluorescence assays on human 
and porcine bladder urothelium sections demonstrated that the distribution of 
GAGs was comparable between species (fig 2, 3). Two antibodies for CS stain 
different epitopes and showed a different distribution pattern. Staining with the 
CS56 antibody demonstrated an intermediate expression of CS on the luminal 
surface of the umbrella cells and a high expression of CS in the basal membrane 
and the suburothelial area just below of it (fig 2). In the stainings with the IO3H10 
antibody, no CS was detected on the luminal surface of the umbrella cells (fig 
2). HS was confined to the basal membrane of the urothelium (fig 3). Stainings 
between both HS antibodies were similar. DS was found only in the suburothelium 
and deeper layers of the bladder wall (fig 3). 
Chondroitin sulphate contributes to the bladder barrier
Cultured primary urothelial cells grew a confluent cell layer that expressed both 
CS and HS (fig 4). After one week of culturing, functional tight junctions were 
formed that were comparable with tight junction expression in the normal porcine 
urothelium (fig 5). This was both observed with immunohistochemistry on glass 
slides as in TEER measurements on cultured cell monolayers. TEER increased after 
one week up to 3772 Ω.cm2 which corresponds to a very tight epithelium [20]. 
Results from the in vitro barrier model experiments demonstrated that CS 
had a significant effect on barrier (fig 5). After CS digestion with chondroitin 
ABCase, TEER significantly dropped with 27% (SD; 20%) compared to 3% (SD; 
3%) in untreated controls (p= 0.007). A more severe drop in TEER was seen after 
treatment with protamine (73%; SD; 9; p< 0.001). In both the chondroitin ABCase 
and the protamine treated samples, the TEER fully recovered after 24 hours. No 
significant effect on TEER was seen in the heparinase III (Hep3) treated samples.
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Figure 1. Isolations of GAGs from porcine and human bladders using three different 
sampling techniques. The A, B & C images on left side represent Hematoxylin Eosin (HE) 
histochemical controls of bladder mucosa after different sampling techniques. Right side 
images represent GAGs (chondroitin sulfate (CS), dermatan sulfate (DS) and heparan 
sulfate (HS) ) isolated from the three applied sampling techniques using agarose gel 
electrophoresis and silverstaining. The Reference lanes were loaded with a standard 
solution containing 20ng CS, 20ng DS and 40ng HS. The A,B & C markings of the HE 
stainings correspond to the A, B & C markings of the different GAG isolation techniques. A) 
A complete urothelium sample (deep sampling) included the basal membrane (red arrow) 
and contains CS and HS (red star). B) The urothelial mucous layer samples (superficial 
sampling) shows mild damage only in umbrella cells on HE (purple arrow) and shows 
that a high concentration of CS is present on the urothelial luminal surface with low 
concentrations of HS in these samples (purple star). C) Full thickness biopsy of porcine 
bladder shows an intact urothelium (green arrow). DS is predominantly found in the 
deeper layers of the bladders (green star), which corresponds with the human bladder 
(Hum. biopsy). 
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Figure 2. Immunofluorescence imaging of chondroitin sulphate (CS) on human (HB) (A, C) 
and porcine (PB) (B, D) bladder urothelium using two different antibodies for CS (CS56; A, 
B and IO3H10; C, D ). DAPI was used for nuclei staining. Expression of CS between human 
and porcine bladder urothelium is similar. The CS56 antibody (CS; A, B) shows expression 
of CS on the luminal side of the urothelium (blue arrow), the basal membrane (BM) (yellow 
arrow) and the suburothelial area just below of the BM. Expression of CS in the stainings 
with the IO3H10 antibody (C, D) differed from the CS56 antibody. In the IO3H10 stainings, 
no expression of CS was seen on the luminal side of the urothelium. Images taken at 63x 
magnification using an epifluorescent microscope.  
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Figure 3. Immunofluorescence imaging of heparan sulphate (HS) and dermatan sulphate 
(DS) on human (HB) (A, C) and porcine (PB) (B, D) bladder urothelium. Two different 
antibodies for HS (HS4C3; A, B and AO4B08; data not shown) and one for DS (GD3A12; 
C, D). DAPI was used for nuclei staining. HS was expressed only in the basal membrane 
(yellow arrow) of the urothelium (A, B). Expression patterns between both antibodies for 
HS was similar. DS was not localized in the urothelium, but was expressed on the collagen 
fibers in the suburothelium and the deeper layers of the bladder wall (C, D, red arrow). 
Images taken at 40x magnification using an epifluorescent microscope.  
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Figure 4. Immunofluorescence imaging of chondroitin sulphate (CS) and heparan 
sulphate (HS) on porcine primary urothelial cell culture. Cells cultured for one week 
on glass slides using two different antibodies for CS: CS56 (A) and IO3H10 (B),  two for 
HS: HS4C3; (C) and AO4B08 (D) and one for DS: GD3A12 (E). Omission of the primary 
antibody was used as a control and shown in F (CS56 staining protocol) and G (IO3H10, 
AO4B08, HS4C3 & GD3A12 staining protocol). CS expression differed between the two 
antibodies. The CS56 antibody (A) showed expression of CS epitope on the cell membrane 
of all urothelial cells, while the IO3H10 antibody (B) stainings showed a generally low 
expression of CS epitope in urothelial cells alternated with a strong expression in sporadic 
urothelial cells. HS is located at the cell membrane of all cultured urothelial cells (C, D). No 
signal for DS was detected (E). No fluorescence was detected in the negative controls (F, 
G). Images taken at 63x magnification using an epifluorescent microscope.
137
The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans (GAGs) Chapter 5
Figure 5. In vitro urothelial barrier model. A and B represent immunohistochemistry 
images of occludin (tight junctions) staining on porcine bladder urothelium sections (A) and 
porcine primary urothelial cell culture (B) cultured for 1 week on glass slides. C Represents 
Trans Epithelial Electrical Resistance (TEER) (Ω.cm2) measurements on a monolayer 
of cultured urothelial cells (the in vitro urothelial barrier model). Figures A and B show 
expression of tight junctions in the urothelial cell culture that is similar to the normal 
bladder urothelium. C) Graph shows % decline in TEER compared to baseline values using 
Heparinase III (Hep3) enzymes to digest HS and Chondroitin ABCase (CSabc-ase) enzymes 
to digest CS. Protamine neutralizes all sulphated GAGs and causes mild cell damage and 
was therefore used as positive control. Negative controls were untreated samples. All 
included samples had baseline TEER values of > 500 Ω.cm2 (tight epithelium). After 1h 
of incubation, TEER was significantly (*) reduced (27%, SD 20, p=0.007) in the CSabc-ase 
treated samples compared to untreated controls. No significant effect on TEER was seen 
on the Hep 3 treated (5% reduction, SD 3) samples. Protamine demonstrated a severe 
decline in TEER (73%, SD 9, p<0,001)(*). TEER values were fully restored to baseline values 
after 24 hrs in both the CSabc-ase treated and the protamin treated samples. A two-tailed 
Student’s t-test was used for statistical analysis.        
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Discussion
In this study we investigated the function and location of specific sulphated GAGs 
in the urinary bladder.  The results demonstrate that endogenously produced 
CS is the dominant sulphated GAG on the urothelial luminal surface and TEER 
experiments show that CS is the only sulphated GAG that contributes to the 
protective barrier of the bladder. There is evidence that exogenously applied CS 
can bind to the damaged urothelium [21][22]. However, this was to our knowledge, 
the first study in which the function of endogenous sulphated GAGs in the bladder 
was investigated with TEER measurements. This evidence was lacking, in spite of 
the abundant use of GAG replenishment therapies in the urological clinic. 
Our experiments focussed on the barrier properties of different GAGs in 
the bladder. We did not study the efficacy of GAG replenishment therapies. 
There is evidence from other studies that GAGs like CS inhibit calcium oxalate 
crystallization in the urine [6]. These supposed anti-adhesive effects for bacteria 
and urine crystals were not evaluated in our experiments and go beyond of the 
scope of this investigation. Various studies investigated the pathophysiology of 
BPS/IC and showed that this disease is associated with an increased urothelial 
permeability [3][4][13]. Restoring epithelial barrier is therefore a logical concept 
for treating conditions like BPS/IC. This concept is strengthened by the clinical 
efficacy of different GAG replenishment therapies [8-11].
The location of different GAGs in the bladder was comparable to most studies [13]
[23][24], but showed some differences with others [15]. To our knowledge, the 
GAG isolation techniques we have applied have not been used to investigate the 
GAGs in the bladder. To obtain enough GAGs for an isolation and silver staining 
procedure, a large 5cm² surface for scraping is needed. Porcine bladders were 
therefore chosen for these experiments, because we were not able to obtain 
large enough samples from human cystectomy patients. The porcine bladder 
morphologically resembles the human bladder and has a similar expression 
of GAGs [25]. Although our results demonstrated distinct differences between 
the locations of different GAGs between the urothelial luminal surface and the 
underlying urothelium layers, small contamination due to the applied harvesting 
techniques cannot be fully ruled out. Consecutive immunofluorescence 
stainings were therefore done and confirmed the results from the GAG isolation 
experiments.
The results of our localisation and functional experiments demonstrate that both 
CS and HS are produced by urothelial cells and that the CS expressed on the 
urothelial luminal surface is important for the protective barrier. The function of 
the GAGs at other locations like the urothelial basal membrane, remains unclear. 
HS is known to bind several growth factors [26][27] and GAGs expressed at the 
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basal membrane could play a role in different processes like urothelial proliferation, 
maintaining the blood-urine barrier, cell signalling or urothelial adhesion.    
TEER measurement is a well established technique for the assessment of 
paracellular permeability of epithelia. The influence of sulphated GAG’s on the 
intracellular transport was not evaluated in this study. Other commonly applied 
models for paracellular permeability assessment are assays that use dyes or 
small molecules with and without radio- or FITC-labelling. TEER measurement 
has multiple advantageous over these other barrier models. Firstly, TEER 
measurements do not influence or harm urothelial cells and secondly, evaluation 
is rapid and well suited for routine measurements of a single sample over a 
long time period. A high TEER represents a tight barrier and is predominantly 
dependant on functional tight junction formation [1][20]. The results of this 
study demonstrated that a high TEER can be achieved with the applied culturing 
methods, even though there were some differences in the applied cell culturing 
protocols compared to other groups [25]. The urothelial TEER values in our study 
were comparable to that of bladder tissues from other mammals [28][29] and 
can be classified as ‘tight epithelium’ according to the classification by Fromter 
et al. [20]. Protamine was chosen as a positive control for the TEER experiments 
and causes a barrier defect by eliminating all GAGs and creating mild urothelial 
cell damage. It is therefore frequently used in barrier experiments [30]. The 
application of protamine and selective CS digesting enzymes on cell cultures 
caused a significant drop in urothelial TEER, but also showed a remarkable 
recovery rate.  
As a result, the applied dosage schemes for these GAG replenishment therapies 
can most likely be improved. Currently, the recommended dosage of one bladder 
instillation per week is based on empirical data and is not derived from experiments 
that investigated the normal GAG-layer turnover rate. Based on the results of this 
study, the GAG turnover rate is faster than we had previously considered. After 
damaging the GAG layer, the barrier (TEER) was fully restored within 24 hours. 
Consequently, a more frequent dosage scheme of one instillation per 24 hours 
may improve treatment efficacy. A clinical study comparing one instillation per 
day against one instillation per week is therefore recommendable. 
Conclusions
This study revealed an important role for chondroitin sulphate in bladder barrier 
function and confirms that the bladder glycosaminoglycan (GAG) layer plays a 
significant role in the protective bladder barrier. Therapies aiming at restoring the 
GAG layer in pathologies like BPS/IC are based on a sound principle. 
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Supplemental Data
Primary urothelial cell culture M&M
Primary porcine urothelial cell cultures  were obtained from abattoir derived 
porcine bladders. For processing, thin 10cm long strips of porcine bladder 
lumen were peeled from the muscle layer. Strips were then incubated in filtered 
transport medium for 6h at 4°C, following incubation in filtered stripper medium 
(HBSS CaCl2/MgCl2(-)(Invitrogen, Gibco, 15630, 10mM HEPES, 1% P/S, 1µg/ml 
aprotinin, 2.4U/ml dispase II (Sigma, D4693-16) overnight (4°C). Mucosa was 
then scraped from the strips into stripper medium, homogenised, transferred to 
a tube, and centrifuged (900rpm, 5min). Supernatant was discarded. Mucosa was 
then incubated with collagenase IV (1000U/ml)(Sigma)(20min, 37°C). Complete 
keratinoctye serum free medium (cKSFM)(KSFM, cholera toxin, bovine pituitary 
extract (BPE), 1% P/S,(Invitrogen, Gibco, 10744)) was then added, the urothelial 
cells were homogenised and centrifuged (900rpm, 5min). Cells were resuspended 
in cKSFM and cultured (37°C, 5%CO2).
GAG isolations and silver staining M&M
After harvesting, the samples were rinsed with PBS following treatment with 10U 
of papain/l digestion buffer/250g (overnight, 65°C). Non dissolved tissue was 
removed by centrifuge (20min, 4°C, 10,000g). Trichloro acetic acid was added 
to the supernatant to a final concentration of 15% (v/v) and samples were put 
on ice (30min). To remove the precipitated proteins, samples were centrifuged 
30min, 4°C, 10,000g). The supernatant containing the GAG’s was diluted five 
times to reduce the concentration of salt. To extract the GAG’s, IVSS Vivapure 
spin columns (Q mini M) (Sigma-Aldrich) were washed with 0,5ml 10mM TrisHCl 
(pH 6.8). After this, 0,5ml of the samples were loaded into the columns and 
centrifuged (1min, 10,000g). 0,5ml of 0,2M NaCl in 10mM TrisHCl (pH 6.8) was 
loaded into the columns and centrifuged (1min, 10,000g). The column was then 
placed in a clean eppendorf after which 50µl 2M NaCl in 10mM TrisHCl (pH 6.8) 
was placed into the column (1min) to elude the GAG’s from the column. Columns 
were centrifuged (1min, 10,000g) and GAG’s in the samples were separated by 
Agarose gel electrophoresis. For this, 1µl of each sample was loaded onto gel 
containing 1% agarose(w/v) in 50 mM Ba(Ac)₂ buffer (pH 5,0). As a reference, 1µl 
of a standardized solution containing 20ng CS, 20ng DS and 40ng HS was loaded 
on onto the gel. After electrophoresis (30 mA/gel, 50 min), gels were fixed and 
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stained with 0,1% (w/v) cationic dye azure A, destained with 10 mM NaAc buffer 
(pH5.5) and washed with milliQ. GAG’s were visualized by silver staining. For this, 
gels were fixated for 10min using silver staining fixative (50% methanol, 10% 
acetic acid). After washing for 3 × 10min, gels were stained by adding 5% (w/v) 
Na2CO3 and silver staining solution (0.2% (w/v) ammonium nitrate, 0.2% (w/v) 
silver nitrate, 1% (w/v) silicotungstic acid (Fluka), and 0.036% (v/v) formaldehyde 
added to initiate staining. The staining was intensified by applying fresh 5% (w/v) 
Na2CO3 to the gels. 25% (v/v) acetic acid was used to terminate the staining. The 
gels were air dried overnight and scanned.
TEER measurements on the In vitro urothelial barrier model M&M:
Chondroitin ABCase was diluted 6.6µl/µl cKSFM. Heparanase III (0.2U) was diluted 
to 0.02U/ml cKSFM. After baseline TEER measurements, 50µl (10µl for protamin 
treated samples) of media was aspirated in the upper compartment of the wells, 
and replaced with 50µl of chondroitin ABCase or Heparanase III solution (1h, 
37°C, 5%CO2). Control samples received 10µl of undiluted protamine (1000IE/ml)
(positive control) or 50µl of cKSFM (negative control) for 1h. After incubation, 
reagents were aspirated, washed twice with 0.9% saline, and replaced with 
standard media for primary urothelial cells. Throughout the entire experiment, 
TEER was assessed at regular intervals until TEER was fully restored to baseline 
values. Experiments were conducted in triplo and repeated twice. Graphs 
represent % decline in TEER from baseline. A two-sided Student’s t-test was 
performed for statistical evaluation. 
TEER on transwell membranes without cell culture were < 20 Ω.cm2. Compared 
to a confluent cell layer of the urothelial cancer cell line RT4 (origin ATCC, HTB-2), 
the cell layer of cultured porcine urothelial cells (PUC) in this study formed a 
much higher TEER under the same culturing conditions (mean 178 Ω.cm2 ( = leaky 
epithelium) for RT4 versus mean 3465 Ω.cm2  (= tight epithelium) for PUC.
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Abstract
Purpose: The aim of the study was to develop an experimental ex vivo organoid 
bladder mucosal model that can be used for experimental research purposes to 
create alternatives for current animal models.
Materials and Methods: We developed an in vitro bladder mucosa model by 
immobilizing a type I collagen scaffold on the bottom of a Transwell® insert, 
creating a 2-compartment system. Mucosa biopsies from porcine bladders were 
placed on top of the scaffold and cultured in different mediums. We evaluated 
morphological aspects of biopsy tissue. Cultured samples were assessed with 
scanning electron microscopy (SEM) and immunohistochemical and histochemical 
staining for cell identification, proliferation and morphology.
Results: Cells remained viable in DMEM/F12 and SMCM medium for up to 3 
weeks. The mucosa retained normal morphological characteristics for up to 1 
week. Cells (mostly urothelial cells) proliferated and fully covered the scaffold 
surface within 3 weeks.
Conclusions: We developed an experimental ex vivo organoid model of bladder 
mucosa for preclinical experimental research. This model could be used for 
high volume screening for pharmacology and toxicology experiments. It has the 
potential to replace currently used animal models.
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Introduction 
New regenerative medicine and tissue engineering techniques offer new 
possibilities for replacing animal models and for ex vivo studies of organ and cell 
behavior. The bladder contains a 4 to 6 layer transitional urothelial layer. Its main 
function is to prevent urinary toxic compounds from reentering the body. For that 
reason, the urothelium has evolved into the most impermeable epithelium of the 
mammalian body [1]. In addition, the urothelium contains sensory receptors that 
are key components in bladder sensory pathways [2]. Signaling molecules from the 
urothelium interact with ICCs and afferent nerve fibers located in the underlying 
suburothelial area [2,3]. The suburothelium also contains a network of capillaries 
that provide nutritional support to the urothelium [3]. Many bladder pathologies 
involve urothelial dysfunction, such as bladder cancer, bladder pain syndrome/ 
interstitial cystitis and overactive bladder syndrome [2]. Therefore, the bladder 
wall and urothelium are prime targets for the pharmacological treatment of these 
diseases [4]. Different bladder research fields require preclinical experimental 
models that mimic the human bladder. For this reason cell cultures and laboratory 
animals are frequently used [5,6] Cell culture is practical and suitable for high 
throughput screening assays. For animal models, rodents are preferably used for 
larger screening assays. Subsequently, large animal species, such as pigs, are often 
used as a final preclinical model before the start of the clinical phase. 
Cell culture and animal models have considerable disadvantages. Although 3D cell 
culture models with multiple cell types have been created [7,8], most currently 
applied cell culture models lack the structural architecture of functional organ 
tissue and use only 1 cell type. In vivo experiments have considerable ethical 
drawbacks and they are costly and time-consuming. The goal of regenerative 
medicine is to restore or replace a damaged organ [9]. It involves matrices, 
termed scaffolds, that mimic the extracellular matrix [10–12]. In organ tissue or 
organotypic culture a tissue biopsy is kept viable for longer periods in in vitro 
conditions comparable to those of classic culture [7]. This also serves as a source 
from which multiple cell types are isolated and expanded.
Replacing conventionally used animal models with validated in vitro and ex 
vivo models has been done in other research fields, including dermatology and 
ophthalmology [13,14]. If bladder tissue can be kept viable using in vitro culture 
techniques, it could serve as an experimental model for preclinical bladder 
research. It may aid pharmacology and toxicology research in developing new 
treatments. These models may also be used for pathophysiological research on 
different bladder diseases [15,16]. 
The porcine bladder anatomically and physiologically resembles the human 
bladder and it is easily obtainable [17]. Therefore, we performed a feasibility 
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study and fabricated a straightforward, ex vivo porcine bladder mucosal model 
using a collagen based insert system. To improve organotypic culture protocols, 
we systematically compared different commercially available culture mediums. 
Analysis included biochemical characterization, SEM, immunohistochemistry and 
histochemistry.
Materials & Methods 
Scaffold production 
Transwell insert system 
PET-membranes of a Millicell® 12-well hanging cell-culture insert (Millipore 
Corporation, Billerica, USA) were removed using sandpaper and replaced by type 
1 collagen scaffolds (Fig. 1). Collagen scaffolds were prepared by subsequent 
freezing and freeze-drying of a 0.8% (w/v) collagen suspension. Scaffold were 
glued on the insert systems using silicon glue (BISON, Goes, Netherlands) and 
crosslinked (~80% crosslinked measured with TNBS assay)[10][11][18] (also see 
supplemental data). Inserts were disinfected using four times 70% (v/v) ethanol 
washings, followed by sterile phosphate-buffered saline (PBS) washings.
Preparation of bladder mucosa model 
Freshly dissected pig bladders were provided by the abattoir (Nijmegen, 
Netherlands) and stored on ice until further handling. After opening the bladders 
under sterile conditions, urine was removed and a full thickness biopsy was taken 
as a control. After this, Keratinocyte-Serum Free Medium (K-SFM)(GIBCO™) was 
immediately applied on the tissue. Mucosal tissue was carefully separated with 
curved-tip surgical scissors (Fig. 1A). Biopsies (Ø6mm) were punched out of the 
tissue (Fig. 1B), placed on scaffolds of the Trans-well insert system and cultured 
under static culture conditions (37°C/5% CO₂) in standard 12-well plates (Millipore 
Corporation, Billerica, USA) (Fig. 1C). Another control sample was isolated after 
the procedure. Both controls were fixed in 4%(v/v) formaldehyde in PBS (pH7.4). 
Figure 1D shows a schematic overview of the bladder mucosa model. 
Medium testing 
Six different culture media were evaluated (Table 1). All media contained 1%(w/v) 
penicillin/streptomycin. Media was refreshed every two days. Biopsies (n=54) 
were cultured for 1, 3 and 6 weeks in three separate experiments. 
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Figure 1. Ex vivo bladder mucosa model with insert system. Mucosal tissue was 
mechanically separated using tweezers and scissors (A). Isolated mucosal tissue was 
punched out Ø6mm (B). Insert systems with and without mucosal biopsies in medium (C). 
Schematic overview of the ex vivo bladder mucosa model is represented in D.
Immunohistochemistry and Histochemistry 
After culture, the scaffolds with the attached biopsy were fixed in 4%(v/v) 
formaldehyde in PBS (pH 7.4) o/n at 4°C. After washing in PBS (pH 7.4), the 
samples were embedded in paraffin. Sections were cut transversally (4 μm) using 
a microtome (Leica, Jung-Biocut2035, 6 Rijswijk, Netherlands) and mounted onto 
glass slides (Superfrost®plus, Thermo-Scientific, Waltham, USA). Samples were 
deparaffinized and stained with hematoxylin-eosin (H&E). 
Samples were evaluated using antibodies for Pancytokeratin (CytoPan), 
Cytokeratin 14 (CK14) and Ki67 (proliferation) (Table 2). Additional stainings 
were performed on DMEM/F12 and SMCM cultured samples with antibodies for 
Uroplakin III (umbrella cells), Occludin (tight junctions), Vimentin (ICC’s; (myo-)
fibroblasts), alpha Smooth Muscle Actin (αSMA) (myofibroblast & smooth muscle 
cells) and Desmin (smooth muscle cells) (Table 2). Cytokeratin stainings were 
pre-treated with 0.1%(v/v) pronase (Merck) for 5min at 21°C. Stainings with other 
antibodies were pre-treated (in citrate buffer (pH 6) for 7min in microwave). All 
sections were blocked with 3%(v/v) hydrogen peroxidase (Merck), followed by 
5%(v/v) normal goat serum (Merck). Poly-HRP-α-RA/Rb/Mo IgG (Immunologic) 
was used as secondary antibody. Bound antibodies were visualized by DAB 
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(Immunologic). Omission of the first antibody was taken as a control. In addition 
to this, a DeadEnd™ Colorimetric TUNEL assay (Promega, Madison, Wisconsin, 
USA) was performed on a sample that was cultured for 1 week in DMEM/F12 
(see supplements for methods and results). Specimens were evaluated for 
urothelial viability and morphology in a semi-qualitative analysis. This included 
the following criteria (scored with: 0, 1, 2, 3; see legends Table 3): General 
urothelial morphology, presence of a basal and umbrella cell layer, number of cell 
layers in the urothelium and Ki67 and TUNEL activity. Secondary, urothelium was 
evaluated for occludin (tight junction) and uroplakin III expression for terminal 
differentiation (umbrella cells). Finally, expression of CK14, Vimentin, Desmin and 
αSMA was evaluated. 
Table 1. List of culture media & supplements (all media contained 1% (w/v) penicillin/
streptomycin)
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Scanning Electron Microscopy 
After culture, the scaffolds with biopsy were fixed in 2%(v/v) glutaraldehyde 
(Merck) in 0.1M PBS (pH 7.4) o/n at 21°C. Samples were washed with 0.1M 
PBS (pH 7.4) and subsequently dehydrated using ascending series of ethanol 
solutions in ultrapurified water (MilliQ) (30%, 50%,70%,100%(v/v) and dried 
using the Polaron (Quorum Technologies, East-Grinstead, UK) critical point dryer. 
For SEM-analysis, the scaffolds of the trans-well system (including biopsy) were 
carefully removed, cut and mounted onto a stub. Samples were then sputtered 
with an ultrathin gold layer and examined in a JEOL Scanning Electron Microscope 
6310 at an accelerating voltage of 15kV.
Table 2. List of antibodies
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Table 3. Semiqualitative analysis of tissue viability by medium
#     General morphology
№   Number of cell layers (L) present in specimen
*     hardly any submucosa  present in specimen
**   no urothelial cell layer in specimen
Table 3. Immunohistological scoring. Pig bladder mucosa biopsies were cultured 
on collagen scaffolds for 1, 3 and 6 weeks using six different culture media. Paraffin 
sections were stained and evaluated for: general urothelial morphology, presence of a 
basal and umbrella cell layer, number of cell layers in the urothelium and Ki67 and TUNEL 
activity. Secondary, urothelium was evaluated for occludin (tight junction) and uroplakin 
III expression for terminal differentiation (umbrella cells). Finally, urothelium (CytoPan), 
basal cell layer of stratifying epithelial cells (Cyto14), proliferating cells (Ki67), skeletal and 
visceral smooth muscle cells (Desmin) and (myo-) fibroblasts (Vimentin and αSMA) were 
evaluated.
Scoring, except for number of cell layers, was divided in numbers between 0 and 6. 3 
represents: results comparable to baseline, 2 represents slight reduction compared to 
baseline, 1 represents severe decline compared to baseline, but still visible and 0 represents 
not or sporadically visible in specimen. In the other direction: 4 represents slight increase 
compared to baseline. 5 represents increase compared to baseline and 6 represents severe 
increase compared to baseline.   
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Results 
Hematoxylin and eosin findings of bladder biopsies harvested before and after 
mucosal isolation were generally comparable (data not shown). Results were 
consistent with little variation in outcomes between mucosal biopsies taken at 
different areas from an individual bladder or between mucosal biopsies taken 
from different bladders. Six mediums were evaluated. Table 2 shows the results 
of tissue viability semiqualitative analysis for all mediums. Results revealed 
that samples cultured in DMEM/F12 and SMCM for 1 week were comparable 
to baseline controls. However, after 3 weeks of culture, the overall condition of 
the urothelium deteriorated with an increase in apoptotic cells. After 6 weeks of 
culture, the urothelium was reduced to 1 layer or absent with many apoptotic 
cells.
Figure 2 shows bladder biopsy immunohistochemical staining after 1 week of 
culture in DMEM/F12 medium. Urothelium was composed of an interconnected 
multilayer of CytoPan positive cells, comparable to normal controls. Vimentin and 
αSMA positive cells were visible in the submucosal area and showed different 
cell subpopulations, which were most likely ICCs, myofibroblasts or fibroblasts. 
Almost no smooth muscle cells were present in biopsies when using desmin 
staining (Fig. 2). After 3 weeks, urothelial cells were still present as a disorganized 
cell layer. Vimentin and αSMA positive cells were observable in the suburothelium 
after 3 weeks.
Figure 3, a to c shows bladder biopsy hematoxylin and eosin results under optimal 
(DMEM/F12) and suboptimal (EpiLife®) conditions. After 1 week of culture, 
hematoxylin and eosin staining revealed that the urothelium and suburothelium 
of biopsies cultured in DMEM/F12 retained normal bladder morphological and 
structural characteristics (fig. 3, a and b). SMCM showed similar results (table 2). 
After 3 weeks of culture, hematoxylin and eosin staining demonstrated considerably 
altered urothelial morphology in all mediums. After 3 weeks, samples cultured in 
SMCM had morphological characteristics that were more comparable to normal 
urothelium than DMEM/F12 cultured samples.
Figure 3 further shows immunohistochemical staining of bladder biopsies cultured 
in DMEM/F12. CK14 staining revealed that the urothelial cell sheet differentiated 
upward, as indicated by the Cyto14 positive basal layer (Fig. 3, d to f). Proliferating 
Ki67 cells were seen throughout the urothelial basal and intermediate layers, and 
in the submucosal area. After 3 weeks, the relative amount of proliferating cells 
decreased in the biopsy (fig. 3, g to i). In DMEM/F12 cultured samples almost no 
apoptotic cells were observed (Fig. 3, k). In contrast, biopsies cultured in other 
mediums, such as K-SFM, had many apoptotic cells (Fig. 3, l).
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Figure 4 shows baseline and DMEM/F12 cultured biopsies. SEM analysis, and 
images of immunohistochemical stainings for tight junctions (occludin) and 
uroplakin III were included. In SMCM and DMEM/F12 cultured biopsies the luminal 
urothelial cells expressed tight junctions and uroplakin III proteins on the outer 
membrane. This suggests that the urothelium maintained the normal terminally 
differentiated state. However, the intensity of uroplakin III staining was decreased 
compared to baseline, implying a reduction in surface membrane molecules. This 
pattern was also visible on SEM analysis with a reduction in cell surface
molecules. After 3 weeks of culture, we observed no tight junctions or uroplakin 
III expression. SEM analysis showed that on the luminal urothelial surface the cell 
membranes were exposed and the cell junction ridges were clearly visible.
Finally, SEM revealed a cell sheet containing urothelial cells that migrated and 
proliferated from the biopsy to the scaffold surface (Fig. 5). These cells covered 
the entire scaffold after 3 weeks of culture. Migrated urothelial cells were also 
seen on the serosal sides of the biopsies.
Figure 2. Immunohistochemical evaluation of DMEM/F12 after 1 week of culturing. 
Pancytokeratine stained the urothelial layer (A). Alpha smooth muscle actin  (αSMA) (B) 
and Vimentin (C) positive cells are visible in the suburothelium. These represent different 
populations of (myo)fibroblasts. Hardly any Desmin (smooth muscle cells) positive cells 
were observed. Magnifications are 40x.
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Figure 3. Histology and immunohistochemistry. A-C Histology of ex vivo bladder model 
(Hematoxylin & Eosin staining (H&E)). This figure represents H&E staining of biopsies under 
optimal (B, DMEM/F12) and suboptimal conditions (C, EpiLife) after 1 week. A shows the 
native bladder tissue. Images D-F show 16 CK14 stainings, whith no CK14 staining visible 
in native tissue (D), but positive in the basal layer after 1 week (E) and sporadically visible 
at 3 weeks (F) of culturing in DMEMF/12 (arrow). Images G-I show equal concentrations of 
Ki67 (proliferation) positive cells in both urothelium and suburothelium in native tissue (G) 
and DMEM/F12 samples cultured for 1 week (H) (arrows). Also after 3 weeks of culturing 
in DMEM/F12 there were many Ki67 positive cells in the biopsies. Finally, images J-L show 
apoptotic cells with a TUNEL assay. Almost no apototic cells are seen in native tissue (J) 
and only sporadic in samples cultured in DMEM/F12 for 1 week (K). In contrast, many 
apoptotic cells were seen in for example, KFSM samples that were cultured for 1 week (L) 
(arrows). Magnification is 40x.
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Figure 4. SEM analysis (A-F) and Immunohistochemical stainings (G-L) on DMEM/F12 
cultured samples after 1 and 3 weeks compared to baseline controls. Both uroplakin 
III (umbrella cells (G-I), red arrows) and occludin (tight junctions (J-L), red arrows) are 
markers for urothelial differentiation. In the biopsies cultured in DMEM/F12 for 1 week, 
the luminal urothelial cells expressed tight junctions and uroplakin III proteins on the outer 
membrane. This suggests that the urothelium kept his normal terminally differentiated 
state. The intensity of the uroplakin III staining was reduced compared to baseline, 
implying that there was a reduction of surface membrane molecules. This pattern was 
also visible with SEM analysis with a reduction of cell surface molecules. After three weeks 
of culturing, there was no more expression of tight junctions or uroplakin III visible. SEM 
analysis showed that on the luminal urothelial surface, the cell membranes were exposed 
and cell junction ridges were clearly visible. SEM magnification 2500x (A-C) and 7500x 
(D-F). Immunohistochemical images at 40x magnification.
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Figure 5. Urothelial cell outgrowth on a type I collagen scaffold. Scanning Electron 
Microscopic (SEM) images of the airside of the ex vivo bladder model after 1 and 3 
weeks. After 3 weeks, the scaffold surface was fully covered with cells. Bars indicate 1 
mm (magnification 18x) in the overview images and 100 μm (magnification 1000x) in the 
insets. White dashed line indicates border of the biopsy. B= Biopsy, OG= Outgrowth.
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Discussion
We developed an experimental model by combining a bladder mucosal biopsy 
with a type I collagen scaffold fixed on a Transwell insert. The Transwell system 
can be placed in a standard 12-well culture plate. Bladder mucosal biopsies were 
placed on this scaffold and cultured with time using different protocols. This 
model is intended to be used for standardized, large volume experiments, such 
as pharmacological and toxicology screening assays. It is financially and ethically 
attractive, and can be used in a normal laboratory setting. The 2-compartment 
system is designed to maximize nutritional support.
Cultured bladder tissue remained viable for 3 weeks on the type I collagen scaffolds 
under optimal conditions (SMCM or DMEM/F12). Under the current conditions, it 
would be usable for experiments with a maximum time frame of 1 week. 
The quality of in vitro bladder models is progressing [7]. Improvements in culture 
protocols show that 3D urothelial cell cultures can be created that highly resemble 
normal urothelium in vivo, especially with the formation of tight junctions and 
production of uroplakins [17]. Turner et al developed a well differentiated, 3D 
porcine urothelial cell culture that remained usable for multiple weeks, which is 
longer than our model [17]. The construction of 3D cell cultures with different cell 
types also seems promising [8].
Our approach differs because we want to have a biological substrate available 
that would retain rather than create normal bladder wall architecture in vivo. 
Type I collagen was used as a basic scaffold for our model. Other groups have 
already indicated that collagen supports cell attachment in vitro [19–23]. The 
structure of type I collagen scaffolds is easy to manipulate and can be coated 
with several growth factors, increasing its applicability [11]. The 50 to 100 μm 
pore size of the collagen scaffolds in our model was relatively large compared to 
normal bladder extracellular matrix. The culture protocols that we applied may 
be further improved by altering the type and concentration of growth factors and 
other supplements. 
There are some limitations of this experimental model. Denervated tissue is 
used, which may alter tissue morphology with time. Also, factors released due to 
tissue necrosis and apoptosis may influence cell growth. Furthermore, we used 
standard culture room conditions, including a relatively high oxygen concentration 
compared to the relative hypoxic conditions in vivo [24]. Specialized culture rooms 
are available in which oxygen levels can be manipulated. However, this would 
make the model more difficult to implement and studies have shown that normal 
urothelial characteristics can be achieved with cell culture under standard culture 
conditions. 
Finally, a drawback of using cultured biopsies is that most available culture mediums 
and protocols are intended for cell proliferation and they manipulate tissue into 
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a regenerative state. This can be investigated by looking at CK14 expression in 
the basal urothelial cell layer. Different protocols described by other groups 
are used to push urothelial cell cultures from a proliferative state into terminal 
differentiation [17,25]. Terminal differentiation can be proved with umbrella cell 
markers, such as tight junction and uroplakin expression. Supplementing bovine 
serum in medium induces terminal cell differentiation [7,17]. In our study, the 
culture protocols that included serum, were better in preserving uroplakin III and 
tight junctions. Although these conditions force urothelial cells to differentiate, 
we also observed CK14 expression in basal cells, and urothelial cell migration and 
proliferation.
The main advantages of our model are its reproducibility and the use of organ tissue 
instead of cell cultures. Manufacturing the Transwell system is straightforward 
and can be easily done in high quantities. Also, the biopsy technique is easy to 
learn, resulting in tissue samples that are consistent in size and thickness. The pig 
bladder is anatomically and physiologically comparable to the human bladder and 
the urothelium is morphologically equivalent to that in humans [17]. Obtaining 
large quantities of human biopsies for experimental studies would be difficult. 
Abattoir derived, normal porcine bladder urothelium is readily available and 
inexpensive. As a result, the cost of our model is comparable to that of cell culture 
studies, which is much less than the cost of animal experiments.
The potential uses of organotypic bladder culture for pharmacological and 
toxicology experiments were reported by others. Bolenz et al studied the toxic 
and therapeutic effects of chemotherapy on normal and carcinogenic human 
urothelial cell explants [16]. Urothelial biopsies cultured in K-SFM on gelatin 
matrixes remained viable for 20 days, comparable to our results. Combining our 
experimental model with standardized proliferation and apoptosis assays would 
make it a useful tool to screen for the toxic effects of new compounds for bladder 
cancer as well as for the protective effects of barrier enhancing compounds, such 
as glycosaminoglycan replenishment therapy. If well characterized and compared, 
in vitro and ex vivo models could be used as an alternative to animal experiments, 
thus, accelerating the preclinical research phase of pharmacological development 
[13].
Conclusions
We developed a straightforward, ex vivo organoid bladder mucosal model 
using organotypic culture to advance preclinical bladder research and generate 
alternatives to currently used in vivo models. We systematically compared culture 
protocols to improve tissue viability. This model could be used for high volume 
screening in pharmacology and toxicology experiments.
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Supplemental data 
Trans-well insert system 
Collagen scaffolds were prepared by subsequent freezing and freeze-drying and 
crosslinking techniques [1 Pieper 1999]. Briefly, a 0.67%(v/w) type I collagen 
suspension in 0.25M acetic acid (Merck, Darmstadt, Germany) was made. The 
suspension was poured in a 24-well plate, frozen for 4h at -20°C and subsequently 
freeze-dried using a Zirbus freeze-dryer (Zirbus sublimator 500II, Bad Grund, 
Germany). Then the membranes of a Millicell®12-well transwell-insert(Millipore) 
were removed. Scaffolds were then glued on the insert systems using silicon 
glue (BISON, Goes, Netherlands). The structural integrity was increased using 
carbodiiminde crosslinking according to an earlier described protocol [8 Pieper 
1999 2e]. After crosslinking the inserts were disinfected by 4 washings with 70% 
(v/v) ethanol, followed by 6 washings with sterile phosphate-buffered saline (PBS). 
1) J. S. Pieper, et al., “Preparation and characterization of porous crosslinked 
collagenous matrices containing bioavailable chondroitin sulphate,” Biomaterials 
20(9), 847 (1999). 
Biochemical characterisation (TNBS) 
The degree of crosslinking was determined spectrophotometrically after a 
reaction with 2,4,6-trinitrobenzene sulfonic acid (TNBS) as earlier described [17 
Pieper 2002]. Samples were measured with a microplate spectrophotometer 
(Bio-rad California, USA, ë=420 nm). Glycine p.a. (Scharlau Chemie, Barcelona, 
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Spain) was used for a standard curve. The degree of crosslinking was the sum of 
free-NH2 groups per mg of scaffold.
2) J. S. Pieper, et al., “Loading of collagen-heparan sulfate matrices with bFGF 
promotes angiogenesis and tissue generation in rats,” J. Biomed. Mater. Res. 
62(2), 185 (2002). 
Scanning electron microscopy 
After culture, the scaffold with mucosa was removed from the transwell-inserts 
and analyzed as previously described and fixated in 2% (v/v) glutaraldehyde 
(Merck) in 0.1 M PBS (pH7.4) o/n at 21°C. Samples were washed with 0.1 M PBS 
(pH7.4) and subsequently dehydrated using ascending series of ethanol solutions 
in MilliQ (30%,50%,70%,100%(v/v). To prevent loss of the (ultra)structure, 
samples were dried using the Polaron (Quorum Technologies) critical point dryer 
with liquid CO2. For SEM-analysis, samples were cut, mounted onto a stub and 
sputtered with gold for 120 s using a Scancoat Six SEM Sputter-Coater (Temescal). 
Specimens were analyzed with a JSM-6310 scanning electron-microscope(JEOL). 
Photos were made at 50x, 100x and 250x magnifications. 
TUNEL assay 
Paraffin sections were cut transversally (4 μm) using a microtome (Leica, 
Jung-Biocut2035, Rijswijk, Netherlands) and mounted onto glass slides 
(Superfrost®plus, Thermo-Scientific, Waltham, USA). DeadEnd™ Colorimetric 
TUNEL assay (Promega, Madison, Wisconsin, USA) was conducted via manufacturers 
protocol. For this, slides were fixed in 4% paraformaldehyde for 15 min followed 
by rinsing with PBS (pH 7.4). Each slide was incubated with 100μl of a Proteinase 
K solution (20μg/ml) for 10min followed by rinsing in PBS. Tissue was then refixed 
in 4% paraformaldehyde for 5min and rinsed in PBS. Slides were incubated with 
100μl of equilibration buffer for 5min. Biotinylated Nucleotide Mix was thawed on 
ice and a rTdT reaction mix was prepared according to manufacturer’s protocol and 
100μl per slide was used for incubation (with parafilm covering for 60min, 37°C) in 
humidified chamber. The reaction was terminated by immersing the slides in 2X 
SSC diluted in deionized water (1:10) for 15min followed by rinsing with PBS for 
15min. Endogeneous peroxidases were blocked by immersing the slides in 0,3% 
hydrogen peroxide in PBS for 3,5min at room temperature followed by rinsing in 
PBS 15min. After this, sections were incubated in 100μl Streptavidin HRP solution 
in PBS (1:500) for 30min following rinsing with PBS 15min. DAB solutions were 
freshly prepared by adding 50μl of the Substrate 20X buffer to 950μl deionized 
water followed by 50μl of 20X Chromogen and 50μl of 20X Hydrogen peroxide. 
Slides were incubated in DAB solution for 10min in the dark. Finally, slides were 
rinsed in deionized water and mounted with Permount (Thermo Fisher Scientific 
Inc., Waltham, USA).
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Summary and conclusions.
The aim of this thesis is to contribute to the existing knowledge on how afferent 
signaling and barrier functions in the bladder urothelium work. The focus is on 
normal urothelial physiology. This is important because knowing how the normal 
processes work, helps us to understand and intervene in a pathophysiological 
process. During this PhD, we explored different functions of the urothelium that 
we perceived as interesting. For afferent signaling, we have tried to understand 
the function of Transient Receptor Potential Vanilloid 4 (TRPV4) channels in 
the bladder urothelium. For barrier, we have investigated the roles of different 
glycosaminoglycans (GAGs) in the bladder. Finally, we have made an attempt to 
create an experimental bladder mucosa model to see whether we could improve 
the translational aspect of preclinical bladder research by using a biological 
substrate that does mimic the human bladder, but does not include the use of 
laboratory animals and all its negative aspects. 
Part 2. General introduction & outline of thesis
Part two of this thesis is a general introduction on the preclinical research 
that has been conducted during this PhD. It reviews the current evidence on 
urothelial molecules, structures and pathways that are involved in barrier and 
afferent signaling. It is remarkable that there is still so little known about the 
functions of different molecules that are deposited on the apical cell membrane 
of the urothelium, Especially, considering the evident need for treatments that 
can improve the bladder barrier. Recurrent urine tract infections and diseases 
that cause bladder inflammation have a high impact on quality of life and a 
considerable economic burden. Despite this, there is still little interest from the 
scientific community to study these barrier molecules and to study new ways 
to improve the natural barrier in the bladder. Even the current clinically applied 
barrier enhancing therapies, like GAG-layer replenishment therapies, would 
profit from an improved knowledge on how natural GAG-layer works. Chapter 
1 describes the scientific evidence that supports the roles of different structures 
and molecules in bladder barrier. For instance: glycosaminoglycans, uroplakins, 
cell junctions, apical cell membrane and basement membrane will be discussed.  
For afferent signaling, we focused on what we know and believe is important 
for normal bladder filling signaling and the role of stretch activated (mechano)
receptors in this signaling. The bladder urothelium is not a single entity. It has a 
role within a very dynamic organ that has a unique neurologic control. Therefore, 
we used this chapter not only to outline how the urothelium works, but also how 
to place the functions of the urothelium within the entire scope of neurologic 
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control of the lower urinary tract. Noteworthy are the observations that a lot of 
the currently applied effective pharmacological therapies for overactive bladder 
syndrome (OAB) have been designed to target the efferent pathways of the bladder, 
but are now believed to influence the afferent pathways too. The conclusion of 
this chapter is  that there is an interaction between barrier and afferent signaling 
function in the urothelium. Both functions use similar structures, (mechano)
receptors and signaling molecules in the urothelium.
Part 3. The role of TRPV4 channels in the urogenital tract
Part three of this thesis focusses on the TRPV4 channels in the urothelium. These 
non-selective cation channels are part of the cell membrane and are the most 
dominant TRP-channel in the bladder urothelium. The interest for the TRPV4 
channel are a result of their very interesting characteristics: 1) The channel is 
activated by mechanical stretch, 2) After activation, the channel opens causing a 
Ca²⁺ influx and subsequent ATP excretion by the urothelial cell and 3) A transgenic 
TRPV4 knockout mouse was developed that does not have any TRPV4 channels in 
the urothelium and this mouse has a phenotype with severe lower urinary tract 
dysfunction. We wanted to know more about the presence and function of the 
TRPV4 channel in the urothelium, how it could be activated by stretch and if it 
plays a role in afferent signaling in the bladder.
Chapter 2 focusses on the identification of TRPV4 channels in the human bladder, 
because there was only evidence of TRPV4 channel presence in the rodent 
bladder urothelium. We observed that the TRPV4 channel in the human bladder 
is expressed more on the luminal side of the urothelium with a high density on 
the basolateral membrane of the umbrella cells. 
For the TRPV4 channel to be able to be activated by stretch (e.g. bladder filling), 
there has to be a link to structures that transmit mechanical forces. We detected a 
connection between the TRPV4 channel and the α-catenin protein of the adherence 
junction. The adherence junctions form essential connections between cells and 
are important for structural organization of individual cells in the urothelium. The 
intracellular component (including the α-catenin protein) is connected to the actin 
cytoskeleton, which is an important network for transportation of mechanical 
forces in the cell layers of many different types of tissues. 
Chapter 3 explores the location of TRPV4 channels in the urothelium in other sites 
of the urogenital tract. Specifically, the human bladder, kidney and the ureter. 
In addition we investigated if the absence of TRPV4 channels would have an 
impact on adherence junction formation in a TRPV4 knockout mouse model. Like 
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in the bladder, we observed a similar co-localization between TRPV4 channels 
and adherence junctions in the urothelium. This study also confirmed a molecular 
connection between TRPV4 and α-catenin in human kidney tissues. When 
evaluating the normal and TRPV4 knockout mice bladder on an ultrastructeral 
level with electron microscopy, we observed that urothelial adherence junction 
formation was reduced in the TRPV4 knockout leading to increased intercellular 
spaced in the urothelium. Absence of TRPV4 channels, thus appears to impact 
urothelial structure and could potentially impair barrier function.
In chapter 4 we have studied the physiological role of bladder TRPV4 channels in 
bladder afferent signaling. We used the spinal c-fos model to compare bladder 
afferent signaling in normal and TRPV4 knockout mice. With the c-fos spinal 
cord model, we were able to quantify afferent sensory information from the 
bladder on spinal cord level. To get a sufficient spinal c-fos activity, there needs 
to be a noxious stimulus. By applying different interventions like noxious bladder 
distention, pharmacologically induced bladder inflammation and desensitizing 
noxious C-fiber afferents, we could demonstrate that TRPV4 is indeed important 
in bladder afferent signaling and that this can be measured on a spinal cord level. 
The results were however somewhat unexpected which underlines some of the 
downsides of using transgenic knockout mice models for research. We observed 
significantly higher c-fos activity during bladder distention in the TRPV4 knockout. 
We believe that part of the results from these experiments could be caused by 
adaptations of the TRPV4 knockout mice due to a potential lack of normal bladder 
filling sensations that is caused by the absence of TRPV4 channels in these mice. An 
explanation for this could be an inherent dysfunction of Aδ fibers in the bladders 
of the knockout mouse, resulting in compensatory signaling through the noxious 
C-fiber neurons that leads to more spinal c-fos activity.  Although tight junctions 
were still formed in the TRPV4 knockout mouse bladders, the potential other 
effects of TRPV4 on the urothelium like urothelial adherence junction formation 
and potentially epithelial barrier could also play a role in the abnormal afferent 
signaling in these mice.
Part 4 The function of glycosaminoglycans (GAGs) in the bladder urothelium
Part four of this thesis focusses on the role of glycosaminoglycans (GAGs) on 
barrier properties of the urothelium. GAGs are negatively charged polysaccharides 
that are generally attached to a proteoglycan core protein. Together they form 
what is called the GAG layer that is deposited on the apical membrane of the 
umbrella cells of the urothelium. This layer can bind large amounts of water 
molecules and form a gel-like layer that is believed to form a buffer between the 
toxins in the urine and the exposed apical cell membrane, thereby protecting the 
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bladder wall. Although these molecules have been studied for a long time and 
are even used as a clinical therapy for bladder pain syndrome (IC/BPS), there was 
still no proof that these molecules actually contributed to the bladder barrier. 
Furthermore, it was unknown which type of GAG actually was located where 
in the urothelium. The aim of this project was to answer these fundamental 
questions. Chapter 5 describes how we investigated the location of different 
sulfated GAGs in the human and porcine bladder urothelium. For this, we have 
applied immunohistochemical and immunofluorescence stainings on human and 
porcine bladders and we have performed selective GAG isolation techniques 
on different porcine bladder urothelial layers. With these techniques, we were 
able to objectify that chondroitin sulfate was the only sulfated GAG that was 
located on the apical membrane of the luminal umbrella cells of the human and 
porcine bladder. Secondly we assessed the role of individual GAGs in barrier, by 
conducting Trans Epithelial Electrical Resistance (TEER) measurements on cultured 
monolayers of terminally differentiated primary porcine urothelial cells. We used 
specific enzymes to digest GAG subtypes and demonstrated that chondroitin 
sulfate contributes directly to the bladder barrier. Besides this, we observed that 
after selective damage of the GAG layer in vitro, there was full recovery of barrier 
function within 24 hours.  
Part 5. Experimental models for preclinical bladder muscosa research
Part five of my thesis describes the combined efforts from the female and 
functional urology research group and the tissue engineering research group 
of our department to create a new experimental bladder mucosa model. The 
use of rodents is commonly used in preclinical bladder research. However, 
from a physiological point of view, there are animal models that mimic human 
bladders better than the rodent bladders. Porcine bladders are for instance 
very biocompatible with the human bladder when regarding anatomical size 
and histology. However, using large animals for preclinical research is costly. 
Recent advances in tissue engineering in our own lab and elsewhere sprouted 
the idea that with the combination of tissue engineering techniques and readily 
available freshly dissected porcine bladders from the abattoir, we could create a 
reproducible model for preclinical bladder research that would be applicable in 
for instance toxicology screening. Chapter 6 describes the research that we have 
done to create, improve and systematically analyze this model so it could be used 
for toxicology screening. We created a transwell system with a permeable collagen 
type 1 scaffold as a bottom substrate for organotypical culturing of porcine 
mucosal tissue layers. We applied different culturing media to investigate which 
biopsies performed best. We used different immunohistological characteristics, 
apoptosis assays and prolifraration assays to systematically evaluate tissue 
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viability. We discovered that DMEM-F12 culture medium outperformed the 
other culture media in providing the best tissue viability. During the optimization 
of the experimental model, we were finally able to maintain bladder mucosal 
tissue viable for one week with preservation of normal histological appearance. 
This has the potential to be applicable for preclinical research purposes like 
toxicology screening. Thin biopsies performed best and we observed outgrowth 
of proliferating urothelial cells on the uncovered collagen type 1 scaffolds in the 
transwell system. We believe that there is plenty of room for improvement of 
this basic model, but the key message of this work is that it is possible to create 
qualitative good and cost effective alternatives for laboratory animal studies.      
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Samenvatting en Conclusies
Het doel van dit proefschrift is om de kennis te verbeteren van rol die het 
urotheel speelt in de sensorische signalering en de barrière functie van de 
blaas. De nadruk van dit proefschrift ligt op het begrijpen van de fysiologische 
processen die nodig zijn om de blaas normaal te laten functioneren. Ik ben van 
mening dat je pathofysiologische processen in ziekte pas echt kan doorgronden 
en begrijpen, als je eerst weet hoe de normale processen werken. Gedurende 
dit promotieonderzoek zijn we dan ook verschillende richtingen ingeslagen om 
de functies van het blaasurotheel te kunnen onderzoeken en te begrijpen. Voor 
sensorische (afferente) signalering hebben we de functie van TRPV4 kanalen in het 
blaas urotheel onderzocht. Voor de blaas barrière functie hebben we de rol van 
verschillende glycosaminoglycanen (GAGs) onderzocht. Tenslotte hebben we een 
poging gedaan om een nieuw preklinisch experimenteel blaas slijmvlies model 
te ontwikkelen dat representatief is voor de menselijke blaas, maar geen gebruik 
maakt van proefdieren en alle negatieve facetten die daarmee samenhangen. 
Part 2. General introduction & outline of this thesis
Deel twee is een algemene introductie op het preklinische onderzoek dat 
gedurende deze dit promotieonderzoek is verricht. Het geeft een overzicht van de 
moleculen, structuren en netwerken die in het urotheel betrokken zijn bij barrière 
en sensorische signalering. Het is opmerkelijk dat er nog steeds zo weinig bekend 
is over werking van de verschillende moleculen die op het apicale cel membraan 
liggen van het urotheel, terwijl er een enorme behoefte is aan behandelingen 
die barrière van de blaas kunnen verbeteren. Er sprake is van een hoge ziektelast 
en van hoge kosten die het behandelen van inflammatoire blaas ziekten en 
urineweginfecties met zich meebrengt. Desondanks is er maar relatief weinig 
interesse vanuit de onderzoekswereld om deze moleculen te onderzoeken en om 
nieuwe manieren te bestuderen om de natuurlijke blaas barrière therapeutisch 
te versterken. Zelfs de huidige toegepaste barrière versterkende therapieën voor 
de blaas, zoals GAG-laag versterkende behandelingen, zouden profijt hebben 
van een betere kennis van hoe deze beschermende GAG-laag nu echt werkt. In 
hoofdstuk 1 wordt de wetenschappelijke onderbouwing gegeven voor rol van 
verschillende structuren en moleculen die (eventueel) participeren in de barrière 
van de blaaswand. Besproken worden onder andere: glycosaminoglycanen, 
uroplakines, cell junctions, het apicale cell membraan en het basaal membraan.
Bij het uitdiepen van rol die het blaas urotheel speelt in sensorische signalering, 
concentreren we in dit proefschrift op de sensorische netwerken die normale 
blaasvulling meten en de rol die mechanische rek receptoren hierin spelen. Het 
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blaas urotheel is geen geïsoleerde structuur in de blaaswand. Het is onderdeel 
van een zeer dynamisch orgaan dat een unieke neurologische regulatie heeft. 
Daarom hebben we dit hoofdstuk niet alleen gebruikt om te beschrijven wat de 
functies zijn het blaas slijmvlies zijn, maar ook om het te plaatsen in het geheel 
van de neurologische controle van de lage urinewegen. Noemenswaardig is het 
feit dat veel van de huidige toegepaste farmacologische behandelingen voor OAB 
aanvankelijk zijn gericht op het efferente (motor) systeem, terwijl we nu vanuit 
het onderzoekveld steeds meer inzicht krijgen dat deze therapieën ook een direct 
effect hebben op het sensorische systeem. De rode draad van dit hoofdstuk is dat 
er in het blaas slijmvlies een interactie is tussen barrière en afferente signalering 
functies. Beide functies maken veelal gebruik van dezelfde structuren, (mechano)
receptoren en transmitter moleculen in het blaasurotheel.
Part 3. The role of TRPV4 channels in the urogenital tract
Deel drie van dit proefschrift richt zich op de functie van TRPV4 kanalen in het 
urotheel. Deze niet-selectieve ion kanaal maakt deel uit van het celmembraan 
en is het meest voorkomende TRP-kanaal in het blaasurotheel. De interesse voor 
het TRPV4 kanaal komt voort uit een aantal bijzondere eigenschappen van dit 
ion kanaal: 1) Het wordt geactiveerd door mechanische rek, 2) Activeren van dit 
kanaal zorgt voor een Ca²⁺-influx in de urotheel cel en dit resulteert in de excretie 
van ATP door de cel 3) Na de ontwikkeling en evaluatie van een transgene TRPV4 
knockout muis is er vastgesteld dat deze muizen een afwijkingen hebben in hun 
blaasfunctie. Dit proefschrift richt zich op de locatie en functie van het TRPV4 
kanaal in het urotheel. Daarbij hebben we gekeken naar manieren hoe het kanaal 
geactiveerd zou kunnen worden door mechanische rek in de blaaswand en in 
hoeverre het kanaal een rol speelt in sensorische (afferente) signalering van de 
blaas.
In Hoofdstuk 2 hebben we de exacte locatie van TRPV4 kanalen in het humane 
blaasurotheel onderzocht. Tot die tijd was het kanaal alleen in het urotheel 
van knaagdieren onderzocht. In de humane blaas zijn de TRPV4 kanalen meer 
aan de luminale zijde van het urotheel te vinden. Met name ter hoogte van het 
basolaterale membraan van de paraplu cellen. 
We hebben vervolgens onderzocht hoe deze TRPV4 kanalen geactiveerd kunnen 
worden door mechanische rek. Daarbij hebben wij gekeken of er een relatie was 
tussen TRPV4 kanalen en structuren in de cellen die mechanische rek overbrengen. 
We hebben aangetoond dat het TRPV4 kanaal een moleculaire connectie heeft 
met de α-catenine proteïne van de adherence junction. Deze adherence junctions 
vormen essentiele connecties tussen individuele urotheel cellen en zijn belangrijk 
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voor het behoud van structuur en organisatie van de cellen in het urotheel. De 
intracellulaire component van de adherence junctions (inclusief de α-catenine 
proteïne) is verbonden aan het actine cytoskelet dat een belangrijk transport 
netwerk vormt voor mechanische krachten in de cel-lagen van verscheidene 
weefsels.              
Hoofdstuk 3 gaat dieper in op de locatie van TRPV4 kanalen in andere delen 
van het urogenitale stelsel, zoals de humane nier, ureter and blaas. Daarnaast 
hebben we in dit hoofdstuk onderzocht wat een afwezigheid van TRPV4 kanalen 
doet op de vorming van cell junctions in het urotheel. Voor dit onderdeel van 
het onderzoek hebben wij gebruikt gemaakt van een TRPV4 knock-out muis 
model. We hebben aangetoond dat ook in de nier en ureter er een co-localisatie 
is tussen TRPV4 kanalen en de α-catenine proteïne van de adherence junction. 
Ook in humaan nierweefsel hebben we kunnen aantonen dat er een moleculaire 
connectie is tussen TRPV4 en α-catenine. Hierna hebben we de blazen van gewone 
muizen en TRPV4 knockout muizen op ultrastructureel niveau bestudeerd met 
een electronen microscoop. Hierbij hebben we geobserveerd dat adherence 
junction vorming is verminderd in het urotheel van de TRPV4 knockout blaas, wat 
resulteerde in vergrootte intracellulaire ruimtes in het urotheel van deze muizen. 
Afwezigheid van TRPV4 kanalen lijkt derhalve een invloed te hebben op structuur 
en organisatie van het urotheel. Dit kan gevolgen hebben voor de functies van het 
urotheel in barrière en sensorische signalering. 
Hoofdstuk 4 bevat het onderzoek dat we hebben verricht naar de sensorische 
functies van TRPV4 kanalen in de blaas. Bij het onderzoek naar de fysiologische rol 
van TRPV4 in het functioneren van de blaas, hebben we gebruik gemaakt van het 
spinale c-fos model. Met dit model konden we sensorische signalering in de blaas 
vergelijken tussen normale muizen en TRPV4 knockout muizen. Dit doen we door 
sensorische signalen van de blaas te kwantificeren op ruggenmerg niveau. Daarbij 
is er wel een pijnlijke stimulus nodig om voldoende c-fos activatie te krijgen. 
Door verschillende interventies toe te passen zoals: pijnlijke blaas distensie, 
farmacologisch geïnduceerde blaas inflammatie en desensitisatie van C-vezel 
(pijn) zenuwen in de blaas, hebben we kunnen bewijzen dat TRPV4 kanalen in 
de blaas daadwerkelijk invloed hebben op de sensorische signalen die vanuit 
de blaas via het ruggenmerg naar het brein lopen. Deze experimenten hebben 
echter ook onverwachte resultaten opgeleverd die de nadelen van het gebruik 
van gen-knockout modellen met zich meebrengen. We observeerden in de TRPV4 
knockout muizen een sterk (significant) verhoogde c-fos acitiviteit na een blaas 
distensie vergeleken met normale muizen. Wij denken dat dit resultaat verklaard 
kan worden door adaptaties in de TRPV4 muizen. Er zijn aanwijzingen dat deze 
TRPV4 knockout muizen, door hun levenslange gebrek aan TRPV4 receptoren in 
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de blaas een inherent gebrek hebben aan sensaties die blaasvulling registreren. 
Een verklaring zou zijn dat de normale zenuw geleiding in de blaas via de Aδ vezels 
disfunctioneel is in de TRPV4 knockout, waardoor de sensorische signalering 
meer via de C-vezels (pijn zenuwen) verloopt en zo meer spinale c-fos activiteit 
geeft. Hoewel de tight junctions nog aanwezig waren in de TRPV4 knockout 
muizenblazen, zou het echter ook mogelijk kunnen zijn dat de eventuele effecten 
van TRPV4 op de barrière van het urotheel een rol kunnen spelen in de verhoogde 
activatie van C-vezel neuronen in de blaas. 
Part 4 The function of glycosaminoglycans (GAGs) in the bladder urothelium
Deel vier van dit proefschrift concentreert zich op de rol van glycosaminoglycanen 
(GAGs) in de barrière functie van het urotheel van de blaas. GAGs zijn een 
groep negatief geladen polysacchariden die meestal gebonden zijn aan een 
proteoglycaan proteïne. Samen vormen ze de zogenoemde GAG laag die zich op 
het luminale membraan van de paraplucellen van het urotheel bevind. Deze laag 
heeft als bijzondere eigenschap dat het grote hoeveelheden watermoleculen kan 
binden in een gel-vorm. Deze hydrofiele laag zou een buffer vormen tussen het 
cel membraan van de paraplucel en de toxinen in de urine en zou zo de blaaswand 
beschermen. Hoewel deze moleculen al zeer lang bestudeerd worden en ze 
tevens therapeutisch worden gebruikt in de kliniek voor blaaspijnsyndroom (IC/
BPS), was er tot op heden geen fundamenteel bewijs dat deze moleculen echt 
bijdroegen aan de barrière van de blaas. Ook was het nog onbekend uit welke typen 
glycosaminoglycaan de GAG laag bestond. Het doel van dit project was om meer 
duidelijkheid te krijgen over deze vraagstukken. Hoofdstuk 5 beschrijft hoe we de 
locaties van verschillende GAGs (de grootste groep met sulfaat groepen) hebben 
onderzocht in de humane en varkensblaas. Hiervoor hebben we gebruik gemaakt 
van immunohistochemie, immunofluorescentie en selectieve GAG isolaties van 
verschillende lagen het varkensblaas urotheel. Met deze technieken hebben 
we aangetoond dat chondroïtine sulfaat de enige GAG is die aanwezig is op het 
apicale membraan van de paraplucellen van het urotheel van de mensen- en de 
varkensblaas. Vervolgens hebben we de rol van de GAGs in barrière onderzocht 
door Trans Epitheliale Weerstand (TEER) metingen te verrichten op gekweekte 
monolagen van volledig gedifferentieerde urotheelcellen van de varkensblaas. 
Daarbij is de barrièrefunctie van selectieve GAGs onderzocht door middel van 
specifieke enzymdigestie. Met deze experimenten hebben we aangetoond dat 
chondroïtine sulfaat direct bijdraagt aan de barrière functie van de blaas. Ook 
hebben we in vitro vast kunnen stellen dat na een selectieve beschadiging van de 
GAG-laag, er een volledig herstel optreed van de barrière binnen 24 uur. 
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Part 5. Experimental models for preclinical bladder muscosa research
Deel vijf van dit proefschrift beschrijft het gezamenlijke onderzoeksproject 
dat is verricht door de Functionele onderzoeksgroep met de Regeneratieve 
geneeskunde / Tissue engineering groep van onze afdeling met als doel het 
creëren van een experimenteel blaasslijmvlies model. Er wordt in het preklinisch 
onderzoek naar de blaas frequent gebruik gemaakt van knaagdieren. Echter 
hebben andere diermodellen, zoals het varken, ten aanzien van grootte en functie 
een betere biologische gelijkenis met de humane blaas. Een nadeel is echter de 
zeer hoge kosten die gepaard gaan met het doen van proefdieronderzoek met 
grote dieren. Huidige ontwikkelingen in regeneratieve geneeskunde elders 
en in ons eigen lab hebben tot het idee geleid om te onderzoeken of we met 
de combinatie van ruim voorradige varkensblazen uit het slachthuis en tissue 
engineering technieken een reproduceerbaar en representatief preklinisch model 
konden ontwikkelen voor blaas onderzoek. Hoofdstuk 6 omvat het onderzoek dat 
we hebben verricht om dit model te creëren, evalueren en reproduceren om het 
geschikt te maken voor bijvoorbeeld preklinisch toxicologisch onderzoek van de 
blaas. Hierbij hebben we een transwell systeem ontwikkeld met aan de onderzijde 
een permeabele bodem van collageen type 1 dat als substraat dient voor kweken 
van dunne biopten van varkensmucosa. We hebben onderzocht welke mucosa 
biopten het beste vitaal bleven door verschillende kweek media te testen. De 
vitaliteit van het weefsel hebben we systematisch geanalyseerd middels (immuno)
histochemie, proliferatie en apoptose assays. Uit deze evaluatie kwam naar voren 
dat DMEM-F12 kweek medium superieur was. Na optimalisatie van de protocollen 
zijn we er in geslaagd om mucosa biopten vitaal te houden gedurende 1 week met 
daarbij behoud van normale (immuno)histochemische karakteristieken. Dit zou 
een voldoende tijdspan zijn voor bijvoorbeeld toxicologie testen. Dunne biopten 
presteerde hierbij beter dan dikkere biopten. Ook observeerden we gedurende 
de kweekperiode dat er sprake was van prolifereratie van urotheelcellen op de 
collageen type 1 laag van het transwell systeem. We denken dat er nog veel ruimte 
is voor verbetering is van dit huidige model. De kern boodschap van dit project is 
dat het technisch mogelijk is om kwalitatief goede, kosteneffectieve alternatieven 
voor proefdieronderzoek te ontwikkelen.                   
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Future perspectives
Afferent signaling and the role of the urothelium
The general introduction of this thesis explains that the normal lower urinary tract 
function is based on complex interactions between local, organ confined factors 
and peripheral and central nervous control. This complexity makes the lower 
urinary tract fragile for disturbances. From what the scientific community has 
learned from Overactive Bladder Syndrome (OAB), is that it is a symptom complex 
that can occur in a large variety of diseases like neurogenic bladder disease, pelvic 
organ prolapse and benign prostate hyperplasia (BPH). These diseases can impact 
lower urinary tract function on different levels to cause bladder overactivity. 
OAB is also characterized by a wide range in symptom severity that can be partly 
objectified with urodynamics. This underlines in my opinion that in the future, 
OAB will not be treated as a single disease. In order to accomplish this, we have 
to be able to improve patient stratification to select the correct therapy for each 
individual patient. Our current therapeutic strategy to combat OAB symptoms is 
often based on trial and error of pharmacological treatments and using a step 
up approach. That means we start with the least invasive therapy options and 
continue forward to more invasive treatment options until a satisfied result is 
obtained. Urodynamic investigations are uncomfortable tests for a patient and do 
not tell us anything on what goes on a cellular level. For instance, in theory, one 
OAB patient could have his symptoms, due to an inherent lack of Beta-3 receptor 
expression in the bladder and this will lead to an inability to inhibit uncontrolled 
detrusor contractions. Another patient with exactly the same symptoms, could 
have these symptoms because of an increased M3 receptor expression the 
bladder which may cause an increased excitability of bladder afferents and 
detrusor muscles. These patients are currently getting the exact same treatments, 
but they will likely respond differently to them. To improve patient stratification 
and increase therapy efficacy in the future, we shall have to dig deeper into the 
pathophysiological processes of the individual patient and connect this to therapy 
efficacy.
We currently know of a lot of different receptors that have something to do 
with afferent signaling. However, we still do not fully understand how bladder 
afferent signaling and lower urinary control works. The attributed roles of many 
potential bladder mechanoreceptors are only studied in cell culture and bladder 
strip models and conclusions thus remain preliminary. This work has to continue 
in order to improve our understanding of lower urinary tract (patho)physiology. 
We have evidence of a lot of receptors that are upregulated in OAB. There are in 
fact so many, that it is difficult to comprehend how all these individual receptors 
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are involved in the pathophysiological process of OAB. It seems unlikely that this 
upregulation has an individual cause for each individual receptor. More likely there 
will be one or two overseeing pathophysiological pathways that induce changes 
within the lower urinary tract tissues and the efferent and afferent nerves that 
causes this imbalance by changing receptor expression on different neurons and 
bladder confined cells types. Interesting candidates for this are the Neurotrophins 
like NGF and BDNF that show to modulate receptor expression on urothelial cells, 
ICCs, detrusor cells and nerves, but also other Growth factors could be of interest 
[Cruz 2014].         
Another topic that has to be mentioned in this section is noxious (pain) signaling 
in the bladder. Chronic inflammation and pain and in the bladder region can be 
very debilitating and interstitial cystitis/ bladder pain syndrome (IC/BPS) is still 
is one of the great mysteries in urological disease. Current views on this disease 
is to distinguish and separately treat the group of IC/BPS patients that have 
clear inflammation (Hunner lesions) of the bladder wall. Hyperpermeability of 
the urothelium is a key characteristic in Hunner type IC/BPS and this defect in 
barrier is believed to activate the noxious c-fibers nerves that are also responsible 
for urgency symptoms in OAB. It is therefore important that we learn how pain 
signaling  in the bladder works.
Another topic that has to be mentioned in this section is noxious (pain) signaling 
in the bladder. Chronic inflammation and pain and in the bladder region can be 
very debilitating and interstitial cystitis/ bladder pain syndrome (IC/BPS) is still 
is one of the great mysteries in urological disease. Current views on this disease 
is to distinguish and separately treat the group of IC/BPS patients that have 
clear inflammation (Hunner lesions) of the bladder wall. Hyperpermeability of 
the urothelium is a key characteristic in Hunner type IC/BPS and this defect in 
barrier is believed to activate the noxious c-fibers nerves that are also responsible 
for urgency symptoms in OAB. It is therefore important that we learn how pain 
signaling  in the bladder works. 
IC/BPS has similarities with OAB: 1) It has a wide range of symptom severity, 
2) Symptoms like urgency, frequency and sometimes incontinence overlap, 3) 
Treatment strategies are primarily based on a step up approach that start from 
the least invasive to the more invasive therapies and 4) Research shows that 
the urothelium is involved in the pathophysiology in both diseases. The major 
difference between IC/BPS and OAB is the fact that our understanding of the 
pathophysiological pathways of IC/BPS is even more lacking which also reflected 
by the very limited options for symptomatic treatments. A better understanding 
of the relation between afferent signaling and barrier could help to find better 
therapies to treat IC/BPS.          
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Epigenetics in OAB and IC/BPS 
Part of our future goal is to use novel research tools to help identify and stratify 
patients with lower urinary tract dysfuncion. Epigenetics and whole genome 
expression profiling techniques allow us to compare the gene expression patterns 
of individual patients with OAB and IC/BPS on a scale that was not possible 
15 years ago. In addition, we have a biobank with bladder biopsies of patients 
with OAB symptoms like idiopathic OAB, neurogenic bladder disorders and BPH 
patients with OAB complaints. We have also collected bladder biopsies from IC/
BPS patients. The advantage of whole genome genetic expression profiling is 
that it can be used as a fishing / shotgun tool to identify potential biomarkers, 
without the need for existing knowledge of a known pathophysiological process. 
This strategy can help in identifying novel (patho)physiological pathways, but it 
can also find new biomarkers that can be used for diagnostic purposes to improve 
stratification of patients. Urothelial involvement in the pathophysiological 
processes of OAB and IC/BPS gives us an advantage, because urothelial cells can be 
isolated from urine. These urine derived urothelial cells can therefore be used as a 
non-invasive biological substrate for diagnostic tests. Our strategy is to first detect 
potential biomarker candidates from whole genome gene expression profiling on 
bladder biopsies and to subsequently validate these biomarkers in urine derived 
urothelial cells. The end result would hopefully be 1) a diagnostic test for OAB and 
IC/BPS (subtypes) and 2) gain more insight in novel pathophysiological pathways 
of both diseases.
The role of TRPV4 channels in the lower urinary tract.
Part 1 of this thesis was written to outline the similarities between barrier function 
and afferent signaling function of the urothelium. I am particularly interested 
in the role that mechanoreceptors and the cytoskeleton have on processes like 
vesicular exocytosis and afferent nerve activation. In my opinion, these two 
subjects should be investigated together when urothelial mechanoreceptors are 
being investigated. Fortunaltely, there are good examples of research groups that 
have done just that. For instance, the work on TRPV1 channels in the bladder by 
L. Birder et al. They demonstrated the importance of bladder TRPV1 channels 
in afferent signaling, and simultaneously investigated their effect on urothelial 
capacitance (vesicular exocytosis) [Birder 2002]. We currently do not know if 
TRPV4 has an effect on vesicular exocytosis. Based on the channels’ characteristics 
and our observations in the TRPV4 knockout mice with electron microscopy , this 
would be worthwhile investigating.
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It is currently unknown if TRPV4 plays an active role in the pathophysiology of 
lower urinary tract dysfunction. Based on our results in chapter 4, I believe that 
this could be an interesting topic to investigate. Our attempt to pharmacologically 
block TRPV4 channels in the urothelium did not show a result on spinal c-fos 
expression, but Gevaert et al. and Everaerts et al. were able to demonstrate an 
effect in rodent cystometry experiments. During the formation of this thesis, 
we have discovered the upsides, but also the downsides of the work with small 
rodents and transgenic knockout mouse models and their translation to the human 
situation. Although I do believe in the potency of urothelial TRPV4 channels in 
mechanosignaling in the bladder, I do apply caution to prevent exaggeration of its 
functions and its potency as a promising target for the treatment of OAB. Not only 
does our work show that TRPV4 channel inhibition could influence cell junction 
formation and urothelial integrity, but literature also shows that there are many 
bladder receptors that have been investigated for afferent bladder signaling that 
had first showed promise but eventually did not deliver on the aspect of becoming 
an suitable pharmacological target for therapy. Therefore, I think that our current 
research strategy to invest in epigenetics of lower urinary tract dysfunction has 
a higher chance of becoming successful in making a difference in healthcare for 
OAB and IC/BPS patients.      
Urothelial involvement in barrier.
This thesis contains the results of a study on bladder glycosaminoglycan distribution 
and function. Our results demonstrate an important role for chondroitin sulfate in 
the bladder defensive GAG layer. Instillation of intravesical chondroitin sulfate is 
one of the most clinically applied therapies for IC/BPS patients in the Netherlands 
and it is also used as preventative treatment for frequently recurring urine tract 
infections. These therapies seem to help patients, but there is still a real demand 
for more effective treatments to enhance and repair the bladder barrier. Especially 
in a condition like IC/BPS that has such a high disease burden, but so few effective 
therapeutic options. Therapeutically enhancing the natural barrier properties 
of the bladder could become a valid strategy to combat antibiotic resistance in 
urine tract infections. There is some evidence that instilled chondroitin sulfate 
adheres to the damaged urothelium [Hauser 2009]. However, from my point 
of view, the lack of efficacy of the current GAG replenishment therapies comes 
from an evident lack of understanding how the GAG-layer is built up and how it 
functions. There is much unknown about the relevant proteoglycan core proteins 
that bind chondroitin sulfate to the apical membrane of the umbrella cell. These 
proteoglycans are an essential part of the total GAG layer, but are not included 
in the currently applied GAG replenishment treatments. Combining the right 
GAG with the correct proteoglycan could further improve barrier enhancement 
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and adherence to the urothelium and would likely improve the efficacy of these 
therapies. Our next goal is a project that focuses on the identification of the 
important barrier improving proteoglycans that bind chondroitin sulfate. 
Another goal we have set is to investigate the function and dynamics of the GAG 
layer in bladder wall repair. We currently are not sure if the GAG layer is the final 
puzzle piece to achieve a complete barrier or if GAGs already participate in the 
first phases of bladder wall repair. The research done for this thesis provided 
some clues for this. We have demonstrated that GAGs like chondroitin sulfate are 
also produced by undifferentiated urothelial cells and that after mildly damaging 
chondroitin sulfate with selective enzymes and protamine, the barrier recovery is 
fast (>24 hrs). The aim for the future is to use and improve our preclinical in vitro 
experimental models to study the dynamics of the urothelial GAG-layer in normal, 
chronic inflammatory and regenerative states, to help improve dosage schemes 
for intravesical GAG replenishment therapies.           
Improving translational research tools.
Like stated before, the population that is affected by bladder dysfunction 
disorders is very large and the impairment in quality of life and cost to society are 
considerable. There has been a great effort put into basic, pre-clinical research for 
bladder dysfunction diseases for many decades. Many different in vivo and in vitro 
models have been used to biologically mimic the human lower urinary tract. Large 
numbers of laboratory animals are still used for a wide range of experimental 
models like cystometry, bladder tissue strip experiments, Ussing chamber 
experiments and as substrates for primary cell cultures. The combined research 
efforts from decades of experiments have not translated into a many effective 
treatments for lower urinary tract dysfunction. Although there is a remarkable 
similarity between mammals concerning the neurophysiological control of the 
lower urinary tract, there are also considerable differences [Andersson 2011]. 
Rodents have evident non-voiding microcontractions and compliance increases 
during the storage phase that are not seen humans [Andersson 2002, 2004]. 
Moreover, many different strains of the same mammal, like rats, have known 
differences in lower urinary tract function [Andersson 2011]. Also during the study 
of diseases of the lower urinary tract, we encounter limitations in animal models. 
OAB-like symptoms for instance, can only be approximated by inducing chemical 
inflammation with cyclophosphamide or capsaicin treatments. This does not 
mean that animal models for bladder dysfunction are redundant or inapplicable, 
but standardization and validation of the applied models should be improved 
and limitations of the models should be respected. In return this would greatly 
improve the comparability and reproducibility of the research efforts in this field. 
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Fortunately, efforts for this are currently being undertaken with an example for 
animal cystometry models. 
This thesis showed the upsides and downsides of using knockout mice models. 
I do believe they can tell an investigator a lot about the function of a receptor 
or a protein. However, adaptive processes can be considerable in an animal 
that has lived its entire life with an absent receptor or protein  and this makes 
it difficult to compare them with wild type animals. This makes it also difficult 
to investigate the true function of a receptor on (normal) afferent signaling. The 
current development of inducible knockout techniques, where you can induce 
the knock-out at a controlled time during an animal’s life, are in my opinion very 
promising and could bypass the effects of knock-out induced adaptations.  
During this thesis, I tried to create and validate a pre-clinical model for bladder 
mucosa research using porcine bladder biopsies from the abattoir. Although the 
outcomes of this study show that there is still room for improvement, I do believe 
that the use of abattoir derived porcine bladders has some great ethical and 
translational advantages over the currently applied laboratory animal models. 
From a biologic perspective, there is a high biocompatibility in bladder histology 
and function compared to humans. This makes it a good substrate for harvesting 
urothelial cells for in vitro culturing experiments, but also for a wide range of other 
experiments like: toxicology screening, bladder muscle strip experiments, Ussing 
chamber /  barrier experiments. The biggest advantage of using abattoir derived 
porcine bladders is that, when standardized, it could drastically reduce the need 
for laboratory animals and reduce the costs and administrative burden of these 
experiments. I am also enthusiastic about the use of human bladder biopsies 
for culturing substrate and for in vitro experiments. This idea was explored by 
Bolenz et al as a model for chemotherapy sensitivity for individual patients 
[Bolenz 2009]. Recent emergence and progressive use of organoid cell cultures 
for pre-clinical investigations underlines the importance of the 3D environment 
on cell functioning and behavior. Regenerative medicine, is in my opinion focused 
too much on tearing down the whole organ to obtain different cell types for 
culturing, after which they start an attempt to artificially recreate the same organ 
by assembling all these loose components. A small bladder biopsy contains all the 
needed cells in the correct 3D environment and our study has shown that it can be 
an excellent donor for cell cultures. We also want to approach human proportions 
in our future preclinical research on barrier enhancing installations. Therefore, we 
are currently in a pilot phase to set up a whole porcine bladder model for barrier 
experiments that uses abattoir derived bladders. In this model, we can use the 
whole intact (non-traumatized mucosa) bladder and mimic bladder instillations 
that we perform in humans (see Figure next page).          
183
References
[1] Andersson KE, Arner A. Urinary bladder contraction and relaxation: Physiology 
and pathophysiology. Physiol Rev. 2004; 84:935–986.
[2] Andersson KE. Bladder activation: Afferent mechanisms. Urology. 2002; 59:43–50.
[3] Karl-Erik Andersson KE, Soler R, Füllhase C. Rodent models for urodynamic 
investigations. Neurourol and Urodyn. 2011; 30(5): 636-646. 
[4] Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, Wang E, Ruiz G, De 
Groat WC, Apodaca G, Watkins S, Caterina MJ. Altered urinary bladder function 
in mice lacking the vanilloid receptor. Nat. Neurosci. 2002 5:856–860
[5] Cruz CD. Neurotrophins in bladder function: what do we know and where do we 
go from here? Neurourol Urodyn. 2014; 33(1):39-45.
[6] Hauser PJ, Buethe DA, Califano J, Sofinowski TM, Culkin DJ, Hurst RE. Restoring 
Barrier Function to Acid Damaged Bladder by Intravesical Chondroitin Sulfate. J 
Urol. 2009; 182(5):2477-82.
[7] Bolenz C, Ikinger EM, Ströbel P, et al. Topical chemotherapy in human urothelial 
carcinoma explants: a novel translational tool for preclinical evaluation of 
experimental intravesical therapies. Eur Urol, 56: 504-11, 2009
184
List of Publications
2016 Acta Physiologica. 
Urothelial update. How the bladder mucosa measures bladder filling. Dick A.W. 
Janssen, John P.F.A. Heesakkers, Jack A. Schalken. (adapted from chapter 1 in this 
thesis)
2016 Pflügers Archiv - European Journal of Physiology. 
TRPV4 mediates afferent pathways in the urinary bladder. A spinal c-fos study 
showing TRPV1 related adaptations in the TRPV4 knockout mouse. Dick A.W. 
Janssen, Joost G. Hoenderop, John P.F.A. Heesakkers, Jack A. Schalken. (chapter 4 
in this thesis)
2016 Acta Physiologica. 
TRPV4 channels in the human urogenital tract play a role in cell junction formation 
and epithelial barrier. Dick A.W. Janssen, Kees C.J.F. Jansen, Gerald Verhaegh, Theo 
Hafmans, Joost G. Hoenderop, John P.F.A. Heesakkers, Jack A. Schalken. (chapter 
3 in this thesis)
2012 Journal of Urology. 
A new, straightforward ex vivo organoid bladder mucosa model for preclinical 
research. Dick A.W. Janssen, Paul J. Geutjes, Julia Odenthal, Toin H. van Kuppevelt, 
Jack A. Schalken, Wout F.J. Feitz, John F.P.A. Heesakkers. (chapter 5 in this thesis)
2012 Neurourology and Urodynamics. 
Urgent-SQ implant in treatment of Overactive bladder Syndrome: Nine year 
follow-up study. Dick A.W. Janssen, Fawzy Farag, John P.F.A. Heesakkers
2012 Journal of Urology. 
The distribution and function of chondroitin sulphate and other sulphated 
glycosaminoglaycans (GAGs) in the human bladder and their contribution to the 
protective bladder barrier. Dick A.W. Janssen, Xander M.R. van Wijk, Kees C.F.J. 
Jansen, Toin H. van Kuppevelt, John P.F.A. Heesakkers, Jack A. Schalken. (chapter 
5 in this thesis) 
2011 Journal of Urology. 
The Mechanoreceptor TRPV4 is Localized in Adherence Junctions of the Human 
Bladder Urothelium: A Morphological Study. Dick A.W. Janssen, Joost G. Hoenderop 
, Kees C.F.J.  Jansen, Annemiete W. Kemp, John P.F.A. Heesakkers, Jack A. Schalken. 
(chapter 2 in this thesis)
185
Other: 
2012 Uroscoop, September edition:
 ‘Barrierefunctie van het Urotheel’ Dick A.W. Janssen 
2012 Tijdschrift voor Urologie. 
Quantitative near-infrared spectroscopy voor de non-invasieve diagnose voor 
bladder outlet obstruction bij mannen met LUTS. F. Farag, D.A.W. Janssen, J. 
Meletiades, F. Feitz, J. Heesakkers.
2009 Urologen Vademecum, December edition 2009: 
‘Wat is de effectiviteit van anticholinergica op blaaskrampen ten gevolge van een 
verblijfskatheter’. Dick A.W. Janssen.
186
Dick Albertus Willem was born on 10th of May 1983 in Tilburg. After he passed 
his Atheneum exam at the St. Odulphus Lyceum in Tilburg, he started his study 
medicine at the Maastricht University and was an active student at MSV Tragos 
student society and treasurer of HD Nexus. During his study he completed medical 
internships in Sydney Australia, Bloemfontijn South Africa and an urology internship 
in Canterbury District Health Board hospital in Christchurch New Zealand. He did 
a scientific internship on bladder afferent signaling at the Department of Urology 
at Maastricht UMC under the supervision of prof. G.A. van Koeveringe. After 
graduation in 2008 he moved  to Nijmegen to start his PhD in at the Dept. of 
Urology of the Radboud university medical center under the supervision of prof. 
Jack A Schalken and dr. John P.F.A. Heesakkers. Here he focused on Overactive 
bladder syndrome and Bladder pain syndrome and he performed research on 
afferent signaling (TRP-channels) and tissue barrier (glycosaminoglycans) of the 
urinary bladder. He is an active reviewer for 6 peer-reviewed scientific journals 
like European Urology and Neurourology & Urodynamics. His research has been 
presented on many national and international congresses (ICS, EAU and AUA).  
Beside fundamental research, he has expertise on clinical urodynamic studies for 
diagnosing lower urinary dysfunction. He has been hosting  and organizing national 
and international training courses and webseminars to teach urodynamics. 
Examples of this are urodynamic courses in Upsala Sweden in 2011, the EAUN in 
Paris in 2012 and the University of Malaysia in Kuala Lumpur 2016. The webinar 
program has reached over 270 participants from over 35 countries worldwide. 
 
In 2011, he received a AGIKO stipendia grant from the Netherlands Organisation 
for Health Research and  Development (ZonMW) to combine his PHD research 
with residency training to become a urologist. He completed his two-year general 
187
surgery residency at the Canisius Wilhelmina Hospital in Nijmegen in 2013 and 
2014 and has been working at the department of Urology of the Radboud UMC 
since then. In 2016, he and his team were voted 3rd place at the ZonMW Dutch 
Medical Inspirator award.  
Dick has married Judith in 2015 and enjoys his leisure time traveling with here 
wherever and whenever he can.   

PART 7
Dankwoord
190
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Ik ben heel veel mensen, heel erg dankbaar voor hun hulp bij het tot stand komen 
van dit proefschrift. Wetenschap doe je niet alleen en ik heb elke keer weer 
ervaren dat meer samenwerken tot mooiere resultaten leidt.  
Als er iemand pagina’s vol huldes en lofzang verdient, dan is het mijn lieve vrouw 
Judith. We zijn al bij elkaar sinds 2008. Ik was net naar Nijmegen verhuisd om 
aan dit promotieonderzoek te beginnen toen jij plots in mijn leven kwam. Je bent 
sindsdien mijn steun en toeverlaat en ik zou het niet weten hoe ik het al die jaren 
zonder je had moeten stellen. Bijzonder hoe jij je leven hebt aangepast voor mij, 
zodat ik de aandacht op mijn opleiding kon richten. Gelukkig zijn wij als geen 
ander in staat om hard werken te belonen met bourgondisch tafelen, borrelen 
en genieten. En samen de wereld bereizen. Wat heerlijk om bij jou te zijn. De 
grootste uitdagingen liggen nog voor ons. Ik ben ongelooflijk trots op jou en op 
wat we allemaal samen aankunnen. En komen er beren op de weg, dan maken we 
er een foto van en gaan we verder met de mooie reis.    
Dan is het tijd om mijn bazen (co-promotoren en promotor) dr. John P.F.A. 
Heesakkers en prof. dr. Jack A. Schalken te bedanken. John, Ik deel je liefde 
voor goede wijn en lekker eten, maar voor wielrennen moet je me toch echt in 
de bezemwagen zetten om er lol in te hebben. Je bent denk ik de hoofdreden 
dat ik zoveel voldoening uit mijn promotietijd heb gehaald. Je ondersteuning, 
persoonlijke aandacht en je goede raad hebben ervoor gezorgd dat ik met veel 
plezier en zelfstandigheid dit werk heb kunnen uitvoeren en mijn carrière heb 
kunnen vormgeven zoals ik dat graag wil. We zijn gelukkig nog lang niet klaar en ik 
denk dat onze toekomstige projecten nog succesvoller gaan worden. 
Jack, je bent hoofd van het Experimentele Urologie lab en ook nog eens een 
mede-Brabander.  Het zat dus vanaf de eerste dag wel goed. Achter die glimlach 
zit gelukkig ook een goed stel hersens waar ik dankbaar gebruik van heb gemaakt. 
Ik ben in al die jaren nog nooit jouw kamer uitgelopen zonder een nuttig advies. 
Je hebt ondanks je oncologie-roots ook nog eens verrekte veel verstand van 
functionele urologie. De manier waarop je het lab leidt en daarbij zo’n trouwe, 
kwalitatieve groep bijeen houdt is bewonderenswaardig. Je doet dit met oog voor 
goede wetenschap, hard werken en niet onbelangrijk:  met humor. Ook jij bent 
voorlopig nog niet van me af en onderzoek is to-be-continued…   
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en de nieuwe groep doet het gelukkig minstens zo goed! Ook de legendarische 
congressen en appartementen zal ik nooit vergeten. Brave jongens en meisjes, be 
gentle met de foto’s….. 
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